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iNtroDuCtioN
Depression, in a broad sense, is a state of feeling sad. Nowadays, the term is applied to 
several clinically important conditions such as major depressive disorder, dysthymia, minor 
depression, sub-threshold depression and depressive symptoms that are not limited to a 
mood state of sadness. Major depressive disorder is a syndrome including several symp-
toms such as depressive mood, loss of interest, concentration problems and indecisiveness, 
recurrent suicidal ideation, sleep and appetite problems, feelings of guilt and worthless-
ness, lack of energy or irritability 1. 
Major depressive disorder is one of the most common psychiatric disorders with a lifetime 
prevalence of ranging between 15-30% and estimated 12-month prevalence of around 
5% 2, 3. Also, this common disorder is a leading cause of the disease burden worldwide 4. 
Any insight into the etiology of depression would be benefi cial to prevent the occurrence 
of disorder. 
Since it was described in Ancient Greece, biological and non-biological factors underly-
ing depression have been of interest. Several biological mechanisms including hormonal, 
vascular, immune and genetic mechanisms have been identifi ed as contributing to the 
etiology of depression. 
the hypothalamic-pituitary-adrenal axis and depression
One of the earliest fi ndings of biological studies of depression is the disturbed regulation 
of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is the main neurohormonal 
system that regulates acute and chronic stress response. Physiological or psychological 
stress activates the hypothalamus resulting in secretion of the corticotrophin-releasing 
hormone (CRH) and therefore the adrenocorticotropic hormone (ACTH) in the anterior 
pituitary gland. In response to the ACTH secretion, cortisol is released from the adrenal 
glands. The axis is controlled with a negative feedback mechanism in which cortisol sup-
presses the release of the CRH and ACTH to prevent excess cortisol secretion when stressor 
has subsided. Cortisol secretion follows a diurnal rhythm. Before awakening, cortisol secre-
tion starts increasing. It has a peak secretion 30-45 minutes after awakening and then it 
decreases during the day. 
In early clinical studies, hypercortisolemia and a non-suppression of the HPA axis were 
found very frequently. Hence, several attempts has been made to use these fi ndings as 
diagnostic tests in depression 5. However, further studies failed to replicate the initially very 
encouraging fi ndings. Some found no difference in the HPA-axis activity in persons with 
depression and controls, while others found hypocortisolemia and an increased negative 
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feedback suppression of the HPA axis in depressed patients. Inconsistencies among the 
studies most likely stemmed from the different populations evaluated, cortisol collection 
methods, time points, and confounders that were not taken into account. Cortisol can be 
evaluated in different body specimen including blood, urine, and cerebrospinal fluid, all 
with different reference levels and variations on free cortisol levels. 
More recently cortisol assessments in saliva and hair were developed. Measuring cortisol 
in saliva made it possible to use this method in large samples, as it is easy to apply in 
population-based studies. Also, saliva collection is easier than relying on plasma samples 
when assessing diurnal variation of cortisol, which requires several samples during the day. 
This helps researchers to overcome the main disadvantage of the one-time-point cortisol 
assessment in blood: the lack of accounting for diurnal variation of cortisol in large samples 
6, 7. 
Another novel development that is relevant for cortisol research in population-based studies 
is the introduction of low doses of dexamethasone. Low doses of dexamethasone to test 
the negative feedback regulation of the HPA axis is unique, as interventional procedures 
are generally not used in such studies.
An epidemiological approach to cortisol research allows testing many confounders, interac-
tions, and hypothesis-free genome-wide associations, which are important to understand 
how chronic diseases are related to disturbed cortisol regulation. 
In this thesis, we aimed to assess diurnal variation, negative feedback control, and the 
genetics of the HPA axis in general population to explore some missing pieces in the puzzle 
of the association between the HPA axis functions and depression. 
Vascular factors and depression
Recognizing the link between vascular factors and depression has a long history. Since the 
19th century by the work of Durand-Fardel 8, a relationship between vascular disease such 
as atherosclerosis or stroke and depression was reported. More systematic studies were 
published by Alexopoulos in 1997 9. He introduced the ‘Vascular Depression’ hypothesis in 
which he proposed that ‘cerebrovascular disease precipitate, predispose and perpetuate’ 
late life depression. In the same year, Krishnan proposed the same concept focusing on 
vascular lesions such as white matter lesions (WMLs) using magneting resonance imag-
ing (MRI) methods 10. Since then, a wide range of vascular depression studies has been 
performed. Until recently, a large body of studies has focused on the link between overt 
cerebrovascular diseases such as stroke, clinical infarcts and depression indicating a clear 
association bi-directionally. 
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Arguably, it is not suffi cient to test the associations between vascular diseases, which come 
with severe disabling symptoms, and depression to prove vascular etiology of depression. 
Not unlikely, such disabling diseases can cause depression as a psychological reaction to 
disability rather than a vascular pathophysiological mechanism. For that reason, asymptom-
atic cerebrovascular disturbances, so called cerebral small vessel disease has been defi ned 
and tested in etiology studies of depression in the last decades. WMLs and cerebral infarcts 
and lacunes have been explored supporting vascular etiology in depression 11, 12. 
To further our knowledge, relatively novel markers of cerebrovascular damage or functional 
component of the cerebrovascular system must be explored. A recent marker of cerebrovas-
cular damage, cerebral microbleeds has not been tested in relation to depression. Similarly, 
the cerebral hemodynamics of depression have been studied only cross-sectionally in a few 
studies that show an impairment in blood fl ow 13-16. 
In this thesis, we aimed to test the association of non-clinical cerebral small vessel disease 
with depression longitudinally in general population. Also, we aimed to see if amyloid 
pathology, which may affect the cerebrovascular functions, is related to depression.
Genetic factors and depression
Major depressive disorder is a heritable syndrome. Family studies have shown familial ag-
gregation in depression. According to these studies, the heritability of MDD is between 
28% and 44% 17 , whereas the heritability estimate of the depressive symptoms is ap-
proximately 25% 18, 19.  Depression is a genetically complex disorder in which common 
genetic variations with relatively small effect sizes determine the etiology. However, detect-
ing such variants require very large sample size. The advent of human genome projects 
and genome-wide association studies (GWAS) in the 2000s, helped researchers to test 
multiple variants in genetically complex psychiatric traits. While GWAS of psychiatric traits 
such as psychosis, bipolar disorder, attention defi ciency and hyperactivity disorder, autism 
yielded some loci, studies on depressive disorders were not successful until very recently 
(PGC MDD manuscript by Wray N.R. et al. submitted to Nature). One of the most impor-
tant reasons was the relatively heterogeneous phenotype profi le of depression and small 
sample sizes required to detect risk alleles. Two large consortia performed GWAS on MDD 
and depressive symptoms but no genome-wide signifi cant loci were detected in these 
studies. In the current thesis, we aimed to widen the phenotype defi nition in depression 
and meta-analyzed these GWAS of MDD and depressive symptoms to increase the number 
of subjects and reach acceptable statistical power.
In this thesis, we revisit well-researched potential biological causes of depression with new 
technical and epidemiological methods. In chapter 2 we explored cortisol in relation to 
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smoking and genetics to gain more insight on its biology. Also, we adapted an established 
concept, the dexamethasone suppression test, with an adapted method to test sociode-
mographic, health-related and psychiatric determinants in general populations. In chapter 
3 vascular depression hypothesis was revisited with advanced epidemiological designs and 
new imaging markers such as microbleeds and functional measures of cerebrovascular 
systems such as vasomotor reactivity. In chapter 4 we present three GWAS of depression 
with different study designs and phenotype definitions.
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AbstrACt
We investigated concurrent as well as long-term effects of smoking on cortisol. The popu-
lation consisted of 2,508 elderly adults. Current smokers, as opposed to former smokers, 
had higher basal cortisol levels and higher morning increases of cortisol. Overall, pack-years 
was related to morning cortisol rise, but this was accounted for by current smokers. Time 
since quitting was positively associated with a greater decline in daytime cortisol indicating 
that the effects of smoking remit. This suggests that smoking has short-term, rather than 
long-term, consequences on cortisol secretion patterns.
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iNtroDuCtioN
Smoking is a commonly known risk factor for mental and physical health. However, the 
biological mechanisms for this are not always clear. Studies suggest that the effects on bio-
logical systems such, as the endocrine system, may play a role for many chronic disorders 1, 2. 
Cortisol is a stress hormone within the HPA axis, which is infl uenced by smoking and related 
to chronic diseases 3, 4. Thus evaluating the association of smoking to cortisol may help to 
elucidate the mechanism by which smoking infl uences disease. 
Cortisol follows a diurnal pattern, fi rst rising 30-minutes after awakening and then declin-
ing throughout the day. Smoking acutely increases cortisol levels and it has been shown 
that this stimulation is dose-dependent 1. Studies in large samples of younger adults 
demonstrated that, relative to non-smokers current smokers have higher overall basal 
cortisol levels, greater morning increases, and lesser declines in cortisol over the day 1, 5. 
Comparable results were reported in a middle age cohort study, in which current smokers 
had higher salivary cortisol levels and morning increases, when compared with former and 
never smokers, while there were no differences between former and never smokers 6. 
Many smoking-related health problems occur after a long history of smoking, but subse-
quently decrease after smoking cessation (Offi ce of the Surgeon General Report, 2004). As 
cortisol may mediate chronic health consequences of smoking, it is important to explore 
the effects of long-term smoking on cortisol. Older adults generally have longer smoking 
history than younger adults. Additionally, the duration since quitting is longer for former 
smokers in older adults. Although there is evidence for a short-term effect of smoking 
on cortisol in older adults 6, the long-term effects and the diurnal pattern have not been 
fully explored by examining long-term indicators of smoking. Therefore, the current study 
examined the association between short and long-term indicators of smoking and cortisol 
levels in older adults.
MAteriAls AND MethoDs
The current study was based within the Rotterdam study, a population-based cohort of 
adults aged over 55 years which focuses on the occurrences and determinants of common 
chronic diseases 7. The data from the fourth follow-up round (2002-2004), in which salivary 
cortisol was sampled, was used in this cross-sectional study. The population consisted of 
2,508 participants (mean age 74.9 ± 5.8 years, 58% female) whose smoking status data 
was complete, and who had at least one saliva sample. There were 297 current smokers 
(11.8%), 1,389 former smokers (55.4%), and 822 never smokers (32.8%).
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Participants were asked about their smoking status, and current smokers were asked how 
many cigarettes they smoked daily and how long they had been smoking. Former smokers 
were asked about their smoking history with regard to the number of cigarettes they had 
smoked per day and the time since they had quit. Pack-years, a combination of duration 
and intensity of smoking, was subsequently calculated by multiplying the number of packs 
of cigarettes smoked per day by the number of years the person had smoked. The number 
of cigarettes smoked daily provides an indication of whether there is a dose-response 
relationship. Time since quitting makes it possible to determine whether the effect of 
smoking on cortisol was permanent, and pack-years is an indicator of long-term exposure. 
The latter is particularly pertinent to the current study, where, given the older age of the 
population, a longer life history could be obtained.
Because the cortisol level increases 30 minutes after awakening and decline throughout 
the day, multiple measures of cortisol levels during the day provide more valid information 
about daily cortisol release 8. Saliva samples were therefore collected on awakening (C1), 
after 30 minutes (C2), at 5pm (C3) and at bedtime (C4). HPA axis activity was evaluated by 
three summary measures. Total cortisol exposure throughout the day was tested by Area 
Under the Curve (AUC) given by the individual cortisol measurement on the y-axis and 
the time between the cortisol measurements on the x-axis. Cortisol Awakening Response 
(CAR) was used to investigate the morning increase 30 minutes after awakening. CAR was 
calculated as the difference between C2 and C1 over two 9. Diurnal decline was assessed 
by a slope, which was calculated by fitting a linear regression line for each participant, 
which predicted the cortisol values from time since awakening. A greater decline in day-
time cortisol means that the slope of the regression line is steeper (higher or positive ), 
whereas a lesser decline means that the slope is flatter (lower or negative ). 
Sex, age, and marital status were evaluated as covariates. The time between subsequent 
cortisol measurements within the same day was used as a covariate in the analysis of 
C2 and C3. Cognitive status was evaluated with the Mini Mental State Examination 10 
and used as a continuous variable. Education was scaled from primary education (1) to 
university level (7) and used as a continuous variable. Pharmacy records were used to 
collect data on systemic corticosteroid use.
The association between smoking and both the single and summary cortisol measures 
was evaluated. An ANOVA was conducted to determine whether smoking status (cur-
rent, former, never) was associated with cortisol. An ANCOVA was performed to test the 
association between smoking status and cortisol, adjusting for sex, age, marital status, 
cognitive status, education, corticosteroid use, and time between cortisol measures (for 
C2 and C3). The pair-wise comparisons between the three smoking groups were evalu-
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ated using a Bonferroni correction with an adjusted p value of .0167 (three tests were 
conducted; .05/3) for statistical signifi cance. A series of adjusted linear regressions were 
conducted to examine the association between the number of daily cigarettes, pack-years, 
time since quitting and cortisol. All analyses were adjusted for sex, age, marital status, 
cognitive status, education, corticosteroid use, and time between cortisol measures. To 
enhance comparability across the results, missing values of covariates were imputed by 
using the Expectation-Maximization Algorithm. The maximum percent of missing values 
was 12% (corticosteroid use). Missing variables were imputed on the basis of the entire 
baseline population (n=3,539).
results
Participants’ characteristics according to smoking status are presented in Table 1. Current 
smokers reported an average of 12.4 ± 7.4 daily cigarettes. Mean pack-years was 33.6 ± 
21.4 in current smokers and 25.4 ± 23.5 in former smokers (p< .001). Mean time since 
quitting for former smokers was 28.2 ± 13.6 years.
table 1. Participant characteristics by smoking status.
current 
smoker
Former 
smoker
Never 
smoker pa
n= 297 n= 1389 n= 822
Age (years), mean ± (SD) 73.4 ± (5.3) 74.9 ± (5.6) 75.4 ± (6.2) <.001
Gender (female), n (%) 170 (57.2) 596 (42.9) 693 (84.3) <.001
Marital status (married), n (%) 161 (54.2) 941 (67.7) 454 (55.2) <.001
Education (primary school only), n (%) 48 (16.2) 159 (11.4) 135 (16.4) <.001
Mini Mental State Examination, mean ± (SD) 27.5 ± (1.9) 27.6 ± (2.3) 27.4 ± (2.3) .20
Body Mass Index (kg/m²), mean ± (SD) 26.1 ± (3.7) 27.6 ± (3.9) 27.6 ± (4.2) <.001
Number of cigarettes smoked daily, mean ± (SD) 12.4 ± (7.4) N/A N/A N/A
Pack-years, mean ± (SD) 33.6 ± (21.4) 25.4 ± (23.5) N/A <.001
Time since quitting (years), mean ±(SD) N/A 28.2 ± (3.6) N/A N/A
a p values are overall values.
Single cortisol levels and summary measures by smoking status were compared by ANCO-
VA. Results of descriptive and inferential analyses of cortisol among groups are presented 
in Table 2. Adjusted analyses demonstrated that smoking status signifi cantly affects C2, 
C3, C4, AUC, and CAR. Post-hoc comparisons using a Bonferroni correction indicated that 
current smokers had higher mean C2, C3, C4, AUC, and CAR (p <.01) than former and 
never smokers. There were no signifi cant differences in any cortisol measures between 
never and former smokers.
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A series of adjusted linear regressions were conducted to examine the association between 
cortisol and: the number of daily cigarettes, pack-years, and time since quitting. Amongst 
those with a history of smoking, pack-years was associated with higher CAR (β= .020; 
95% confidence interval (CI)= .007-.033; p< .01). Interestingly, when former and current 
smokers were evaluated separately, this association decreased for former smokers (β=.012; 
95 % CI= -.002, .026; p= .08) and increased for current smokers (β= .038; 95 % CI= -.001, 
.077; p= .06). However, the associations were not statistically significant. Finally, a longer 
duration since quitting was associated with a greater decline in daytime cortisol (β= -.003; 
95 % CI=-.005, .000; p= .04) (Table 3).
DisCussioN
In this cross-sectional study, smoking was associated with increased cortisol levels through-
out the day and a greater morning increase. This association was independent of demo-
graphic and health-related factors. Cortisol levels have previously been found to be high 
in current younger adult smokers 4. Previously in a middle aged occupational cohort study 
cortisol levels and a morning increase had been compared in current, former, and never 
smokers. In that study, cortisol release and CAR had been found to be higher in current 
smokers in comparison with former and never smokers 6. Thus, the current study supports 
the findings of prior research and extends it to an older age group. Moreover, the results 
indicate that smoking increases CAR. However, there are conflicting results 11, 12. A morning 
increase of cortisol has been considered as a distinct phenomenon than diurnal profile of 
cortisol. It is most likely associated with the process of awakening (e.g. orientation, activa-
tion of memory in the morning) 13. Because the population used in this study consisted 
of older adults, poor cognitive function may confound the association between smoking 
and CAR. However, this is unlikely, because adjustment for Mini Mental State Examination 
scores did not change the results. 
Previous studies discussed whether the effect of smoking on cortisol changes after quitting; 
however, this had not been directly tested 6. Results of the current study suggest that the 
effects of smoking on cortisol are not permanent. First, current smokers in this study had 
significantly higher overall cortisol levels and greater CAR than former and never smokers, 
whereas former and never smokers did not differ. This suggests that the effect of smoking 
on cortisol recedes after quitting. Second, smoking history as measured in pack-years was 
positively related to a higher CAR; however, this effect was brought about by current 
smoking status rather than by smoking history. Third, time since quitting was associated 
with a greater decline in daytime cortisol which strongly suggests a remitting effect of 
smoking on cortisol. Previous studies compared the effect of short and mid-term smoking 
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cessation on cortisol levels 14. The present study demonstrates that there is a dose-response 
effect of smoking cessation depending on the time since quitting. In other words, a decline 
in cortisol over the day normalizes over a longer period of time. 
Disturbance of cortisol release is an important etiological factor for many chronic situ-
ations, including atherosclerosis, high blood pressure and low-grade infl ammation 1, 15. 
Changes in cortisol release can be a causal factor for various smoking-related chronic 
diseases. However, the risk of smoking-related diseases decreases after quitting 16. This 
observation suggests that some of the potential pathological mechanisms that play a role 
in smoking-related diseases may not continue after quitting. The non-permanent effect 
of smoking on cortisol in this study supports this observation. However, it must be kept 
in mind that many cortisol-related changes may be irreversible once pathology occurs, for 
example atherosclerosis 15, which generally cannot be reversed. 
The mechanism underlying the link between smoking and HPA axis remains unknown. 
However, it has been suggested that nicotine acts on the nicotinic acetylcholine receptors 
(nAChRs) in the hypothalamus and affects HPA axis functions 1, 2. As a distinct phenom-
enon, CAR has been associated with the hippocampal networks, and therefore memory 
and orientation after awakening 13. Nicotine may play role in the hippocampus by acting on 
nAChRs and thus, may alter CAR in older adults. However, to date no study has explored 
this mechanism. 
The sampling adherence was not evaluated in the current study due to lack of reliable 
awakening time data, which must be considered when interpreting these results. This 
may lead to underestimation of the effects on cortisol levels. This is a common problem, 
occurring in the majority of the population-based studies of cortisol. However, if it is not 
strongly associated with smoking, poor sampling adherence does not easily explain the 
observed effects.
In summary, this study, its strengths including a large sample size, a population-based 
background, multiple daily cortisol measurements, longer smoking history, and long-term 
indicators of smoking, suggests that smoking affects daytime cortisol levels and a morning 
rise only in current smokers. Further research should explore to what extent quitting dimin-
ishes chronic consequences of smoking caused by elevated HPA axis activity in smokers.
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AbstrACt
Determinants of the HPA axis functioning are increasingly explored in the population-based 
studies. However, functional tests measuring the negative feedback of the HPA axis cannot 
easily be implemented into large observational studies. Furthermore, high doses of dexa-
methasone often completely suppress the HPA axis in healthy persons. This study aimed 
to detect the effects of the health, lifestyle and sociodemographic factors, psychiatric 
problems and cognitive functions on the negative feedback of the HPA axis using a very 
low-dose (0.25 mg) dexamethasone suppression test (DST).We evaluated the associations 
of several determinants with the saliva cortisol concentrations after dexamethasone intake 
in a confounder-adjusted model also corrected for baseline saliva cortisol concentrations in 
the Rotterdam Study, a large population-based study (N=1822). We found that female sex, 
low income, lack of exercise, instrumental disability and smoking were all independently 
associated with stronger suppression of the HPA axis. Even though there were no linear 
associations between psychiatric measures and cortisol suppression, we found that depres-
sive symptoms and anxiety disorders were more common in persons with non-suppression 
of cortisol. Conversely, psychotropic medication use was related to enhanced suppression 
of cortisol after DST. In this large study, we found that female gender, low socioeconomic 
status and poor health were all related to suppression of the HPA axis. Non-linear associa-
tions were detected between the suppression of the HPA axis and common psychiatric 
disorders in community-dwelling persons.
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iNtroDuCtioN
The HPA axis controls the stress response in the body. To explain the relation between 
diurnal HPA axis functioning and metabolic or stress-related disorders in large cohorts of 
healthy persons, researchers relied on single morning blood measures or used repeated 
saliva sampling. Different measures of the HPA axis such as cortisol awakening response, 
diurnal decline and total cortisol exposure over the day have been assessed using mostly 
saliva 1, 2. More recently, cortisol assessment in hair became possible 3. In contrast, negative 
feedback of the HPA axis is rarely tested in non-clinical studies 4, 5. 
In clinical populations, the negative feedback of the HPA axis is assessed by a DST  test 
requiring oral administration of a dose of dexamethasone. Cortisol secretion after dexa-
methasone intake is typically suppressed. A non-suppression indicates hypercortisolemia 6 
but DST proved very diffi cult to implement in population-based studies.
The DST was originally designed to diagnose patients with Cushing’s Syndrome using 1 
mg or higher doses of dexamethasone with a cut-off value for the plasma cortisol to 
distinguish between non-suppressors and suppressors. A dose of 1 mg in the conventional 
DST fully suppresses the HPA axis in most persons from a non-clinical population 7. Further-
more, the traditional “black and white” outcome defi nition of the negative feedback of 
the HPA axis masks any variation across the continuum of HPA axis reactivity. To this aim, 
cut-points were defi ned for the conventional DST, which relies on plasma cortisol to defi ne 
suppression. In this population-based study, we tested the determinants of the negative 
feedback of the HPA axis with a very low-dose DST (0.25 mg) and assessed the outcome 
(suppression) continuously.
Different determinants of the suppression or non-suppression after DST have been explored 
in the last decades. Over the years, the DST became perhaps the most common func-
tion test in clinically depressed persons 2, 7-10. However, like in other psychiatric disorders 
including post-traumatic stress disorders, anxiety disorders, eating disorders, psychosis, 
personality traits, results of this test are inconsistent 11-19.
The majority of research has been performed in clinical samples with small sample sizes. 
Clinical studies are generally more effi cient to test associations of an exposure and disease 
than population-based cohort studies. However, evaluating background variables is gener-
ally not possible in clinical studies. Often, only few background variables are assessed and 
background variables are related to disease (case) status, which gives rise to selection 
bias. Sometimes if matching is performed in clinical studies to control for the effect of a 
potential confounder. It is not possible to explore the importance of this matching variable 
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for cortisol suppression anymore. Yet, evaluating determinants and potential confounders 
of the negative feedback of the HPA axis is important as numerous psychological and 
physiological stressors can potentially affect this system. Also, knowledge about the pos-
sible confounders of the cortisol suppression is mostly derived from the measurement of 
single cortisol levels or diurnal cortisol secretion. Thus, large population-based studies are 
needed to explore the determinants of the reaction to the DST.  Until now, only one cohort 
explored the determinants (non-psychiatric) of negative feedback of the HPA axis using 
the low-dose DST (0.5 mg dexamethasone) 5. In this study (n=455), a non-suppression of 
cortisol in the low-dose DST was observed in smokers, less active persons and sampling on 
a weekday. However, 86.4% of the study population was below the study-specific cut-off 
for cortisol suppression suggesting that 0.5 mg might be a too high dose to evaluate 
functioning of the HPA axis in the general population. 
Here, we aimed to explore the most important determinants of the negative feedback 
sensitivity of the HPA axis using a very low-dose (0.25 mg dexamethasone) DST in a large 
population-based study evaluating several determinants of health, lifestyle and sociodemo-
graphic factors, psychiatric problems and cognitive functions.
MAteriAls AND MethoDs
The Rotterdam Study is a prospective population-based cohort investigating occurrence 
and determinants of chronic diseases. It has been approved by the institutional review 
board of the Erasmus University Medical Center and by the review board of The Nether-
lands Ministry of Health, Welfare and Sports. All participants provided written informed 
consent after complete description of the Rotterdam Study.
The current study was embedded in the third cohort of the Rotterdam Study (RS-III), which 
was initiated in 2006 and ended in 2008. Details regarding the study design of the RS-III 
are provided elsewhere 20. This cohort included 3,932 subjects aged 45 to 54 years and 
those who had moved to the study district regardless of age. Among those, 3,247 (82.6 
%) participated in the day-curve saliva cortisol collection. We invited these participants 
for the DST and 2076 (63.9 %) agreed to also take a dexamethasone tablet and to collect 
two additional saliva samples. Fifty-eight participants did not report time of sampling of 
a saliva sample, and 130 did not produce enough saliva to analyze cortisol. Further, we 
excluded participants from all analyses if the time difference between the two samples 
deviated more than 3 h from the specified 24h (n=59) (see sensitivity analysis for more 
stringent exclusion criteria based on sampling interval). Finally, we excluded participants, 
who reported the use of systemic corticosteroids (n=7) leaving 1822 participants for the 
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current study. When compared to the participants (n=1822), non-participants who did not 
participated in the DST or were excluded from the analyses (n=1425) were more likely to 
be male (p=.007) and younger (p < .001). 
Assessment of the Dexamethasone suppression test
Participants were asked to collect saliva samples at home using the Salivette sampling de-
vices (Sarstedt, Nümbrecht, Germany). They received detailed oral and written instructions 
with particular emphasis on the importance of compliance to sampling time. Participants 
were instructed to collect the fi rst saliva sample at 8 am, to take the dexamethasone pill at 
11 pm at the same day, and to collect the second saliva sample the next morning at 8 am. 
This approach was chosen as similar sampling times have commonly been used in clinical 
and population-based studies. High early morning levels of cortisol maximize the power to 
detect differences 2. Additionally participants were instructed not to eat and not to brush 
their teeth 15 minutes before collecting the samples and to report the exact time and date 
of the sampling and dexamethasone intake on a form provided by the researchers. More 
detail about the instructions given to the participants are provided in the supplement. 
We kept the Salivettes at -80 ºC until they were sent to the Laboratory of Biopsychology, 
Technical University of Dresden, Germany. Salivary cortisol concentrations were measured 
using a commercial immunoassay with chemiluminescence detection (CLIA; IBL Hamburg, 
Hamburg, Germany). Intra-assay and interassay coeffi cients of variation were less than 6% 
and 9%, respectively (obtained for control samples with average cortisol levels 4.1 nmol/l 
and 29.5 nmol/l). The lower limit of detection was 0.4 nmol/liter. Saliva cortisol levels were 
below the detection limit in one person for the second saliva sample in our sample. A level 
of zero nmol/l was used for this participant. Before dexamethasone intake, none of the 
participants had a cortisol level below the detection limits in the current study sample. 
Assessment of Determinants
We selected possible determinants of cortisol suppression after DST on the basis of previous 
literature and grouped them into four categories similar to the previous epidemiological 
studies: Sociodemographic indicators, health and lifestyle variables, psychiatric problems 
and cognitive functions and sampling variables 1, 5. 
Sociodemographic indicators were age, gender, education and monthly household in-
come. Educational attainment was assessed in seven categories from primary education to 
university level on the basis of the Standard Classifi cation of Education. In this study, we 
grouped education into three categories including low, intermediate and high. Monthly 
net household income was reported in 13 ordinal categories (from < 500 € to ≥ 2900 €) 
and analyzed continuously. 
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We studied body mass index, smoking status, disability, exercise, diabetes mellitus and 
hypertension as indicators of health and lifestyle. Height (meters) and weight (kilograms) 
were measured and body mass index was calculated as kg/m2. Smoking status was coded 
in three categories as never, former, and current smoker. Different dimensions of disability 
were evaluated using Activities of Daily Living (ADL) from the Stanford Health Assessment 
Questionnaire 21 and Instrumental Activities of Daily Living (iADL) 22 scales. We used a pre-
defined cut-off ADL score of 0.5 to define a mild or severe disability 23. A cut-off score of 
0.23, which is one standard deviation of the mean iADL score was used to define persons 
with instrumental disability. Exercise was evaluated using a single item from a questionnaire 
that was prepared by researchers evaluating sport habits on a regular basis. Diabetes mel-
litus was diagnosed if participants were on antidiabetic medication or if their fasting blood 
glucose concentrations were 200 mg/dL or higher. Systolic and diastolic blood pressures 
were measured twice in the resting state with a random-zero sphygmomanometer and the 
mean of two consecutive measurements was calculated. Hypertension was defined as a 
systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg or the use 
of antihypertensive medication. 
We examined general cognitive functions, clinically relevant depressive symptoms, depres-
sive disorders, anxiety disorders, psychotic experiences, and psychotropic medication as 
psychiatric variables. General cognitive functions were measured with the Mini–Mental 
State Examination (MMSE) 24 and a g-factor. This g-factor was derived from principal 
component analysis of processing speed, executive function, verbal fluency, verbal recall 
and recognition, visuospatial ability and fine motor skills 25. Persons with an MMSE score 
of less than 24 were categorized as cognitively impaired. Depressive symptoms were evalu-
ated with the Center for Epidemiological Studies-Depression (CES-D) scale and a cut-off 
of 16 was used to detect participants with clinically relevant depressive symptoms 26, 27. All 
participants with clinically relevant depressive symptoms were invited for a semi-structured 
clinical interview, the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 28 to 
detect DSM-IV-TR diagnosis of depressive disorders. These interviews were performed by 
trained clinicians and psychologists in close proximity in time to screening (on average 2 
weeks). Anxiety disorders were diagnosed with an adapted version of the Munich version 
of the Composite International Diagnostic Interview (M-CIDI) 29, 30. All DSM-IV based anxiety 
disorders (except obsessive-compulsive disorder and post-traumatic stress disorder) were 
assessed and studied as a categorical variable. Psychotic experiences were evaluated with 
the Community Assessment of Psychic Experiences (CAPE)-positive experiences scale (20 
self-reported items) 31, 32. Each item assesses frequency and distress related to the psychotic 
experience. Data on psychotropic medication use was obtained from pharmacy records. 
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As sampling variables, we considered cortisol concentrations before dexamethasone intake 
and the day of the sampling. The day of the sampling was categorized as weekday or 
weekend. In addition, all analyses were adjusted for the times of saliva sampling before 
and after dexamethasone intake. 
statistical Analyses
We used the natural-log function to transform the cortisol concentrations after dexa-
methasone intake because of the skewed distribution (Figures A and B in S1 fi le). We 
present effect estimates only for the transformed values. First, we examined the relation 
of the individual determinants with cortisol concentrations after dexamethasone intake 
using linear regression analysis. The basic model was adjusted for age, sex and cortisol 
concentrations assessed the previous day. This adjustment is considered a more reliable 
method than change score (cortisol after- cortisol before) and percentage change ([cortisol 
after- cortisol before / cortisol before]*100) methods. Moreover, a simulation study showed 
that analysis using percentage change has very low statistical power when compared to 
the model in which a post-test value is used as an outcome and a pre-test value is used as 
a confounder. 33, 34. Second, we fi tted a multivariable model in which all determinants used 
in the current study were included in the same model. Because of the well-known effect of 
body weight on the associations of gender and smoking status with cortisol, these analyses 
(both basic and multivariable models) were additionally adjusted for body weight. 
In addition, non-linear associations of psychiatric traits were explored contrasting the high-
est and lowest tenth percentiles versus the middle group. The highest tenth percentile was 
used to defi ne participants with non-suppression and the lowest tenth percentile was used 
to defi ne participants with enhanced suppression. 
All analyses were further adjusted for time of the fi rst and second cortisol samplings.
In addition, we performed sensitivity analyses to further test the possible effect of the 
time interval between the fi rst and second cortisol sampling. We reran the multivariable 
model including only participants who complied fully with a time interval of 24 ± 1 hours 
(n=1632) between the moments of saliva sampling and also including only those with a 
time interval of 24 ± 2 hours (n=1766).
In a supplementary analysis, we tested the associations of the selected variables with the 
baseline cortisol concentrations (i.e., the concentrations before dexamethasone intake) to 
explore the associations with the non-suppressed basal cortisol secretion. These contrast-
ing analyses help to evaluate which fi ndings of the very-low dose dexamethasone test are 
specifi c for cortisol suppression.
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To facilitate the comparison of the effect estimates of the various variables independent 
of the units of variables, we reported the standardized regression coefficients. All deter-
minants had less than 10% of missing values. To enhance the comparability across the re-
sults, we imputed missing values of the determinants using the Expectation-Maximization 
Algorithm. 
SPSS version 20 (SPSS, Inc., Chicago, IL) was used for all analyses. 
results
The participant characteristics are presented in Table 1. The mean age was 57.8 years (stan-
dard deviation [SD] = 6.8 years) and 59.6 % (n=1086) of the study population was female. 
The mean cortisol concentration before dexamethasone intake was 15.6 nmol/L (SD= 10.9) 
and the mean concentration after dexamethasone intake was 7 nmol/L (SD=8.5). Gender 
specific mean cortisol concentrations before and after dexamethasone intake are shown 
in Fig 1.
Table 2 shows the results of the associations between determinants and the negative 
feedback control of cortisol as indicated by cortisol concentrations after the very low-
dose DST adjusted for baseline cortisol concentration. The baseline cortisol concentrations 
table 1. Characteristics of the study population
characteristics
study sample 
N=1822
sociodemographic indicators
Age, years, mean (SD) 57.8 (6.8)
Women, n (%) 1086 (59.6)
Low education, n (%) 183 (10)
Paid job, n (%) 975 (53.5)
Net income, median (range) 11a (1-13)
Married, n (%) 1433 (78.6)
Health & lifestyle variables
Mild/severe disability, n (%) 313 (17.2)
Instrumental disability, n (%) 215 (11.8)
Regular exercise, n (%) 1104 (60.6)
Smoking status, n (%)
Current smoker 377 (20.7)
Former smoker 847 (46.5)
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before dexamethasone intake were substantially and positively associated with cortisol 
concentrations after dexamethasone intake (β= 0.41, p< .001); i.e., high cortisol concen-
trations before dexamethasone intake were related to high cortisol concentrations after 
dexamethasone intake. 
table 1. Characteristics of the study population (continued)
characteristics
study sample 
N=1822
Never smoker 598 (32.8)
Body mass index, kg/m2, mean (SD) 27.7 (4.4)
Diabetes mellitus, n (%) 158 (8.7)
Hypertension, n (%) 901 (49.5)
Psychiatric problems & cognitive functions
Depressive symptom score, mean (SD) 5.7 (7.3)
Clinically relevant depressive symptoms, n (%) 180 (9.9)
Major depressive disorder, yes, n (%) 31 (1.8)
Anxiety disorders, n (%) 148 (8.1)
MMSE score, mean (SD) 28.1 (1.9)
Cognitive impairment, yes, n (%) 37 (2)
The g-factor of the cognitive tests, mean (SD) 0.02 (0.99)
Psychotic experiences (CAPE-positive items) frequency score, mean (SD) 1.1 (0.12)
Psychotropic medication, yes, n (%) 270 (14.9)
sampling variables
Day of the sampling, weekday, n (%) 1784 (97.9)
Cortisol before dexamethasone intake, nmol/L, mean (SD) 15.6 (10.9)
Time of the fi rst sampling, hh:mm, mean (SD) 07:58 (00:44)
Cortisol after dexamethasone intake, nmol/L, mean (SD) 7.0 (8.5)
Time of the second sampling, hh:mm, mean (SD) 07:53 (00:37)
Notes: Imputed values are presented.
Abbreviations: MMSE, Mini Mental State Examination; CAPE, The Community Assessment of Psychic 
Experience
a 11 represents monthly household income between 2100-2500 Euro.
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Fig 1. Cortisol concentrations before and after dexamethasone intake
Cortisol concentrations were significantly lower after dexamethasone intake in both men (p< .001) and 
in women (p< .001). The difference in cortisol concentrations before dexamethasone intake between 
women and men were not significantly different (p= .23). In contrast, there was a significant difference 
in cortisol concentrations after dexamethasone intake between women and men (p< .001). 
Cortisol suppression after dexamethasone intake was higher in women when compared to 
men (β= -0.16, p< .001). As women were lighter than men (74.38 kg, SD= 13.77 vs. 88.12 
kg, SD= 13.4), we corrected the basic and mutually adjusted models for body weight. 
However, the gender difference in cortisol levels remained significant (results not shown). 
Older age was also associated with stronger cortisol suppression after dexamethasone 
intake (β= -0.05, p= .017), but this association was not significant in the multivariable 
model in which several health-related variables were included. Low income was related 
to stronger cortisol suppression after very low-dose DST in the multivariable model (β= 
0.06, p= .020). Indicators of poor health such as instrumental disability (β= -0.07, p= 
.002), lack of exercise (β= -0.05, p= .019) and smoking (β= -0.07, p= .002) were all re-
lated to increased negative feedback control of cortisol in the multivariable models. To 
eliminate the possible effect of weight on the association of smoking status and cortisol 
suppression, we adjusted the basic and mutually adjusted models for weight instead of 
BMI; results remained significant (results not shown). Poor global cognition function (β= 
0.07, p= .01) was related to stronger cortisol suppression after dexamethasone intake in 
the basic model. However, this association was not significant in the multivariable model. 
Use of psychotropic medications was related to enhanced cortisol suppression following 
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dexamethasone intake in the age- and gender adjusted model (β= 0.04, p= .05). This 
association disappeared after adjustment in the multivariable model. Clinically relevant de-
pressive symptoms, depressive disorders, anxiety disorders, psychotic experiences were not 
related to the negative feedback control of cortisol in any of the models. To test non-linear 
associations of psychiatric traits with cortisol suppression, we defi ned non-suppression and 
enhanced cortisol suppression patterns. Depressive symptom scores (OR= 1.02, p= .03), 
clinically relevant depressive symptoms (OR= 1.93, p= .01) and anxiety disorders (OR= 2.42, 
p= 0.001) were related to non-suppression. In contrast, psychotropic medication use was 
related to enhanced cortisol suppression (OR= 2.08, p< .001) (Table B in the supplement).
The multivariate model explained 22% of the variance (F (18, 1803)= 29.46, p< .001). 
Adjustment for time of sampling did not change the results in any of the models (data 
not shown). Day of the sampling was not associated with cortisol suppression after dexa-
methasone intake. 
To contrast the results with the determinants of basal cortisol secretion, we also examined 
the relation of these variables with cortisol concentration before dexamethasone intake. 
In this analysis, a different pattern of associations emerged: instrumental disability, BMI 
and cognition were all related to basal cortisol concentrations (Table A in the supplement). 
However, sex, smoking, low income and lack of exercise were not associated with basal 
cortisol levels. In summary, only instrumental disability determined both the degree of 
cortisol suppression and basal cortisol concentrations.
The sensitivity analyses excluding poor self-reported compliers suggests that excluding 
people with poor compliance to the DST protocol did not change the effect estimates 
meaningfully (Figure C in the supplement.). 
DisCussioN
In this large population-based study, we found that female sex, low income, lack of ex-
ercise, instrumental disability and smoking were all associated with stronger suppression 
of the HPA axis as determined by lower cortisol concentrations after a very low-dose DST. 
We observed that women had stronger suppression of the HPA axis than men. Our result 
is consistent with a previous report in which an increased negative feedback control of 
cortisol was found in women without psychopathology 5. This gender difference might be 
related to circulating gonadal steroids in women. The mechanisms are not well understood; 
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it is known that high concentrations of estradiol may alter the negative feedback control 
of cortisol leading to high cortisol levels 35. In contrast, a decrease in estradiol levels during 
the menopause, as probably experienced by the women in our study (mean age of 57.8 
years), may cause stronger suppression of the HPA axis 36, 37. The gender difference might 
also results from weight differences as, on average, women are lighter than men. This dif-
ference could explain a greater effect of dexamethasone in lean people (i.e. women in our 
study) leading to more cortisol suppression. However, our results did not change when we 
adjusted for body weight. Low income, an indicator of low SES, was also associated with 
stronger suppression of the HPA axis. It is known that ongoing financial strain may give rise 
to chronic stress 38 which has repeatedly been linked to stronger suppression of the HPA 
axis. Low income has previously been associated with high 39-41 and low cortisol concentra-
tions in studies with single time-point cortisol sampling 42. However, our results cannot be 
compared straightforwardly with the findings of these studies, because income was not 
tested in relation to the negative feedback of the HPA axis in the general population. 
Health and lifestyle variables including physical disability, lack of exercise, and smoking 
were associated with increased negative feedback sensitivity. Physical activity is considered 
as a direct stimulator of the HPA axis 43. In a previous population-based study, however, 
physical activity as measured by metabolic equivalent (MET) of the number of calories 
expended per minute in an activity and cortisol level after dexamethasone intake were 
not related. In the same study, less MET was related with lower cortisol suppression ratio 
indicating a non-suppression 5. In the current study, the questions on physical activity ad-
dressed whether a person performed at least one sport activity on a regular basis. Like 
in most measures, a positive answer indicates physical activity and fitness but may also 
reflect general health. Good health is a prerequisite for sports participation and this may 
contribute to the inconsistency between two studies.
Smoking has been associated with a hyperactive HPA axis in previous population-based 
studies 5, 44, 45, although habitual smokers have low basal cortisol concentrations. Habitual 
smokers develop desensitization to nicotine exposure at the acetylcholinergic receptor 
level. Unless the nicotine exceeds a certain threshold, the HPA axis may not be activated at 
the hypothalamic level, which may lead to a hyper-suppression of the HPA axis in habitual 
smokers in line with our observation 46. Additionally, it was shown that habitual smokers 
have an attenuated response to the stress, which might be due to the stronger suppression 
of the HPA axis 46, 47.  As mentioned previously, body weight may affect the pharmacody-
namics of dexamethasone. Smokers are generally leaner than non-smokers and difference 
in weight might affect the association between smoking status and cortisol suppression. 
However, our results remained essentially unchanged when the analysis was adjusted for 
weight.
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None of the characteristics associated with the HPA axis suppression showed any associa-
tion with morning cortisol levels alone, except instrumental disability. This suggests that 
the degree of cortisol suppression after the pharmacological stimulation cannot be inferred 
from basal cortisol levels. 
Cognitive functions were related to the negative feedback of the HPA axis.  Poor global 
cognitive functioning as assessed with the g-factor was related to low cortisol levels after 
dexamethasone intake at the age- and gender-adjusted model. However, this association 
was not signifi cant in the multivariable model, in which analyses were adjusted for physical 
health and mental health items. Still, it is important to consider global cognitive functions 
as a possible determinant of the negative feedback control of the HPA axis in the general 
population. Also, instrumental disability, as an early indicator of cognitive problems 48, was 
associated with low cortisol levels after dexamethasone intake. Instrumental activities of 
daily living is a measure of the skills required to live independently and perform activities 
which are more complicated and higher-level tasks than in ADL such as shopping, managing 
fi nances, answering the telephone, preparing meals, or using transportation 49. Disability 
in iADL often refl ects severity of chronic, disabling diseases and is associated to decreased 
quality of life and disturbed social life 50, 51. Moreover, iADL is disturbed earlier than ADL in 
people with cognitive problems 52 and it is used as a proxy of cognitive functioning. Further 
studies are needed to explore cognition in more detail in DST studies. 
Symptoms of depression and major depressive disorders were not related to basal cortisol 
or suppression in linear models. Given the extensive evidence from clinical research on 
the relation between clinical depression and DST, there is little doubt that a certain per-
centage of depressed patients show non-suppression in the DST 53. Results of the studies 
in outpatients or in the general population, however, vary largely 53-55. In our study, we 
evaluated depressive symptoms in the general population, which may differ from the clini-
cal populations in terms of severity of the disorder and socio-economical characteristics. 
Either, the depressive symptoms observed in this population have too little impact on HPA 
axis regulation, or the association is not uniform, i.e., depressive symptoms or disorders in 
some patients are related to a stronger and in others to less suppression of the HPA axis; 
this is possibly explained by subtypes of depression. Also, there is possibly a non-linear 
association between depression and the extremes of HPA axis functioning in the general 
population, which explains inconsistent results 56-58. This is supported by an association 
of depressive symptoms with non-suppression of the HPA axis by very low doses of dexa-
methasone in the absence of an association along the continuum of suppression.  Such a 
non-linear pattern was not observed for MDD most likely this was due to the small sample 
of persons with clinical depression. 
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Similarly, previous research on anxiety disorders and the negative feedback of the HPA 
axis provided conflicting findings, such as non-suppression 59, 60 and suppression 61, 62 in 
different anxiety disorders. These inconsistencies in the literature could stem from differ-
ent physiological features of individual anxiety disorders, chronicity of the disorders and 
comorbid psychiatric diseases, mainly depressive disorders 62. Similar to depression, there 
was a non-linear association between anxiety and the negative feedback control of the 
HPA axis. In our study, we found that having an anxiety disorder was related to the non-
suppression of the HPA axis after dexamethasone intake. HPA axis abnormalities are also 
seen in psychotic patients. A stronger suppression of the HPA axis after dexamethasone 
intake has been reported in patients with psychosis 15. In the current study, we assessed 
psychotic experiences indicating a very mild form of psychosis. Research exploring the 
association between the HPA axis functioning and psychotic experiences is very limited and 
is restricted to assessments of cortisol levels or stress reactivity rather than the negative 
feedback control of the HPA axis 63. In the current study, we did not detect any associations 
between psychotic experiences and cortisol levels after dexamethasone intake.  
In the main analyses, we did not find any associations between psychotropic medications 
and the cortisol levels after dexamethasone intake. However, psychotropic medication use 
was related to the enhanced suppression of cortisol after dexamethasone intake. Both an-
tidepressants and antipsychotics have been related to increased cortisol suppression after 
dexamethasone intake previously 15, 64, 65 yet the underlying mechanisms remain unclear. 
Our study had several strengths. First, this study had a large sample size, which is not 
common in studies using an interventional diagnostic test. Second, the population-based 
design of the current study increases the external validity of the results. Third, the very 
low-dose DST in this population-based study allowed us to detect subtle changes, which 
cannot be easily detected with a high dose DST in healthy people 7. Fourth, the large 
sample size and extensive data collection of the study allowed us to evaluate several 
variables and determine which are the strongest predictors of the cortisol response after 
dexamethasone intake. Some limitations, however, should be considered. First, when used 
in outpatients or in the general population, the DST can suffer from the noncompliance to 
the dexamethasone protocol. Yet, noncompliance to dexamethasone intake was not very 
frequent in studies monitoring compliance, not even if participants with psychiatric disor-
ders were included 5, 66. Also, compliance in reporting the exact time of sampling could be 
a problem in the current study, as we did not use a saliva collection device recording time 
of sampling automatically. However, we instructed our participants only to return the saliva 
samples if they had taken the dexamethasone. We also emphasized the importance of 
recording the exact time of sampling. Participants were encouraged to report the true time 
of sampling to allow us to calculate the deviations from the planned times. As an indicator 
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of compliance, the time interval between the fi rst and second cortisol sampling was used in 
the sensitivity analyses. We detected no difference between compliers and non-compliers 
(according to an arbitrary defi nition of compliance) and therefore presented the results of 
the whole group to minimize selection bias. However, our results might suffer from residual 
information bias if noncompliance was not measured well. Second, our results cannot be 
generalized to the clinical psychiatric populations as coping styles, perceived stress and SES 
determinants may differ largely between clinical cohorts and general population. Third, 
we did not evaluate trauma history or PTSD, which might be an important determinant to 
evaluate 16-19. However, the prevalence of PTSD is low. Moreover, obtaining a valid trauma 
history in older persons is challenging in the general population. Finally, testing non-linear 
associations with centiles increases the risk of type I error due to multiple testing. At the 
same time, it may lead to small subgroups, which reduce the statistical power Indeed, the 
lack of an association between MDD and non-suppression can most likely be attributed to 
the small sample size of persons with MDD in the current study.
In this large population-based study, we found a consistent pattern of increased negative 
feedback control of cortisol using the very low-dose DST in females, smokers, less active 
persons, and those with low income and instrumental disability. In contrast, clinical and 
subclinical psychiatric and cognitive conditions were less important determinants than 
gender, low socioeconomic status and poor health. Prospective studies are needed to test 
to what extent increased suppression of cortisol is related to disease.  
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sUPPLemeNtAry text 
instructions of saliva sampling
Participants were instructed about the procedure. A detailed explanation of the reasoning 
of the test was given. Also, sampling times and time of dexamethasone intake were detailed 
and the importance of recording the exact time was emphasized. We informed participants 
about fasting and not brushing their teeth for 15 minutes before saliva sampling. 
Participants were trained about using saliva-sampling devices, collecting saliva, storing 
them until the samples were collected. A dexamethasone pill was shown to the partici-
pants at the study center. 
They were instructed to make an appointment as soon as they finish the procedure. 
Samples were either brought by participants or were collected by the study centre staff. 
Figure A. Distribution of cortisol levels before dexamethasone intake (x-axis represents categories of 
cortisol values and y-axis represents percentage of people within the cortisol range)
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Figure B. Distribution of cortisol levels after dexamethasone intake (x-axis represents categories of cor-
tisol values and y-axis represents percentage of people within the cortisol range)
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Figure c. Effect of compliance to saliva cortisol sampling on the association of different determinants 
with cortisol suppression after dexamethasone intake. Regression coefficients and the confidence inter-
vals of the associations between determinants and cortisol concentrations after dexamethasone intake 
in people with a time interval of 24 ± 1 hours (n=1632) between cortisol samplings and in people with 
a time interval of 24 ± 2 hours (n=1766). These estimates derived from the mutually adjusted model.
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table A. Relations of determinants with cortisol concentrations before dexamethasone intake
cortisol concentration before dexamethasone 
intake 
mutually adjusted model
sociodemographic indicators β B 95% ci p
Age (years) 0.04 0.004 -0.001; 0.01 .14
Sex (0=male, 1=female) -0.03 -0.04 -0.10; 0.03 .25
Education
Low -0.02 -0.04 -0.16; 0.08 .54
Intermediate -0.04 -0.05 -0.13; 0.02 .17
High (reference)
Net income (ranked 1 to 13) -0.002 -0.01 -0.02: 0.01 .66
Health & lifestyle variables
Mild/severe disability (0=no, 1=yes) -0.04 -0.07 -0.16; 0.01 .09
Instrumental disability (0=no, 1=yes) -0.06 -0.12 -0.22; -0.02 .02
Regular exercise (0=yes, 1=no) -0.04 -0.07 -0.12; 0.004 .07
Smoking
Never smoker (reference)
Former smoker 0.02 0.03 -0.04; 0.09 .46
Current smoker -0.02 -0.04 -0.12; 0.05 .42
Body mass index (kg /m2) -0.09 -0.01 -0.02; -0.01 <.001
Diabetes mellitus (0=no, 1=yes) 0.01 0.03 -0.08; 0.14 .54
Hypertension (0=no, 1=yes) -0.02 -0.02 -0.09; 0.04 .51
Psychiatric problems & cognitive functions
Depressive symptom score -0.02 -0.002 -0.01; 0.003 .50
Clinically relevant depressive symptoms 
(0=no, 1=yes)
 -0.01  -0.03 -0.14; 0.08 .62
Major depressive disorder (0=no, 1=yes) 0.04 0.18 -0.07; 0.42 .16
Anxiety disorders (0=no, 1=yes)  -0.01  -0.02 -0.14; 0.10 .75
Mini Mental State Examination score 0.07 0.03 0.01; 0.04 .002
Cognitive impairment (0=no, 1=yes) -0.06 -0.26 0.47; -0.04 .02
The g-factor of the cognitive tests 0.06 0.04 0.003; 0.08 .04
Psychotic experiences (CAPE-positive items) 
frequency score
-0.06 -0.30 -0.65; 0.05 .09
Psychotropic medications (0=no, 1=yes) -0.04 -0.08 -0.17; 0.01 .08
sampling variables
Day of the sampling 
(0=weekend, 1=weekday)
0.00 0.00 -0.21; 0.21 .99
Time of the sampling -0.00 -0.11 -0.00; -0.00 <0.001
Abbreviations: β, standardized beta; B, unstandardized beta; CI, Confi dence Interval of the unstan-
dardized beta; MMSE, Mini Mental State Examination; CAPE, The Community Assessment of Psychic 
Experience
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table B. Relations of determinants with cortisol suppression categories
Non-suppression
n=182
enhanced suppression
n=183
or 95 % ci p or 95 % ci p
Depressive symptom score 1.02 1.002; 1.05 .03 1.002 0.98;1.02 .85
Clinically relevant depressive symptoms* 1.93 1.18; 3.17 .01 1.05 0.63; 1.74 .86
Major depressive disorder* 1.51 0.50; 4.52 .46 0.61 0.14; 2.68 .51
Anxiety disorders* 2.42 1.46; 4.00 .001 0.72 0.39; 1.34 .30
Mini Mental State Examination score 1.05 0.95; 1.17 .35 0.98 0.91; 1.05 .52
Cognitive impairment* 1.51 0.44; 5.16 .51 1.45 0.57; 3.67 .43
The g-factor of the cognitive tests 0.97 0.79; 1.19 .76 0.87 0.72; 1.04 .13
Psychotic experiences (CAPE-positive items) 
frequency score
1.16 0.19; 7.13 .87 1.59 0.28; 9.01 .60
Psychotropic medications* 1.55 0.99; 2.45 .06 2.08 1.43; 3.02 <.001
*0=no, 1=yes
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 chapter 2.3
Genome wide association identiﬁ es common variants 
at the serPiNA6/serPiNA1 locus inﬂ uencing plasma 
cortisol and corticosteroid binding globulin.
Jennifer L Bolton, Caroline Hayward, Nese Direk, John G Lewis, et al.
PLoS Genetics. 2014 Jul;10(7):e1004474. PubMed PMID: 25010111.
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AbstrACt
Variation in plasma levels of cortisol, an essential hormone in the stress response, is associ-
ated in population-based studies with cardio-metabolic, inflammatory and neuro-cognitive 
traits and diseases. Heritability of plasma cortisol is estimated at 30 - 60% but no common 
genetic contribution has been identified. The CORtisol NETwork (CORNET) consortium 
undertook genome-wide association meta-analysis for plasma cortisol in 12,597 Caucasian 
participants, replicated in 2,795 participants. The results indicate that <1% of variance 
in plasma cortisol is accounted for by genetic variation in a single region of chromosome 
14. This locus spans SERPINA6, encoding corticosteroid binding globulin (CBG, the major 
cortisol-binding protein in plasma), and SERPINA1, encoding a1-antitrypsin (which inhibits 
cleavage of the reactive centre loop that releases cortisol from CBG). Three partially inde-
pendent signals were identified within the region, represented by common SNPs; detailed 
biochemical investigation in a nested sub-cohort showed all these SNPs were associated 
with variation in total cortisol binding activity in plasma, but some variants influenced total 
CBG concentrations while the top hit (rs12589136) influenced the immunoreactivity of 
the reactive centre loop of CBG. Exome chip and 1000 Genomes imputation analysis of 
this locus in the CROATIA-Korcula cohort identified missense mutations in SERPINA6 and 
SERPINA1 that did not account for the effects of common variants. These findings reveal 
a novel common genetic source of variation in binding of cortisol by CBG, and reinforce 
the key role of CBG in determining plasma cortisol levels. In turn this genetic variation may 
contribute to cortisol-associated degenerative diseases. 
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iNtroDuCtioN 
The adrenal steroid hormone cortisol plays a vital role in adaptation to environmental 
stress. In response to stressors such as starvation, infection or injury, cortisol secretion is 
elevated by activation of the HPA axis. Cortisol acts predominantly through glucocorticoid 
receptors to induce a wide range of physiological responses, including liberating fuel (by 
facilitating gluconeogenesis and lipolysis), maintaining cardiovascular homeostasis (by 
inducing sodium retention and vasoconstriction), altering mood and memory (in favour 
of focusing on ‘fi ght or fl ight’ responses), and acting as a ‘brake’ on the innate immune 
response (preventing bystander damage from unrestrained infl ammation)1. Chronic eleva-
tions in cortisol, however, may be maladaptive, as exemplifi ed in patients with tumours of 
the pituitary or adrenal gland causing Cushing’s syndrome; here, elevated plasma cortisol is 
responsible for obesity, type 2 diabetes, hypertension, dyslipidaemia, depression, memory 
loss, impaired wound healing, osteoporosis, myopathy, and many other features.
Epidemiological data suggest that subtle activation of the HPA axis associates with many of 
these traits within the population, in people who do not harbour the tumours which cause 
overt Cushing’s syndrome. In these studies higher plasma cortisol concentration, measured 
in the morning, provided a robust marker of the activation of the HPA axis which accom-
panies high blood pressure, hyperglycaemia and dyslipidaemia2-5, age-associated cognitive 
dysfunction6 , and low mood7 . Conversely, lower cortisol associates with immunological 
abnormalities8 , post-traumatic stress disorder (PTSD)9, and obesity1  (the inverse associa-
tion with obesity is likely due to increased metabolic clearance of cortisol and confounds 
the positive association of cortisol with other cardiovascular risk factors, explaining some 
inconsistencies in the associations of cortisol with ‘metabolic syndrome’ 1). Mechanisms 
underlying these associations remain uncertain, with most investigators suggesting ab-
normal central control of the HPA axis1, 10, 11. A high proportion of cortisol in plasma is 
protein bound, mostly to corticosteroid binding globulin (CBG). Although variations in 
total CBG concentrations have been associated with features of metabolic syndrome12, 13, 
this does not account entirely for associations of total plasma cortisol with other quantita-
tive traits5, 14, 15.
Morning plasma cortisol has a heritability of 30 – 60% 16-18 . Identifying genetic variants 
which contribute to variation in morning cortisol values could provide key insights into the 
mechanism of HPA axis activation associated with common quantitative traits, and an op-
portunity to dissect causality using Mendelian randomisation19 . Attempts to identify these 
genetic variants to date have been limited to small candidate gene studies18 . We therefore 
established the CORtisol NETwork (CORNET) consortium with the initial aim of identifying 
genetic determinants of inter-individual variation in HPA axis function.
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results
Genome-wide Association meta-analysis
We conducted a discovery meta-analysis of genome-wide association studies (GWAMA) of 
morning plasma cortisol levels, investigating ∼2.5 M SNPs in 12,597 men and women, aged 
14–102 years, of European origin (Table S1 for participant characteristics). There was very 
little inflation of test statistics (λGC = 1.005, Table S2). The −log10(p) values by chromosome 
for age- and sex-adjusted cortisol z-scores are shown in Figure 1A. A quantile–quantile 
plot (Figure 1B) showed marked departure from the null for SNPs with low p values, listed 
in Table S3. Analysis of data for men and women separately showed no sex-specific effects 
(data not shown). The results were similar between all multivariable adjusted models, and 
whether or not time of sampling was included as a covariate. The results reported are 
therefore adjusted only for age and sex.
Figure 1. Meta-analysis of genome wide association studies for morning plasma cortisol
A  Manhattan plot of –lop10(p) values by chromosome. The red horizontal line indicates genome-wide 
significance (p <5x10-8) and the blue horizontal line indicates moderate significance (p< 5x10-5). The 
lead SNP rs12589136 (chr14:94,793,686; b37) in red is genome-wide significant. SNPs within ± 50 
kb of cortisol-related candidate genes (listed in Table S6) are highlighted in colours.
B  Quantile-quantile plot of –log10(p), comparing the distribution of observed –log10(p)-values and that 
expected by chance
There was strong evidence for associations between plasma cortisol and genetic variation 
found at chromosome 14q32. In an additive genetic model, the lead SNP rs12589136 
reported a per minor allele effect of 0.10 cortisol z-score (95% CI 0.07, 0.13; p= 
4.0×10−12 after genomic control). The effect allele frequency was 0.22 and this variation 
explained 0.13% of the morning plasma cortisol variance. A forest plot showed consistent 
directional effects in all studies, with the T allele at rs12589136 associated with higher 
morning plasma cortisol (Figure 2). Only minimal heterogeneity was observed between 
studies (I2 = 0.18).
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Figure 2. Forest plot of association of morning plasma cortisol with rs12589136
Plot shows association as beta values with 95% CI for morning plasma cortisol z-scores for rs12589136 
(T allele) in discovery cohorts (blue) and meta-analysis (red).
A recombination boundary containing SERPINA6 and SERPINA1 was found to contain all 
variants at this locus contributing to association with plasma cortisol (Figure 3). A clumping 
procedure20 identifi ed rs12589136 (4 kb upstream of SERPINA6), rs11621961 (1 kb down-
stream of SERPINA6) and rs2749527 (30 kb upstream of SERPINA6) as markers representing 
genome-wide signifi cant signals in this region. Individually, the beta (for effect on cortisol 
z-score, 95% CI) for minor (all T) alleles at rs12589136, rs2749527, and rs11621961 were 
0.10 (0.07, 0.13; p = 3.3×10−12), −0.08 (−0.11, −0.06; p = 5.2×10−11), and −0.08 (−0.10, 
−0.05; p = 4.0×10−8); joint analysis showed these SNPs have partially independent effects, 
with beta (95% CI) 0.07 (0.04, 0.10; p= 3.1×10−5), −0.04 (−0.07, −0.01; p = 0.012), and 
−0.03 (−0.07,0.00; p = 0.037), respectively.
The SERPINA6 gene encodes corticosteroid binding globulin (CBG). The neighbouring 
(upstream) gene, SERPINA1, encodes a1-antitrypsin, the inhibitor of neutrophil elastase 
which cleaves and inactivates CBG21.
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Figure 3. Regional associations surrounding lead SNP rs12589136 in genome-wide meta- analysis of 
morning plasma cortisol.
Regional plot shows –log10(p) values of all SNPs, and degree of correlation between all SNPs and lead 
SNP rs12589136. SNPs with lower P values span SERPINA6 and SERPINA1 genes within a recombination 
boundary
conditional Analysis
A quantile-quantile plot after removal of the SERPINA6/SERPINA1 region (chr14: 
94,768,859–94,843,565; Genome Reference Consortium build 37) showed no evident in-
flation of test statistics (not shown). Conditional analyses adjusting for each of the partially 
independent genome-wide significant variants (rs12589136, rs11621961, rs2749527) in 
a subset of the meta-analysis population reduced the significance of all other SNPs to p 
>1×10−5 for an association with plasma cortisol.
Gene-centric Associations
We used a gene-centric approach to analyse the combined effect of all SNPs within a 
gene, rather than individual SNP associations, using VEGAS22 . This produced a gene-
based test statistic from meta-analysis results, allowing identification of genes contain-
ing multiple SNPs that individually did not reach genome-wide significance (Table S4). 
Only SERPINA6 and SERPINA1 were identified as gene-wide significant (p< 3×10−6); both 
included rs12589136 in the gene boundary.
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candidate Gene Analysis
A list of 61 candidate genes thought likely to infl uence plasma cortisol was collated by a 
panel of experts. A Manhattan plot of the −log10(p) values highlighted for SNPs in these 
candidate genes showed that only SERPINA6 reached genome-wide signifi cance (Figure 
1A). Using gene-based p-values from VEGAS, after adjusting for multiple testing, only SER-
PINA6 was associated with plasma cortisol (Table S5). SERPINA1 was not included in the 
candidate gene list.
replication
In 2,795 participants in additional cohort studies, the association with plasma cortisol 
was replicated for the lead SNP rs12589136 (p = 0.0002), rs11621961 (p =  0.003) and 
rs2749529 (used as proxy for rs2749527, p = 0.019) (Table 1; Table S1 for participant 
characteristics; Table S6 for results in each cohort).
Functional consequences of Genetic Variation in the serPiNA6/serPiNA1 
region
We explored the associations between rs12589136, rs11621961, rs2749527 with cortisol 
and CBG phenotypes in more detail in 316 subjects from the CROATIA-Korcula cohort 
(Table 2). Together these three SNPs explained 0.54% of the variance in total plasma 
cortisol in CROATIA-Korcula. However, there were distinct patterns of association of ‘high 
cortisol’ alleles with CBG. After adjusting for age and sex, although all three variants were 
associated with differences in total cortisol binding activity, measured by the binding of 
[3H]-cortisol, there were different associations with CBG immunoreactivity. The T allele 
at rs2749527 was associated with higher ‘total’ CBG concentration by radioimmunoas-
say, and there were similar, but weaker associations of total CBG immunoreactivity with 
variation at rs11621961. Differences in calculated free plasma cortisol refl ected these 
differences in total CBG immunoreactivity, which is used in the calculation of free cortisol. 
In contrast, however, the minor (T) allele at rs12589136 was not associated with ‘total’ 
CBG immunoreactivity but was strongly associated with the proportion of CBG bound by 
a monoclonal antibody against an epitope in the reactive centre loop of CBG23 . None of 
these SNPs representing signals in the SERPINA6/SERPINA1 region was associated with 
a1-antitrypsin concentrations in blood. However, a1-antitrypsin levels were negatively 
correlated with plasma total cortisol (beta −0.17 (95% CI −0.28, −0.06); p =  0.002) and 
calculated free cortisol (beta −0.13 (95% CI −0.24, −0.02); p = 0.021), although they did 
not correlate with ratio of intact/total CBG (beta 0.02 (95% CI −0.09, 0.13; p= 0.715).
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We investigated exome chip data for this locus in all CROATIA-Korcula participants to 
identify non-synonymous variants in the SERPINA6/SERPINA1 region associated with 
plasma cortisol. From 34 variants on the exome chip in this region (chr14:94,770,585–
94,857,029, build 37), 9 were polymorphic in this sample (Table S7) but only two were 
associated with plasma cortisol: rs113418909 in SERPINA6 (Leu115His in CBG, previously 
reported as the Leuven mutation associated with low total cortisol24); and rs28931570 
in SERPINA1 (Arg63Cys in a1-antitrypsin, not recognised as a disease-causing variant25). 
We also analysed 735 additional SNPs in the same region imputed from 1000 Genomes 
data in all CROATIA-Korcula participants but did not fi nd any additional SNPs associated 
with plasma cortisol, using a p-value threshold of 0.05/735 = 7×10−5. The two rare variants 
rs113418909 and rs28931570 were in perfect linkage disequilibrium amongst participants 
with detailed biochemical phenotyping performed, so results are reported for rs113418909 
only (Table 2). Prevalence of the Leuven variant in CROATIA-Korcula was higher than ex-
pected (MAF = 0.017, compared with MAF = 0.0046 in dbSNP). After adjusting for age, sex, 
and accounting for kinship, participants who were heterozygote for the Leuven variant 
had lower total cortisol and markedly lower total cortisol binding activity, but normal CBG 
immunoreactivity (Table 2).
After removing subjects with the rare Leuven variant (ie. heterozygotes), rs12589136 re-
mained associated with total cortisol (beta 0.15, 95% CI 0.04, 0.26; p= 0.009), calculated 
free cortisol (0.17, 95%CI 0.02, 0.32; p= 0.031), and the proportion of CBG bound by the 
reactive centre loop antibody (−0.45, 95% CI −0.60−0.29; p = 2.8×10−8).
table 2. Functional consequences of variants in loci signifi cantly associated with morning plasma cortisol 
in GWAMA, and of the Leuven variant, in CROATIA-Korcula
Beta (95%ci) p3
rs11621961
tt ct cc
Total cortisol1 655 (618,694)
[129]
664 (644,685)
[411]
675 (654,696)
[357]
-0.05 (-0.14,0.05) 0.305
Calculated free cortisol 42 (35.0,51)
[56]
47 (42,52)
[126]
50 (46,55)
[136]
-0.14 (-0.28,0.00) 0.049
Measured free cortisol2 14 (11,17)
[27]
14 (11,16)
[70]
13 (10,16)
[67]
0.01 (-0.2,0.22) 0.933
Total CBG 0.90 
(0.82,0.99)[56]
0.90 (0.85,0.94)
[126]
0.96 (0.92,1.01)
[136]
-0.12 (-0.26,0.02) 0.103
Intact/total CBG 0.76 
(0.71,0.80)[56]
0.77 (0.74,0.79)
[125]
0.76 (0.73,0.78)
[136]
0.01 (-0.14,0.15) 0.940
a1-antitrypsin 2.74 
(2.37,3.16)[56]
2.74 (2.51,2.99)
[124]
2.66 (2.43,2.91)
[134]
0.02 (-0.14,0.17) 0.840
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rs12589136
tt Gt GG
Total cortisol1 706 (656,760) 
[53]
681 (657,706)
[302]
655 (638,673)
[540]
0.13 (0.02,0.24) 0.017
Calculated free cortisol 47 (41,54) 
[52]
54 (45,65) 
[47]
46 (42,50) 
[217]
0.13 (-0.01,0.26) 0.073
Measured free cortisol2 13 (11,16) 
[39]
n/a 13 (12,15) 
[125]
0.03 (-0.15,0.2) 0.777
Total CBG 1.01 (0.95,1.07)
[52]
0.91 (0.82,1.02)
[47]
0.91 (0.87,0.95) 
[217]
0.06 (-0.07,0.20) 0.371
Intact/total CBG 0.68 (0.64,0.71)
[52]
0.69 (0.65,0.73)
[47]
0.80 (0.78,0.82) 
[216]
-0.49 (-0.64,-0.34) 9.4x10-11
a1-antitrypsin 2.68 (2.36,3.05)
[51]
2.77 (2.43,3.16)
[47]
2.69 (2.50,2.90) 
[214]
0.06 (-0.09,0.22) 0.421
rs2749527
cc ct tt
Total cortisol1 659 (635,684)
[251]
668 (649,687)
[431]
674 (643,707)
[212]
0.03 (-0.06,0.12) 0.495
Calculated free cortisol 49 (43,55) 
[102]
45 (41,50) 
[123]
48 (42,55) 
[92]
0.02 (-0.11,0.16) 0.717
Measured free cortisol2 16 (14,19) 
[60]
11 (8,15) 
[51]
13 (11,15) 
[53]
-0.11 (-0.29,0.07) 0.246
Total CBG 0.87 (0.82,0.92)
[102]
0.92 (0.87,0.98)
[123]
1.00 (0.96,1.05) 
[92]
0.17 (0.03,0.30) 0.014
Intact/total CBG 0.76 (0.73,0.79)
[102]
0.76 (0.74,0.79)
[122]
0.76 (0.73,0.79) 
[92]
-0.02 (-0.16,0.13) 0.824
a1-antitrypsin 2.58 (2.31,2.88) 
[101]
2.86 (2.62,3.12)
[121]
2.65 (2.38,2.94) 
[91]
0.08 (-0.06,0.23) 0.268
rs113418909 (Leuven)
AA At
Total cortisol 673 (658,688)
[792]
562 (500,631) 
[28]
-0.63 (-1.01,-0.25) 0.001
Calculated free cortisol 48 (45,52) 
[280]
38 (27,52) 
[9]
-0.43 (-1.06,0.20) 0.182
Measured free cortisol2 14 (12,15) 
[147]
13 (8,20) 
[5]
-0.04 (-0.92,0.83) 0.924
Total CBG 0.93 (0.90,0.96) 
[280]
0.94 (0.82,1.07) 
[9]
0.05 (-0.58,0.68) 0.870
Intact/total CBG 0.76 (0.74,0.78) 
[279]
0.82 (0.78,0.87) 
[9]
0.51 (-0.18,1.19) 0.146
a1-antitrypsin 2.67 (2.51,2.84) 
[277]
2.40 (1.91,3.03) 
[9]
-0.12 (-0.83,0.58) 0.732
1Data for total cortisol is from the whole Croatia-Korcula sample, n=898 
2Samples selected for measured free cortisol assay were age and sex matched homozygotes at 
rs12589136
3adjusted for age, sex, and first three principal components, used kinship matrix derived from GWAS 
data 
Data are geometric mean (95% CI) [n]. Cortisol values are nmol/L, CBG micromol/L and a1-antitrypsin 
g/L
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DisCussioN
These results clearly attribute inter-individual differences in morning plasma cortisol 
amongst Europeans to genetic variation within a region on chromosome 14 containing 
the SERPINA6and SERPINA1 genes. The association of this region with plasma cortisol 
was consistent across multiple cohorts and was observed not only in genome-wide 
meta-analysis of individual SNPs, but also in gene-based hypothesis-free analysis, and in a 
candidate gene analysis. Investigation of the functional consequences of genetic variation 
in this region in a genetic isolate population in Croatia indicates that the effects of variation 
at SERPINA6 and SERPINA1on plasma cortisol are likely to be mediated through alterations 
in total cortisol binding by corticosteroid binding globulin (CBG). In part, this is determined 
by differences in total CBG concentrations, and in part in association with a previously 
unrecognised variability in the immunoreactivity of the reactive centre loop of CBG. Since 
the process of CBG cleavage by neutrophil elastase and resultant reconfi guration of the 
reactive centre loop is considered important in the release of bioavailable cortisol within 
target tissues21, 26, this fi nding provides a novel insight into a biological pathway controlling 
cortisol action.
The diverse actions of cortisol, and the striking clinical consequences of glucocorticoid 
excess or defi ciency, have led many investigators to propose a central role for variations in 
cortisol levels in determining common quantitative traits. However, cortisol has not been 
measured as widely in epidemiological cohort studies as many other phenotypes. This may 
refl ect the perceived diffi culty of obtaining samples at a fi xed time of day and in un-stressed 
conditions, to avoid confounding effects. The CORNET consortium had to decline samples 
from many cohorts in which time of sampling was inadequately controlled, and even then 
there was high variability in plasma cortisol. Thus, although the variants we identifi ed in 
the SERPINA6/SERPINA1region of chromosome 14 accounted for <1% of the variance in 
plasma cortisol, this signal may be obscured by substantial unmeasured confounding and 
measurement error and may comprise a considerable component of the estimated 30–60% 
heritability of plasma cortisol16-18 . We identifi ed 3 SNPs with partially independent effects 
on plasma cortisol. There may be a small degree of linkage disequilibrium between these 
SNPs, but they also show different associations with CBG biochemistry, suggesting that 
they represent independent effects. None of these 3 SNPs appears directly to affect CBG 
function; although rs12589136 is close to a consensus estrogen response element, there 
was no gender difference in its association with plasma cortisol.
Previous investigations of the genetic determinants of plasma cortisol18 have been under-
powered candidate gene studies, including some which included a tandem repeat in intron 
1 of SERPINA627, 28 . Interestingly, many of the genetic variants previously associated with 
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cortisol, eg for glucocorticoid1  and mineralocorticoid29, 30 receptors, showed no signal 
whatsoever in the adequately powered GWAMA and candidate gene analysis conducted 
here.
Rare mutations in SERPINA6 have been described which cause absent CBG protein or, more 
often, reduced affinity of CBG for cortisol31-34 . Affected individuals have low total plasma 
cortisol but normal free plasma cortisol. However, they also have abnormal pulsatility of 
plasma cortisol, and non-specific symptoms including fatigue which are unresponsive to 
cortisol supplementation; features which have been attributed to abnormal function of 
CBG in delivering cortisol to target tissues, including in brain regions involved in negative 
feedback regulation of the HPA axis21. Although one of these mutations, A51V, has been 
found to be surprisingly prevalent (MAF>3%) amongst Chinese subjects34, it has not been 
found in non-Asian populations and we did not find Caucasians carrying this mutation 
when tested by exome chip analysis. In cohort studies, plasma CBG concentrations have 
been associated with features of the metabolic syndrome12, 13, 15 and one previous candidate 
gene study with >900 participants showed that SNPs in SERPINA6, including some identi-
fied as being associated with plasma cortisol in this GWAMA, were predictive of somatic 
symptoms35. We found evidence that genetic variation in the SERPINA6/SERPINA1 region 
influences total plasma cortisol not only through changes in total CBG concentrations, but 
also in association with alterations in the immunoreactivity of the reactive centre loop of 
the CBG protein.
Cleavage of the reactive centre loop (RCL) of CBG by neutrophil elastase and inhibition of 
elastase activity by a1-antitrypsin has been recognised for more than 20 years26. However, 
the recent development of monoclonal antibodies which recognise the intact RCL of CBG 
has allowed this process to be studied in vivo for the first time23. Using these tools in 
samples from Croatia-Korcula has provided the novel insight that immunoreactivity of the 
RCL of CBG is variable in the population, and further that this is explained in part by 
genetic variations in the SERPINA6/SERPINA1 region. It remains to be determined whether 
this difference in immunoreactivity of the RCL represents altered susceptibility to CBG 
cleavage. We show that a common variant (rs12589136) associated with impaired RCL 
antibody binding was associated with higher total plasma cortisol and higher cortisol bind-
ing activity. These observations are inconsistent with the interpretation that impaired RCL 
antibody binding represents enhanced RCL cleavage23 , given that cleaved CBG has a lower 
affinity than intact CBG for cortisol binding36. Alternatively, the altered immunoreactivity of 
the RCL epitope may represent resistance to cleavage and hence enhanced cortisol bind-
ing. It is possible that the genetically determined difference in the RCL epitope of CBG is 
associated with impaired negative feedback of the HPA axis due to reduced tissue delivery 
of cortisol by CBG, analogous with findings in CBG knockout mice37. Although we could 
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not confi rm associated elevation in free plasma cortisol concentrations, these measure-
ments are notoriously unreliable, for example being similarly unhelpful in dissecting the 
consequences of CBG defi ciency described above.
We found further evidence for the importance of CBG using exome chips in the genetic 
isolate population of Korcula in Croatia, where we discovered an unusually high prevalence 
of heterozygotes for the Leuven mutation in SERPINA624. These individuals have lower total 
plasma cortisol despite normal total CBG concentrations, and we confi rmed substantial 
reductions in total cortisol binding activity, without any difference in RCL antibody binding. 
The presence of the Leuven variant, however, did not account for the association of the top 
hit SNPs identifi ed by GWAMA with plasma cortisol or CBG RCL antibody binding.
It is possible that a combination of alterations in CBG substrate as well as in neutrophil 
elastase level and/or activity may determine cleavage of CBG and tissue delivery of corti-
sol, especially in local sites of infl ammation21. Intriguingly, we found inverse associations 
between levels of a1-antitrypsin, the inhibitor of neutrophil elastase, and plasma cortisol 
concentrations, consistent with instability of CBG resulting in HPA axis activation as pro-
posed above; however, we could not identify a genetic infl uence on this relationship, or 
confi rm its association with CBG RCL immunoreactivity. Specifi cally, we did not identify 
independent signals for SERPINA6and SERPINA1 in conditional analysis, and the rare vari-
ant Leuven mutation was in linkage disequilibrium with the only rare variant we identifi ed 
in SERPINA1. Recent studies have identifi ed variants in SERPINA1 that are associated with 
coronary artery calcifi cation38 and serum lipid profi le39, the latter represented by rs1303 
which is in linkage disequilibrium with the top hit rs12589136 identifi ed by GWAMA 
(r2 = 0.35). These fi ndings are consistent with variation in the SERPINA6/SERPINA1 locus 
affecting downstream actions of cortisol, but it remains unclear if an interaction exists 
between the variants at these two genes. Mutations in SERPINA1 cause the syndrome of 
a1-antitrypsin defi ciency, but we are not aware of any investigations of CBG or cortisol in 
these patients, and their HPA axis may be disturbed anyway by un-restrained neutrophil-
mediated tissue damage. Rare variants in SERPINA1 (notably rs112635299) have been 
associated with α 1-globulin plasma protein levels, of which a1-antitrypsin is a major 
constituent, using GWAS with 1000 Genomes imputation40. However, in the CROATIA-
Korcula cohort neither rs1303 (Table S7) nor SNPs imputed from 1000 Genomes (including 
rs112635299) were associated with plasma cortisol. More detailed phenotyping amongst 
participants with contrasting genotypes at the SERPINA6/SERPINA1region will be required 
to clarify the basis for altered interaction between the two gene products.
These fi ndings emphasise the biological importance of plasma protein binding for steroid 
hormones, and are analogous to recent fi ndings that a common variant in sex hormone 
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binding globulin contributes to variation in total testosterone levels21, 41. Given the 
consequences of altered binding protein function for steroid volume of distribution and 
clearance, and documented effects on HPA axis function21, this is an important finding 
of itself. However, potentially of greater importance is the novel observation that a key 
protein domain of CBG, the reactive centre loop, is subject to inter-individual differences 
which are influenced by genetic variation and may constitute a novel influence on tissue 
steroid action.
MAteriAls AND MethoDs
Gene Discovery
We performed a meta-analysis of genome-wide association studies of morning plasma cor-
tisol in 12,597 subjects from 11 western European population-based cohorts: CROATIA-Vis 
(n = 885), CROATIA-Korcula (n = 898), CROATIA-Split (n = 493), ORCADES (n = 886), Rotter-
dam Study (n = 2945), NFBC1966 (n = 1195), Helsinki Birth Cohort Study 1934–44 (n = 451), 
ALSPAC (n = 1567), InChianti (n = 1207), PREVEND (n = 1151), and PIVUS (n = 919). Replica-
tion was tested in 2,795 subjects from three independent cohorts: Raine Study (n = 797), 
ET2DS (n = 1,069), and MrOS-Sweden (n = 929). Cortisol was measured by immunoassay 
in blood samples collected from study participants between 0700 and 1100 h. Inclusion 
criteria were adults aged 17 years or older from Caucasian populations; exclusion criteria 
were current glucocorticoid use, pregnant or breast feeding women, and twins (exclusion 
of one). Characteristics of the study populations are presented in Table S1 and details of 
each cohort are provided in Text S1. All participants provided written informed consent 
and studies were approved by local Research Ethics Committees and/or Institutional Review 
Boards.
Association Analysis with morning Plasma cortisol
Each study performed single marker association tests, and study-specific linear regression 
models which used z-scores of log-transformed cortisol, additive SNP effects, and were 
adjusted for age and sex (model 1); age, sex, and smoking (model 2); or age, sex, smoking 
and body mass index (model 3). Imputation of the gene-chip results used the HapMap CEU 
population, build 36. In cohorts with consanguineous populations (ORCADES and Croatia), 
adjustments for principal components in kinship matrices were performed using ProbABEL; 
for other cohorts, Identity-By-Descent coefficients were calculated using PLINK and related 
participants excluded. In the majority of cohorts, participants were only included if blood 
samples had been obtained within a 60 minute time interval, when variations in time 
of sampling were ignored. In a subset of cohorts, samples were obtained over a wider 
time interval (but always in the morning before 11:00 h) and time of blood sampling 
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recorded; for these cohorts, three further models were run as above but also including time 
of sampling, calculated as minutes from fi rst sampling time, as an additional covariate42.
Quality control was carried out on the imputed genome-wide data for all 11 studies prior 
to meta-analysis; this excluded all samples with a minor allele frequency (MAF) <2%, call 
rate <95%, Hardy-Weinberg equilibrium (HWE) <1×10−8 and poor imputation quality 
(MACH R2_HAT< 0.30, IMPUTE PROPER_INFO< 0.60, BEAGLE INFO< 0.30, as appropriate). 
Quantile-quantile (Q-Q) plots and genomic control (lambda) were used to confi rm quality 
control. Sex chromosomes were not analysed.
meta-analysis of Association results
We performed fi xed effects meta-analysis, which used combined allelic effects weighted 
by the inverse of their variance for each of the models using the GWAMA program43. This 
aligned all studies to the same reference allele at each SNP, thus avoiding strand errors, 
and excluded SNPs with obvious input errors (eg. discrepancies in effect allele frequen-
cies). The results from analysis with or without genomic control were nearly identical, as 
expected with GC = 1.005. The genome-wide signifi cance threshold for the meta-analysis 
was p<5×10−8. Percentage variation of cortisol was calculated from meta-analysis results 
as (2*effect allele frequency)*(1-effect allele frequency)*(beta2/sd2). A regional plot was 
generated using LocusZoom44, and heat map using snp.plotter45 in R version 2.15.2. Joint 
analysis of meta-analysis was performed with the GCTA program46.
clumping Analysis
To detect independent top SNPs on the basis of empirical estimates of linkage disequilib-
rium between the SNPs, we used the clumping function as implemented in PLINK20. All 
the SNPs with a p-value<5×10−5 in meta-analysis were used for clumping. We grouped the 
SNPs within 500 kb of the index SNP that have r2 >0.2 with the index SNP.
replication Genotyping and Analysis
Genes identifi ed in the meta-analysis were evaluated in the Raine Study, MrOS-Sweden, 
and Edinburgh type 2 Diabetes Study (ET2DS). Raine Study and MrOS-Sweden had 
GWAS data so we extracted the replication SNP results, and ET2DS was genotyped at 
the Wellcome Trust Clinical Research Facility Genetics Core Laboratory in Edinburgh using 
the OpenArray genotyping platform. rs2749527 failed manufacture for the OpenArray, 
and was replaced with rs2749529 (r2 = 0.905, D′ = 1.0) in all replication cohorts. Genotypic 
association analysis in these studies followed the same methods as those described above 
for the discovery meta-analysis, adjusting for age and sex.
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conditional & sex-specific analysis
We performed meta-analyses of sex-specific GWAS and conditional GWAS in a subset of 
populations, using single marker association tests of z-scores of log-transformed cortisol. 
For the sex-specific analysis, each study adjusted for age in both men (n = 3,546) and 
women (n = 5,956). For the conditional analysis, each study adjusted for age, sex, and each 
of the SERPINA6 loci SNPs rs12589136 (n = 9,308), rs11621961 (n = 7,687), and rs2749527 
(n = 9,307) individually. We then did fixed effects meta-analysis using GWAMA program.
Gene-based Analysis
We used the Versatile Gene-based Association Study (VEGAS) program22 to perform gene-
centric analysis. This used individual SNP p-values derived from the meta-analysis results to 
compute a gene-based p-value. We used two methods: all SNPs within a gene, or a subset 
of the 10% most significant SNPs in each gene boundary. VEGAS accounted for linkage 
disequilibrium between SNPs using the HapMap phase 2 population (CEU). SNPs were 
assigned to ∼18,000 genes based on positions in build 36 (hg18), with gene boundaries of 
±50 kb of the UTR. Bonferroni corrected threshold for gene-wide significance was 3×10−6. 
The overlap of SNPs included in the gene boundaries in our results indicates this is likely to 
be an overly conservative correction factor22.
A list of 61 candidate genes with known biological function in the regulation of cortisol 
was compiled by a panel of experts in the field. All SNPs within and ±50 kb of these genes 
were examined in the GWAMA results, and gene-based p values were inspected in VEGAS 
results.
exome chip and 1000 Genomes imputed Data Analysis
Genotypes for the SERPINA6/SERPINA1 gene region (chr14:94,770,585–94,857,029, build 
37) in the CROATIA-Korcula samples (n = 898) were extracted from an Illumina Exome Chip 
v1 analysis. Genotypes were called in GenomeStudio (Illumina) using the CHARGE Consor-
tium joint calling cluster file (http://www.chargeconsortium.com/main/exomechip)47. 1000 
Genomes imputation was performed using genotypes from Illumina HumanHap370CNV 
after quality control (Individual Call Rate 97%, SNP Call Rate 98%, MAF 0.01, HWE 1×10−6); 
prephasing was performed using ShapeIt v248 and imputation using IMPUTE249 and the 
ALL (Phase 1 integrated release v3, April 2012) reference panel. Associations with plasma 
cortisol were analysed in GenABEL50.
Detailed Biochemical studies
More detailed phenotyping was undertaken in samples from 316 participants in the 
CROATIA-Korcula cohort, comprising 158 age- and sex-matched homozygotes at the top 
hit variant rs12589136 (53 T/T, 106 G/G; however, one T/T sample had insufficient sample 
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for CBG measurement resulting in 52 T/T and 106 G/G). An additional 160 randomly 
selected samples had CBG measured, however two samples failed genotyping resulting in 
an additional 47 T/G and 111 G/G.Total plasma cortisol was measured with a commercial 
radioimmunoassay (MP Biomedicals, UK). Total CBG was also measured in CROATIA-
Korcula samples using a commercial radioimmunoassay (DiaSource, Louvain-la-Neuve, 
Belgium). Total cortisol binding capacity was measured using a ligand-saturation assay, 
with [3H]-cortisol (PerkinElmer Life Sciences, Waltham, MA) as the labelled ligand and 
dextran-coated charcoal to separate the CBG-bound [3H]cortisol, as previously described51. 
a1-antitrypsin was measured with a commercial ELISA (Genway Biotech, San Diego, USA). 
Unbound free plasma cortisol was calculated from measured total plasma cortisol and total 
CBG values using Coolens’ equation52. Free cortisol was also measured by ELISA following 
equilibrium dialysis. Briefl y, dialysis tubing (12–14 kD, Medicell, London, UK) was heated 
to 80C for 30 min in 2% Na bicarbonate and 1 mM EDTA before overnight dialysis of 
plasma into phosphate buffered saline containing 1% gelatin at 37C and measurement 
of dialysed free cortisol by commercial ELISA (Salimetrics Europe Ltd, Newmarket, UK). 
CBG were also measured, as previously described23, by ELISAs using monoclonal antibodies 
12G2 and 9G12. Antibody 9G12 binds to an epitope in the reactive centre loop (RCL), the 
elastase cleavage site on CBG, and has been used to infer intact (uncleaved) CBG, whereas 
antibody 12G2 binds to a distant epitope and measures total (cleaved and uncleaved) CBG.
As CROATIA-Korcula is a population isolate, we used the polygenic and mmscore functions 
in GenABEL50. All regression equations included the fi rst three principal components and 
kinship matrix derived from GWAS data in this population and used z-scores of the traits. 
All variables were normalised using log transformation (cortisol, calculated free cortisol, 
measured free cortisol, CBG, a1-antitrypsin), and reported means are geometric means, 
the ratio of intact/cleaved was normally distributed.
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AbstrACt
Cortisol is an important stress hormone affected by a variety of biological and environ-
mental factors, such as the circadian rhythm, exercise and psychological stress. Cortisol is 
mostly measured using blood or saliva samples. A number of genetic variants have been 
found to contribute to cortisol levels with these methods. While the effects of several 
specific single genetic variants is known, the joint genome-wide contribution to cortisol 
levels is unclear. Our aim was to estimate the amount of cortisol variance explained by 
common single nucleotide polymorphisms, i.e. the SNP heritability, using a variety of cor-
tisol measures, cohorts and analysis approaches. We analyzed morning plasma (n=5,705) 
and saliva levels (n=1,717), as well as diurnal saliva levels (n=1,541), in the Rotterdam 
Study using genomic restricted maximum likelihood estimation. Additionally, linkage dis-
equilibrium score regression was fitted on the results of genome-wide association studies 
(GWAS) performed by the CORNET consortium on morning plasma cortisol (n=12,597) 
and saliva cortisol (n=7,703). No significant SNP heritability was detected for any cortisol 
measure, sample or analysis approach. Point estimates ranged from 0% to 9%. Morn-
ing plasma cortisol in the CORNET cohorts, the sample with the most power, had a 6% 
[95%CI: 0-13%] SNP heritability. The results consistently suggest a low SNP heritability 
of these acute and short-term measures of cortisol. The low SNP heritability may reflect 
the substantial environmental and, in particular, situational component of these cortisol 
measures. Future GWAS will require very large sample sizes. Alternatively, more long-term 
cortisol measures such as hair cortisol samples are needed to discover further genetic 
pathways regulating cortisol concentrations.
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iNtroDuCtioN
Cortisol secretion is regulated by the hypothalamic-pituitary-adrenal axis in response to 
various biological and environmental factors, including physical stressors such as intensive 
resistance exercise1 or injury2, and psychological stressors such as public speaking and 
demanding cognitive tasks3. Cortisol secretion has a marked circadian rhythm: secretion 
peaks shortly after awakening and then drops throughout the day, refl ecting the hormone’s 
role in regulating energy metabolism4. Additionally, cortisol is secreted rhythmically result-
ing in a pulsatile ultradian rhythm5. The combination of these factors leads to substantial 
systematic and unsystematic variation of cortisol levels throughout the day.
Cortisol levels can be assessed with a variety of methods, the most common being blood 
in plasma and saliva samples. Plasma samples represent bound and unbound cortisol 
concentrations, whereas saliva represents the bioactive free cortisol. These measures 
have a modest to good correlation6, 7 and have been associated with various traits and 
states: BMI8, cardiovascular risk factors including hyperglycaemia9, psychiatric disorders, 
such as post-traumatic stress disorder, schizophrenia or bipolar disorder10, 11 and treatment 
response to depression12. Saliva cortisol can be sampled non-invasively, which may reduce 
the chance of inducing stress, makes repeated measurements more feasible, and facilitates 
mapping of day-time profi les. Repeated cortisol measures tend to show higher between-
visit reliability than single measures at awakening or 8am13, 14.
Plasma and saliva cortisol have been investigated in twin studies to determine the extent 
of the genetic contribution underlying the hormone. For acute plasma cortisol measures, 
the estimates range from low (14%) to moderate heritability (45%)15-17. Wüst, Federenko, 
Hellhammer, & Kirschbaum (2000)18 reported 0% heritability for acute saliva levels at 8am 
and total day-time profi les, and observed a large contribution of shared environment 
(>40%). These family studies rely on relatedness information obtained from known famil-
iar relationships instead of direct molecular measurements such as SNP arrays. Molecular 
genetic studies that can clarify the nature and extent of the genetic effects underlying 
cortisol are lacking, although they could advance our understanding of the genetic con-
tribution to stress vulnerability as assessed by cortisol.  A genome-wide association study 
(GWAS) by the cortisol network consortium (CORNET) successfully detected and replicated 
one genetic locus associated with morning plasma cortisol levels, suggesting that com-
mon autosomal gene variants are associated with this phenotype19. It is plausible that a 
substantial number of variants associated with cortisol were not identifi ed due to stringent 
multiple testing corrections required in GWAS. If this is the case, then the joint effect of all 
SNPs should be larger than the variance explained by the locus found (<1%).
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In the present study, we aimed to quantify the SNP heritability of cortisol, i.e the vari-
ance jointly explained by common autosomal single nucleotide polymorphisms. The SNP 
heritability information represents a more direct measure of the genetic predisposition 
to high or low cortisol stemming from additive genetic effects of common gene variants 
compared to the broad-sense heritability estimated in family studies. SNP heritability can 
therefore inform future GWA studies about sample size and potential success. We focus 
on cortisol measured in plasma and saliva measured in elderly participants from the Rot-
terdam Study and in mixed ages from the CORNET cohorts. This allowed the study of 
acute morning levels (plasma and saliva) and day-time profiles (saliva) in large sample sizes. 
SNP heritability can be estimated with different methods. In this study we used genomic 
restricted maximum likelihood estimation (GREML)20 in the Rotterdam Study as well as LD 
score regression in the CORNET GWAS results.
MAteriAls AND MethoDs
rotterdam study Participants
The Rotterdam Study is a population-based cohort investigating chronic disease and their 
risk factors in elderly, see Hofman et al. (2015)21 for details. The Rotterdam Study includes 
14,926 participants aged 45 and older. Study protocols were approved by the medical 
ethics committee according to the Population Study Act Rotterdam Study, executed by the 
Ministry of Health, Welfare and Sports of the Netherlands. Written informed consent was 
obtained from all participants.
Plasma cortisol information was available in 9836 participants performed in 1997-2008. 
For 8501, complete information on genetics was available. 2796 participants were re-
moved from GREML analyses due to excessive relatedness (see 2.1.2), resulting in a GREML 
sample of 5705. In the time adjusted analyses, a further 83 were excluded due to missing 
information regarding timing of sampling.
Saliva cortisol was available in 2034 participants of which 1982 had complete data on 
genetics. After removal of 265 participants due to excessive relatedness 1717 individuals 
remained with acute saliva level upon awakening. Of those, 1541 had also information 
on later time points for total day-time cortisol computations. See Table 1 for participant 
characteristics.
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table 1: Descriptive statistics of the Rotterdam Study cortisol measurements and participant character-
istics
cortisol 
Phenotype
median cortisol levels 
in nmol/l
(25%-75% quantile)
median age in 
years (25%-75% 
quantile)
sex 
(% female)
median time of 
collection in Hr
 (25%- 75% quantile)
Plasma 345.6 (281.7;418.1) 63.6  (58.2;72.4) 57% 09:42 (09:00;10:30)
Saliva (awakening) 13.2 (8.7;18.8) 74.3 (70.5;78.9) 56% 07:30 (07:00;08:06)
Saliva (AUCg) 7.9 (5.7;10.4) 74.3 (70.5;78.8) 55% -
measurements
Plasma cortisol was collected from 8:00h to 20:00h. 75% of samples were collected before 
10:30 and 99% before 15:30. Cortisol was measured using the LC-MS/MS method with 
the CHS MSMS Steroids Kit (Perkin Elmer, Turku, Finland) containing 2H3-cortisol as internal 
standard. Chromatographic separation was performed on a Waters (Milford, MA, USA) 
Acquity UPLC HSS T3 1.8μm column and quantifi ed by tandem mass spectrometry using a 
Xevo TQ-S system (Waters, Milford, MA).
Sarstedt Cortisol Salivette collection tubes (Sarstedt, Rommelsdorf, Germany) were used 
to collect saliva after awakening, 30 min after awakening, at 17:00 and at bedtime by 
the participants22. Participants were instructed to note the exact time of saliva collection, 
and not to eat or brush teeth 15min before collection. An enzyme immunoassay (IBL 
International Gmbh Hamburg, Hamburg, Germany) was used to analyze the samples. We 
investigated awakening cortisol levels and diurnal cortisol, calculated by the area under the 
curve in respect to ground (AUCg). 
In the Rotterdam Study genotyping was performed using Illumina HumanHap 550v3 and 
Illumina HumanHap 610. The genotyped dataset was restricted to persons who reported 
that they were from European descent. Ethnic outliers were further excluded by removing 
samples which showed more than 4SD difference to the study population mean on any of 
the fi rst 4 principal components of a mutidimensional scaling analysis. We also excluded 
samples with gender mismatch and excess autosomal heterozygosity as well as duplicates 
and monozygotic twins (>97% estimated identity-by-descent proportion). Furthermore, 
second degree cousins or closer relatives were excluded during the GREML analysis by 
using a GRM cutoff of 0.025 to avoid bias from shared environment. MACH 1.0 software 
was used to impute to ~30M SNPs based on the 1000 genomes Phase I version 3 reference 
panel23. SNPs included in imputation met the thresholds minor allele frequency>=1%, 
Hardy-Weinberg equilibrium p >10E-06, and a SNP call rate >=98.0%.
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GremL
SNP heritability of the cortisol measurements in the Rotterdam Study were estimated us-
ing individual level data with GREML, as implemented in Genome-wide Complex Trait 
Analysis (GCTA) 1.25.3 (Yang et al., 2011). GREML quantifies how well the similarity in the 
genotype between study participants explains the similarity in phenotype. Genetic similar-
ity was established by computing a genetic relatedness matrix (GRM). We used 8,131,668 
imputed autosomal SNPs to create the GRM, after filtering for imputation quality (R² > 
0.5) and minor allele frequency (MAF) >= 0.01, the GRM was specified as a random ef-
fect predicting cortisol levels. To test whether this genetic effect statistically significantly 
predicts the phenotype, we compared the GRM to a simpler model without the GRM using 
a likelihood ratio test.
Visual examinations of the total genetic effect and residuals using QQ-plots showed de-
viations from normality for the saliva measurements. The distribution was normal after 
square root transformation of hormone levels for saliva cortisol.  A constant (+1) was 
added before transformation to avoid zero values. We report results from analyses on 
transformed saliva and untransformed plasma levels. Additionally, we performed a power 
analysis as described by Visscher et al. (2014) 24. The plasma cortisol GREML analyses 
were well powered to detect 16% heritability (power=80% alpha =0.05 and 2E-5 genetic 
relationship). The power to detect SNP heritability was less in the saliva GREML analyses 
and thus these analyses have less precision. 
covariates and confounders
We adjusted the phenotype in all analyses for age, sex and four principal components 
(PC) of ancestry (computed with GCTA). This was achieved by regressing the phenotype 
on the covariates and using the residuals as outcome in the GREML analysis. The residuals 
were computed in R 3.2.3.25 Since plasma cortisol levels were measured in three different 
Rotterdam Study cohorts, a random intercept on the cohort level was introduced in the 
regression model of plasma cortisol using the lme4 1.1-10 package 26.
Additionally, we performed a sensitivity analysis with the plasma data aimed at reducing 
the environmental variance. This model was adjusted for time and fitted in participants 
with blood sampling before 11am and no self-reported corticosteroid use (n=4,696). To 
account for non-linear effects, time-of-day was specified using cubic splines with three 
degrees of freedom. The residuals, representing time-adjusted plasma levels, were then 
used in further GREML analyses. 
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corNet consortium Plasma and saliva cortisol GWAs
Detailed description of the CORNET GWAS on plasma cortisol can be found in Bolton et 
al. (2014)19. Briefl y, basal morning plasma cortisol was measured in 12,597 participants 
in 11 western European cohorts. Blood samples were collected between 7am and 11am 
and analyzed using immunoassays. All participants were at least 17 years old and of Euro-
pean ancestry, were not using glucocorticoids, pregnant, or breast feeding. In total 2945 
participants (23%) were included from the Rotterdam Study. However, the measurements 
were collected in a different study wave than the one used for GREML analyses. HapMap-
imputed autosomal SNPs were associated with z-scores of log-transformed plasma cortisol 
levels in an age, sex and time adjusted additive model. The SNP effects were meta-analyzed 
with a fi xed effect model using inverse-variance weighting. After quality control, the data 
featured 2,660,191 SNPs with minor allele frequency >2%.
In parallel, an additional GWAS of morning saliva levels was performed. This study is un-
published and therefore is presented in more detail. Morning (at awakening) saliva cortisol 
was measured in 7,703 participants in 8 cohorts: the British 1958 Birth Cohort-Type 1 
Diabetes Genetics Consortium (N=1762); the British 1958 Birth Cohort-Wellcome Trust 
Case-Control Consortium (N=1052)27; the Netherlands Study of Depression and Anxiety 
(N=1220) 28; the Netherlands Twin Register (N=162)29, the Rotterdam Study I (N=1767); the 
Rotterdam Study III (N=1119); the Multi-Ethnic Study of Atherosclerosis (N=166)30, and the 
Tracking Adolescents’ Individual Lives Survey (N=455)31. Only awakening samples collected 
before 11 am were included in the analyses. Participants using systemic corticosteroids and 
pregnant and breast-feeding women were excluded from the analyses. All subjects were 
at least 16 years old and of European ancestry. Details of the genotyping and imputation 
are given in Table S2. Genotype quality control was performed in each study separately 
(HWE P-value >10-6, MAF >0.01, SNP-call-rate >95%). A z-score was calculated (cortisol 
at awakening per SD-score in the cohort) to standardize cortisol measurements across 
cohorts. A linear regression analysis was performed on z-scores of morning saliva cortisol 
levels adjusted for sex, age and genetic ancestry (cohort specifi c) using all imputed SNPs.
The meta-analysis was performed with a fi xed-effects inverse variance model using the 
software METAL32. In addition to study-specifi c pre-imputation quality control, SNPs with a 
MAF <0.05 and an observed to expected variance ratio (imputation quality) less than 0.3 
were excluded at the meta-analysis level and SNPs. Furthermore, only SNPs with informa-
tion from 4 or more studies were included, resulting in a fi nal SNP number of 2,156,702 
SNPs. Genomic control correction was applied to each study. This GWA morning cortisol 
saliva meta-analysis has an overlap with the GREML analysis of 1767 participants/mea-
surements (23%) from the Rotterdam Study. QQ and Manhattan plots were created with 
qqman 0.1.4.33.
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LD score regression
LD Score regression exploits the relationship between SNP-Phenotype association strengths 
and linkage disequilibrium (LD) patterns34 . Some SNPs show stronger associations than 
expected due to chance. Assuming true causal effects, the SNPs which are in higher linkage 
disequilibrium (LD) with nearby SNPs are expected to have more inflated test statistics, be-
cause they are more likely to tag causal variants with stronger effects. This makes it possible 
to use a LD score of a SNP, defined as the sum of r² in a 1cM region, as a predictor of the 
association strength in a regression. The variance explained by the LD score is equivalent to 
the SNP heritability estimated by GREML. The advantage of LD score regression is, that it 
can be conducted with summary data from a GWAS and no individual level information is 
required. However, this analysis tends to have larger standard errors compared to GREML, 
which uses individual level data and thus can test SNP heritability effects directly. 
The SNP h² was estimated using LD score regression 1.0.0 34 in the CORNET GWAS data. 
Since imputation quality can confound LD score regression results, we restricted the analy-
sis to a list of well-imputed SNPs, as recommended by the software authors. After applying 
default quality control settings (see Table S3), the final SNP number was 1,028,327 for 
plasma cortisol and 951,308 for saliva cortisol. 
results
sNP Heritability
Descriptive statistics of the plasma and saliva cortisol levels can be found in Table 1. SNP 
heritability estimates were low for all cortisol measurement methods, analytical approaches, 
and cohorts. See Table 2 for full results.
table 2: SNP Heritability estimates of plasma and saliva cortisol measurements.
cortisol 
Phenotype
Analysis 
method Nr. of sNPs n sNP h² se p
Main Analyses:
 Plasma GREML 8,131,668 5,705 0.006 0.059 0.460
 Plasma LD Score 1,028,327 12,597 0.061 0.035 -
 Saliva GREML 8,131,668 1,717 0.090 0.200 0.329
 Saliva (AUCg) GREML 8,131,668 1,541 0.041 0.210 0.420
 Saliva LD Score 951,308 7,703 -0.083 0.060 -
Sensitivity Analysis:
Plasma-11am GREML 8,131,668 4,696 0.000 0.073 0.500
Analyses were adjusted for age, sex and ancestry. Plasma cortisol GREML analyses were further adjusted 
for cohort effects. Additionally, a sensitivity analysis with adjustment for time-of-day and a subset of 
participants with measurements before 11am and no reported corticosteroid use is reported (Plasma-
11am). Negative heritability values can occur for LD score regression analyses due to sampling variance.
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Plasma cortisol
We estimated the SNP heritability of plasma cortisol using individual level data of the 
Rotterdam Study (n=5,705) with GREML. In this cohort approximately 1% [95%CI: 0-12%] 
of variance in plasma cortisol could be explained by common autosomal gene variants. 
Adjusting for time of day and excluding participants with plasma cortisol measurements 
after 11am or those using corticosteroids did not meaningfully change results. 
We further investigated the SNP heritability of plasma cortisol in a larger consortium sam-
ple: the CORNET cohorts (ncohorts= 11, nparticipants=12,597). We applied LD score regression 
to estimate SNP heritability of plasma cortisol across multiple cohorts using the summary 
results of a GWAS meta-analysis. The variance explained for this larger sample was also low 
with 6% [95%CI: 0-13%].
saliva cortisol
In addition to plasma cortisol, we estimated the SNP heritability of two saliva cortisol 
phenotypes: awakening and diurnal levels. First, we estimated the variance explained of 
saliva awakening levels in the Rotterdam Study with GREML (n=1,717). The heritability 
in this sample was 9% [95%CI: 0-48%]. Repeating the analysis in the larger CORNET 
sample (ncohorts= 8, nparticipants=7,703) using LD score regression on GWAS meta-analysis 
summary statistics showed a negative heritability estimate (-0.0833). Phenotypes with 
low heritability can be estimated as negative due to sampling variance, which suggests 
population heritability close to 0 and an upper 95% confi dence interval of 3%. Finally, we 
estimated the SNP heritability of diurnal cortisol levels (AUCg). These were only available 
in the Rotterdam Study (n=1,541). In this sample the heritability was estimated at 4% 
[95%CI: 0-45%]. 
morning Plasma and saliva cortisol GWAs
The CORNET GWAS meta-analysis of plasma cortisol, which was previously published 
(Bolton et al., 2014), identifi ed 4 SNPs in the SERPINA6/SERPINA1 locus, namely 
rs12589136, rs2749527, rs2749529 and rs11621961.
However, no SNP reached genome-wide signifi cance (p < 5x10-8) in the GWAS for awaken-
ing saliva cortisol. Table S4 shows results of the top 1000 associated SNPs and Figure 2 
displays a Manhattan plot. Two loci showed suggestive associations (p < 5x10-7). The T 
allele of rs1170109 (chr13:42779694) was associated with a 0.12 SD increase in cortisol 
levels (SE=0.02, p=3.95x10-7, MAF=12%, n=7,690) with a homogeneous effect across 
the cohorts (I²=0%). Several SNPs from the same locus, close to the gene DGKH, showed 
suggestive effects as well (see Figure 3 for a LocusZoom plot35). The locus was not associ-
ated with plasma cortisol (β=0.03, SE=0.02, p=0.17, I²=0%, n=12,592). In the second 
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locus, the A allele of rs6768297 (chr3:168334386) was associated with 0.34 standard 
deviations (SD) lower cortisol levels (SE= 0.06, p= 2.01x10-7). Furthermore, the SNP showed 
a nominally significant (a =0.05) association with plasma cortisol in the same direction 
(β= -0.08, SE= 0.03, p= 0.01, I²=0%, n= 11,441). rs6768297 had a low MAF (6%), high 
effect heterogeneity (I²=85.5%) and information was only available in 40% of the sample 
(n=3054). None of the four SNPs associated with plasma cortisol were associated with 
saliva cortisol (all p< 0.56). 
The LD score intercept was 1.0031 (SE= 0.0066) and 1.0085 (SE= 0.0073) for the plasma 
and saliva GWAS, respectively, suggesting no inflation due to population stratification. The 
QQ plots also showed no problematic inflation (see Figure 1 for saliva).
Figure 1 Quantile-quantile plot of observed -log10(p) values vs expected -log10(p) values assuming chance 
findings. Diagonal line indicates a p value distribution compatible with chance finding. Upward devia-
tions indicate p values more significant than expected. 
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Figure 2 Manhattan plot of -log10 (p) values vs SNP position. SNPs above the horizontal line indicate 
suggestive fi ndings (p <5x10-7).
Figure 3 Regional plot around lead SNP rs1170109. -log10 (p) values of rs1170109 and other top1000 
SNPs in the region are displayed color coded for strength of correlation.
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DisCussioN
The low heritability of plasma cortisol in two large samples estimated by two different ap-
proaches strongly suggests that plasma cortisol is not substantially affected by the additive 
effects of autosomal SNPs. The same conclusion can be drawn for morning saliva cortisol, 
which was also estimated by two analytical approaches, and to a lesser extent for diurnal 
cortisol. 
No SNP reached genome-wide significance in a GWAS of morning saliva cortisol levels, 
which is expected for traits with low SNP heritability analyzed in relatively small samples. 
Two loci showed suggestive associations. Interestingly, one top SNP rs6768297 lies within 
the EGFEM1P gene, which has a high and specific expression in the pituitary according to 
RNA expression data (1.5 reads per kilobase per million)36, 37. Furthermore, the SNP showed 
a nominally significant association with plasma cortisol in the same direction as saliva 
cortisol. 
However, the lack of genome-wide significance, low sample size, low MAF and high effect 
heterogeneity also cast doubt as to whether the rs6768297 association with cortisol would 
replicate in a completely independent sample. The SERPINA6/SERPINA1 locus identified in 
the plasma cortisol GWAS19 appears to be specific to plasma cortisol levels.
The results are consistent with phenotypic studies indicating that only a small proportion of 
cortisol variance shows a stable trait-like pattern. In three different studies Ross, Murphy, 
Adam, Chen, & Miller (2014)38 found that 44.4%-75.5% of total day-time cortisol output 
variance was under day-to-day fluctuations. Studying children through ages 9-15, Shirtcliff 
et al. (2012)39 found that situation-specific environmental influences can explain 52% of 
cortisol variance (excluding circadian rhythm). The authors conclude that only 13% of the 
cortisol variance at a given time shows trait-like stability over the years, which coincides 
with the upper confidence intervals found for the heritability of acute plasma levels. These 
studies highlight the fact that cortisol secretion and metabolism is a highly dynamic process 
adapting to not only short-term, but also long-term situational contexts, which results in 
considerable “noise” in genetic studies. 
This notion is supported by the low heritability of the diurnal cortisol measurements. Re-
ducing the within-day variation appears to be insufficient to reduce the contextual noise. 
This conclusion is further supported by the small effect adjusting for time-of-day had on 
the plasma cortisol estimates and the low heritability of awakening saliva cortisol. The 
latter has a precise circadian definition, though sampling can be difficult to time in a home 
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environment. Furthermore, after excluding participants with plasma cortisol measurements 
after 11am and corticosteroid use, heritability estimates remained under 1%.
Interestingly, long-term associations between single cortisol measures in adulthood and 
psychosocial problems and adversities in childhood have been found40, 41 . The variability 
might thus refl ect environmental exposures, but for genetic studies more long-term pro-
fi les of cortisol may be needed. These can be measured using hair samples, which might 
represent more trait-like effects with less environmental infl uence42, 43. However, long-term 
environmental contexts spanning months or years also contribute to the cortisol variance 
and it is unclear yet to what extent 3 to 6 month measurements shall reduce environmental 
noise.
Therefore there may not be a single simplistic genomic heritability of cortisol levels. It is 
tempting to speculate that the heritability of other cortisol phenotypes is higher. Indeed 
the reliability of, for example, the total daily cortisol values (AUCg) is higher than single 
morning samples13, 14, but it represents a distinct feature of the cortisol secretion pattern. 
The cortisol awakening response or diurnal slopes are two other examples of characterizing 
diurnal changes. These may show a different balance of genetic and environmental infl u-
ences than total daily values or hair cortisol. The awakening response or diurnal slopes may 
show higher heritability than the tested phenotypes, though, it should be noted that they 
show less stability than total daily output38. Another potentially interesting phenotype is 
cortisol reactivity to various stressors. Here again the heritability may be different and may 
even change depending on the stressor. Unfortunately, sample sizes for stress reactivity 
will likely be smaller. Future research is required to determine the SNP heritability of these 
alternative phenotypes and characterize potential differences between them, although this 
may be a challenging research fi eld.
The very low diurnal cortisol heritability is in line with a twin-study reporting no genetic 
effects for day-time profi les18 . The same study found a non-signifi cant heritability of 26% 
for awakening cortisol, which is compatible with the non-signifi cant point estimate of 9% 
SNP heritability in the GREML analysis. Further, the observed 0% to 6% SNP heritability for 
(mostly morning) plasma and saliva levels (LD score regression) are similar to the 0% and 
14% twin heritabilities reported for saliva and plasma morning levels15, 18. However, they 
show a substantial difference to twin studies fi nding a 45% heritability of acute plasma 
levels16, 17. 
SNP heritability is expected to be lower than twin heritability, since this estimate does 
not include the effects of rare, structural and X-linked variants, which are captured in 
twin studies. Gene-gene and gene-environment interactions can also substantially increase 
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standard twin heritability estimates44. Alternatively, 45% twin heritability of acute cortisol 
measurements might be an overestimation, which would be consistent with the fact that 
the twin studies are highly inconsistent.
The LD score regression and GREML analysis of plasma cortisol in the CORNET and Rot-
terdam Study samples had good power to detect modest heritability. The negative findings 
in addition to the convergent evidence from the smaller saliva cortisol samples suggest 
that acute cortisol measures have low SNP heritability. However, the evidence is less clear 
for day-time profiles. These were only available in a small sample and have very wide 
confidence intervals, thus firm conclusions cannot be made. Another limitation is that 
the CORNET and Rotterdam Study data have an overlap in participants of approximately 
20%. The samples were thus not completely independent. However, considering that the 
majority of the observations did not overlap and the measurements were taken at different 
times and assessed in different laboratories, the data nevertheless support robustness of 
the largely negative results.
The findings suggest that common autosomal SNPs are poor predictors of acute cortisol 
levels. However, predictive power is not equal to importance. Crucial cortisol regulating 
loci are highly conserved: mammals and fish have a similar stress physiology. Among oth-
ers, corticotrophin-releasing hormone genes are orthogonal with substantial overlap in 
amino acid identity45. This highlights the importance of cortisol related genes, but also 
suggests that natural selection restricts the amount of variation and in turn effect sizes 
and predictive power. This may suggest, that if SNPs are identified despite the low SNP 
heritability, such as SNPs of the SERPINA6/SERPINA1 locus in the plasma cortisol GWAS, 
they are all the more important.
Unfortunately, it follows from the presented results that detecting these SNPs will be 
difficult. Since most SNPs are expected to have a relatively low predictive contribution 
compared to the environment and stochastic factors, very large sample sizes are probably 
required to discover further loci. Given the apparent importance of cortisol genetics, GWAS 
seems nevertheless a worthwhile endeavor to uncover further cortisol related biological 
pathways.
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AbstrACt
The present study included 1047 elderly participants. At baseline, brain magnetic resonance 
imaging (MRI) was performed to detect infarcts and white matter lesions; further, depres-
sive disorders were assessed. Participants were followed up during 3.6 years to determine 
incident and recurrent depression. We found an increased risk of recurrent depression 
associated with silent brain infarcts.
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iNtroDuCtioN
A relationship between cerebrovascular disease and depression in the elderly has been es-
tablished 1. However, it remains unclear to what extent depression is a direct consequence 
of vascular damage or a psychological reaction to physical disability caused by stroke. 
Studies investigating the relation between cerebral white matter lesions (WMLs) and 
depression provided evidence that subclinical cerebrovascular disease is associated with 
depression 2, although not consistently 3. Also, silent brain infarcts (SBIs) detected by mag-
netic resonance imaging (MRI) in the absence of clinical stroke are frequent in depressed 
patients 4. The association between SBIs and depression in the elderly has not been studied 
longitudinally; only the prognosis of prevalent depression in patients with silent brain 
infarct has been examined 5. Furthermore, previous studies were based on small, clinical 
samples. Previous research on the relationship between SBI and the poor prognosis of 
patients with depression or lack of response to antidepressant treatment prompted us to 
investigate the possible relationship between SBI and recurrent depression 5, 6.
Therefore, we aimed to assess whether SBIs and WMLs in community-dwelling elderly 
increase the risk of incident and recurrent depression.
MAteriAls AND MethoDs
setting
The current study is embedded in the Rotterdam Scan Study in the elderly, a large popula-
tion-based neuroimaging study.
We randomly selected participants from two large ongoing population-based studies, 
the Zoetermeer Study and the Rotterdam Study 7. After 2000, only the Rotterdam Study 
subcohort was followed. Together with non-participation and death of respondents, this 
substantial reduction in participants, precluded longer follow-up analysis.
The study was approved by the medical ethics committee of Erasmus Medical Center and 
participants gave written informed consent.
Participants
The study sample consisted of 1077 non-demented elderly persons aged over 60 years 
(mean age 70 years, 52% women), who were screened for depressive symptoms and un-
derwent structural MRI to assess cerebral changes at baseline in 1995–1996. Participants 
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were continuously monitored by reviewing medical records. Follow-up was complete until 
March, 2000. Participants with no information on depression (n= 16), those who screened 
positive but without psychiatric diagnostic interview (n= 6), and those diagnosed as having 
other psychiatric disorders during follow-up (n= 8) were excluded.
Brain infarcts and White matter Lesions
Axial T1-weighted, T2-weighted, and proton density scans were performed on 1.5 T MRI 
scanners. Infarcts were defined as focal hyperintensities on T2-weighted images, ≥ 3 mm 
(Fig 1). A physician scored infarcts, their location and size at baseline. We obtained a 
history of stroke and transient ischemic attack (TIA) by self-report and medical records. 
Subsequently, an experienced neurologist categorized the MRI-defined infarcts as silent or 
symptomatic 4. 
Fig. 1. Silent brain infarct and white matter lesions in participants of the Rotterdam Study at baseline. 
Vascular brain changes on 1.5 T MRI are shown. Arrow indicates the abnormality in the image. (A) Peri-
ventricular white matter lesions on T2 weighted sequence. (B) Subcortical white matter lesions on T2 
weighted sequence. (C) Lacunar infarct on T1 weighted sequence.
We defined SBIs as evidence of one or more infarcts on MRI, without a history of a cor-
responding stroke or TIA. 
WMLs were considered to be present if visible as hyperintense on proton-density and 
T2-weighted images, without prominent hypointensity on T1-weighted scans. Two rat-
ers scored periventricular and subcortical WMLs independently. Severity of periventricular 
WMLs was rated semi-quantitatively in three regions (grade range 0-9) 8.
Assessment of Depressive Disorders
At baseline, we assessed depressive symptoms with a validated Dutch version of the 
Centre for Epidemiologic Studies Depression (CES-D) scale and by checking indications 
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of prescribed drugs in all the participants. Prevalent depressive disorders were defined 
as depressive symptoms (CES-D scores ≥16) or the use of antidepressant medication at 
baseline.
Information on recurrent and incident depressive disorders during follow-up was estab-
lished by re-examining 787 participants with the CES-D scale between 1999 and 2000. 
Screen positives were assessed by a psychiatrist with a Dutch version of the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN), to ascertain a Diagnostic and Statistical 
Manual of Mental Disorders-Fourth Edition (DSM-IV) depression diagnosis. In addition, 
we continuously monitored the general practitioner’s medical records and the Regional 
Institute for Ambulatory Mental Health records for depressive episodes. Medicals records 
allow the identification of depressed participants during the interval between assessments.
Incident depressive disorders were defined as depressive disorders during follow-up with-
out depression at baseline. Recurrent depressive disorders were defined as a depressive 
disorder during follow-up in persons with prevalent depression at baseline. A history of 
depression was defined as a depressive episode before the baseline examination lasting 
more than 2 weeks.
covariates
Age, sex, education and cognitive function assessed by Mini-Mental State Examination 
(MMSE) score were used as possible confounders.
Data Analysis
We tested whether the presence of any brain infarcts and the severity of WMLs were 
associated with incident or recurrent depression with logistic regression. Analyses were 
adjusted for age, sex, education, and baseline MMSE score.
Separate analyses were run to test the association of symptomatic brain infarcts, SBIs, 
periventricular and subcortical WMLs and depression. Severe periventricular and subcorti-
cal WMLs were defined as ≥5 points for periventricular WMLs and ≥2 ml for subcortical 
WMLs.
Additionally, in sub-analyses participants with any history of depression were excluded 
(n= 249). We also repeated the analyses after exclusion of participants who developed 
dementia during follow-up (n= 34).
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results
At baseline, of the 961 participants without depressive symptoms, 36 persons had symp-
tomatic brain infarcts and 182 had SBIs. Of the 86 participants with depressive symptoms, 
seven had symptomatic brain infarcts and 25 had SBIs.
During a mean follow-up of 3.6 years, 60 (6.2%) participants without depressive symp-
toms and 32 (37%) participants with depressive symptoms at baseline were diagnosed 
with depressive disorders.
Symptomatic brain infarcts and SBIs were not associated with incident depressive disorders 
in longitudinal analyses. However the presence of SBIs at baseline almost tripled the risk of 
recurrent depressive disorders (Table 1).
table 1. Brain infarcts and white matter lesions and the risk of incident depression or recurrent depression. a
Brain Lesions
incident depressive disorders 
(60/961)
recurrent depressive 
disorders (32/86)
or* 95% ci** or 95% ci
All infarcts 1.1 0.6-2.9 2.1 0.8-5.2
Asymptomatic infarcts 1.0 0.5-1.8 2.9 1.0-8.2
Symptomatic infarcts 1.1 0.7-1.7 0.8 0.1-5.9
White matter lesions 1.1 1.0-1.2 1.1 0.8-1.4
Severe periventricular 1.3 0.6-2.6 1.0 0.8-1.2
Severe subcortical 2.1 (1.1-3.9) 0.9 0.3-2.7
a All analyses were adjusted for age, sex, education and baseline Mini Mental State Examination 
(MMSE) score. * OR= odds ratio. ** CI= confidence interval.
Severe subcortical WMLs doubled the risk of incident depressive disorders whereas severe 
periventricular WMLs were not related to incident depression. WMLs were not associated 
with recurrent depression (Table 1).
Exclusion of participants with history of depression and exclusion of participants who 
developed dementia during follow-up did not change the results (data not shown).
DisCussioN
We found that older adults with SBIs had an almost three-fold risk of recurrent depression. 
In contrast SBIs were not associated with incident depression.
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So far only an association between SBIs and the prognosis of clinical depression has been 
studied4, 6, showing a poor long-term prognosis and a decreased remission rate in hospital-
ized patients with SBIs. Our findings are in line with these studies and suggest that SBIs 
cause depression immediately and lastingly but are not associated with a higher risk of 
incident depressive episodes during follow-up.
There are several possible explanations for the association between SBIs and recurrent 
depression in older adults. First, depressive disorders may be a direct consequence of 
ischemic brain damage. It is known that damage to small vessels supplying subcortical 
pathways disrupts the neurotransmitter circuitry that is involved in mood regulation 9. 
Also, the location and nature of these lesions may affect individuals differently. When 
the accumulation of the infarcts exceeds a certain threshold, people could become more 
vulnerable to depression. Second, it has been suggested that depression may contribute 
to the evolution of vascular risk factors, which in turn increase the risk of cardiovascular 
disease. Following this reasoning, the underlying vulnerability to depression precipitates 
the future episode independent of the vascular burden.
Our findings showing the association between severity of subcortical WMLs, which are 
generally seen as indicating ischemia damage, and incident depression are in accordance 
with most other studies.
The observed findings remained after exclusion of participants, who developed dementia 
during follow-up (n= 34), suggesting that associations of SBI and WML with depression 
are not due to dementia. Moreover, these associations were independent of a history of 
depression, suggesting that vascular brain damage precedes the depressive disorder, rather 
than being a consequence of depression.
A potential methodological limitation of our study is the possibility of misclassification. 
Participants tend to underreport depressive symptoms, and physicians probably underdi-
agnose depressive disorders, which may have resulted in an under- estimation of the true 
numbers of events. However, in addition to information from medical records, we actively 
screened participants for the presence of depressive symptoms. Strengths of this study are 
its large number of elderly people and its prospective population-based design.
In summary, our data show that among elderly persons the presence of SBIs is associated 
with recurrent depressive disorders.
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AbstrACt
The vascular depression hypothesis postulates that cerebral small vessel disease can cause 
or exacerbate depression in elderly persons. Numerous studies explored the association of 
imaging markers of cerebral small vessel disease including white matter lesions (WMLs) 
and lacunar infarcts with depressive symptoms or disorders. However, cerebral microbleeds 
have not been tested in depression. In the current study, we aimed to explore the as-
sociation of WMLs, lacunar infarcts and cerebral microbleeds with depression continuum 
in a large population-based sample, the Rotterdam Study. Study population consisted of 
3,799 participants (aged 45 or over) free of dementia. WML volumes, lacunar infarcts 
and cerebral microbleeds were measured with brain magnetic resonance imaging. Depres-
sive symptoms, depressive disorders and co-morbid anxiety disorders were assessed with 
validated questionnaires and clinical interview. WML volumes and lacunar infarcts were 
associated with depressive symptoms and disorders. Cerebral microbleeds, especially in 
deep or infratentorial brain regions, were related to depressive disorders only. Our results 
indicate that WMLs and lacunar infarcts might be non-specific vascular lesions seen in 
depressive symptoms and disorders. Association of cerebral microbleeds with more severe 
forms of depression may indicate impaired brain iron homeostasis or minor episodes of 
cerebrovascular extraversion, which may play a role in depression etiology. 
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iNtroDuCtioN
The co-occurrence of cerebrovascular diseases and depression led researchers to propose 
the vascular depression hypothesis in late-onset depression. Since the hypothesis was fi rst 
described by Alexopoulos et al. 1 and Krishnan et al. 2, research on the etiology of vascular 
depression has been advanced along two conceptually different lines. Some researchers 
have focused on the localization of the vascular lesions to explain the etiology of the vas-
cular depression 3. Others have explored the cognitive defi cits due to the vascular cerebral 
lesions predisposing to depression. In the last decade, this approach has led researchers to 
defi ne “the depression-executive dysfunction syndrome” in which symptoms of executive 
dysfunctions such as diffi culty with planning, organizing, abstracting are seen as part of 
clinical depression 3, 4. Despite the supporting evidence, it is still debatable whether the 
vascular depression exists as a clinical entity. Extracerebral vascular diseases seem to be 
less consistently associated with depression in elderly than to cerebral vascular diseases 5, 6. 
While vascular risk factors, lesions and diseases are very common in elderly, the prevalence 
of depression does not increase in parallel. If the vascular depression hypothesis was of 
public health importance (i.e. vascular factors strongly predispose, precipitate, and per-
petuate depression), the prevalence of depression in elderly would be expected to rise 
more strongly with age 6. 
Early studies have tested the link between depression and clinically overt vascular events. In 
these patients, the effects of the functional defi cits on depression as a result of the vascular 
event are diffi cult to control for. In a recent report of the Rotterdam Study, myocardial 
infarction was related to depression in men, only when recognized that supporting the 
importance of psychosocial effects of an overt disease 7. 
Nowadays, a narrower defi nition of vascular depression hypothesis is used in which the 
vascular component is considered as clinical or non-clinical cerebrovascular events. Non-
clinical vascular events are consisted of imaging fi ndings of cerebral small vessel disease. 
Such fi ndings occur as a result of hypertension, arteriolosclerosis, infl ammation or amyloid 
deposition in small arteries, arterioles or venules of the brain 8. These imaging fi ndings are 
common in the elderly people. The most commonly explored imaging fi ndings of cerebral 
small vessel disease are white matter lesions (WMLs) and lacunar infarcts. For decades, 
WMLs have been explored in different severity degrees of depression. Cross-sectional and 
longitudinal association of WMLs with depressive symptoms, major depressive disorder 
(MDD), poor treatment response, and occurrence and recurrence of MDD 9-16 and comorbid 
anxiety disorders have been demonstrated 17. Similarly, lacunar infarcts has been related to 
depressive symptoms 18, 19, MDD, and recurrence of MDD 13.
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Cerebral microbleeds are now recognized as an imaging phenotype of the cerebral small 
vessel disease. 8, 20-22). Cerebral microbleeds are perivascular collections of hemosiderin 
induced by prior tiny hemorrhage. Similar to the WMLs and lacunar infarcts, cerebral mi-
crobleeds are detected commonly in elderly 23. In general, there are two types of cerebral 
microbleeds on the basis of location: deep or infratentorial microbleeds and lobar micro-
bleeds. Deep or infratentorial microbleeds were generally related to vascular risk factors 
whereas lobar microbleeds were associated with cerebral amyloid angiopathy 24. Cerebral 
microbleeds and their locations have not yet been extensively tested in depressive disorders. 
Studies assessing the relation between cerebral microbleeds and depressive disorders are 
mostly limited to the stroke cases in clinical settings 25-28. In a recent longitudinal study, it 
was shown that cerebral microbleeds were not related to incident depressive symptoms 29. 
However, the relation of cerebral microbleeds with different severity degrees of depression 
including depressive symptoms, depressive disorders and comorbid conditions of depres-
sive disorders have not been tested in general population. 
The link between cerebral small vessel disease and depressive symptoms has been tested 
in large population-based studies. However, the association between cerebral small vessel 
disease and depressive disorders was assessed mostly in small clinical studies. 
In the current study, we aimed to test the associations of several imaging phenotypes 
of cerebral small vessel disease with different severity degrees of depression including 
depressive symptoms, depressive disorders and depressive disorders with comorbid anxiety 
disorders in general population. We hypothesized that WMLs, lacunar infarcts, and cerebral 
microbleeds are all related to the depression continuum.
MAteriAls AND MethoDs
study sample
This study was embedded in the Rotterdam Study, a prospective population-based cohort 
of middle-aged and elderly persons 30. From 2005 to 2008, a random sample within the 
Rotterdam Study was formed for the regular research center visits. They were invited for 
brain magnetic resonance imaging (MRI). In total 3,855 participants were involved. Of 
these, 44 (1.1%) had no depression assessment and 10 (0.3%) persons with dementia 
were excluded. This left 3,799 people in the study sample. 
Of the 3,799 persons in one or more analysis, 3,741 had a valid WML measurement, 3,742 
had data on microbleeds and 3,701 participants had data on lacunar infarcts. 
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The Rotterdam Study has been approved by the institutional review board of the Erasmus 
University Medical Center and by the review board of The Netherlands Ministry of Health, 
Welfare and Sports. All participants provided written informed consent after complete 
description of the Rotterdam Study.
Assessment of Depressive symptoms and Anxiety Disorders
We diagnosed depressive disorders with a two-step procedure. First, we tested all partici-
pants for depressive symptoms using the Center for Epidemiological Studies-Depression 
(CES-D) scale during the home interview at study entry. A cut-off of 16 was used to defi ne 
“clinically signifi cant depressive symptoms”. This cut-off score has a very high sensitivity 
for major depression in older adults in the Netherlands 31, 32.In the second step, we invited 
the participants with a CES-D score of 16 or greater to a semi-structured interview, the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 33. Clinicians were conducted 
the interviews in close proximity in time to screening. Clinical depressive disorders included 
DSM-IV-TR–defi ned major depressive disorder and dysthymia. Thus, both clinically signifi -
cant depressive symptoms and DSM-IV depressive disorders were assessed in this study. 
To determine participants with depressive disorders and comorbid anxiety disorders, we 
used a slightly adapted version of the Munich version of the Composite International 
Diagnostic Interview (M-CIDI). The interview was performed by trained interviewers 34. All 
DSM-IV anxiety disorders including generalized anxiety disorders, panic disorder with or 
without agoraphobia, social phobia and specifi c phobia were assessed except obsessive-
compulsive disorder and post-traumatic stress disorder (rare and diffi cult to diagnose 
reliably in the general population). We grouped anxiety disorders into a category of “any 
anxiety disorder”.
Brain mri
Brain MRI was performed on a 1.5-T scanner (GE Healthcare, Milwaukee, WI) with an 
8-channel head coil including T1-weighted, proton-density weighted, fl uid-attenuated 
inversion recovery, and T2*-weighted gradient echo sequences 35. 
Post-processing steps have been described elsewhere and include a conventional k-nearest-
neighbor brain tissue classifi er extended with WML segmentation 35.  Using this classifi er, 
we obtained quantitative measures of WML volume and intracranial volume (in mL). 36.
We defi ned lacunar infarcts as focal hyperintensities that are ³ 3 mm on FLAIR and T2-
weighted images. An experienced physician scored all infarcts.
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All scans were reviewed by 1 of 5 well-trained raters who were blinded to the clinical data. 
Intra-observer (n=500, 1 rater) and inter-observer (n=300) reliabilities were κ= 0.87 and 
κ= 0.85, which indicates very good agreement. In line with previous studies, we defined 
categories of microbleeds restricted to a lobar location (strictly lobar microbleeds) and 
microbleeds in a deep or infratentorial location 37, 38.
covariate Assessment
Age, sex, education, smoking status, hypertension, diabetes mellitus, body mass index, 
total and HDL cholesterol concentrations and cognitive function were used as potential 
covariates on the basis of prior literature 39. Education was grouped into eight categories 
in an ordinary scale from primary education (1) to university level (8) on the basis of the 
Standard Classification of Education. For the analyses, we further categorized it into three 
categories; low, intermediate, and high. Smoking status was coded in categories as never, 
former and current smokers. Systolic and diastolic blood pressures were calculated as the 
average of two consecutive measurements. Hypertension was defined as a systolic blood 
pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg or the use of antihyperten-
sive medication according to pharmacy records. Data on diabetes mellitus was collected on 
the basis of the general practitioners’ reports and the assessment at the research center. 
Participants were considered as having prevalent diabetes when they had at least one of 
the following four criteria: plasma glucose concentration ≥7.0 mmol/L, random plasma 
glucose concentration ≥11.1 mmol/L, antidiabetic medication, and/or diabetes treatment 
by diet. Height and body weight were measured. Body mass index was calculated as weight 
in kilograms divided by height in meters squared. Cholesterol levels were evaluated with an 
automated enzymatic procedure. Cognitive function was assessed with the Mini-Mental 
State Examination (MMSE) 40.
statistical Analyses
We log-transformed the WML volumes to achieve a normal distribution. WML volumes 
were used as continuous measures and lacunar infarcts and cerebral microbleeds were 
used as binary variables. 
To evaluate the cross-sectional associations of the imaging phenotypes of cerebral small 
vessel disease with depression continuum, we performed a series of analyses. First, we 
modeled depressive symptoms score continuously (the CES-D score) and tested the as-
sociations between the cerebral small vessel disease and depressive symptoms score with 
linear regression analyses. Second, we used a pre-defined cut-off of 16 for the CES-D to 
detect participants with clinically significant depressive symptoms and tested the associa-
tions of cerebral small vessel disease with clinically significant depressive symptoms using 
logistic regression analyses. Third, we examined the associations of the cerebral small ves-
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sel disease with the DSM-IV depressive disorders (major depressive disorder and dysthymia) 
with multinomial logistic regression. In these latter analyses, participants below the CES-D 
score of 16 formed the reference category. All analyses were adjusted for age and gender. 
Analyses were further adjusted for education, smoking status, hypertension, diabetes mel-
litus, total and HDL cholesterol concentrations and MMSE score except for lacunar infarcts 
because of small sample size. Analyses of cerebral microbleeds were additionally adjusted 
for WML volume and intracranial volume. Analyses of WML volume were further adjusted 
for intracranial volume.
Next, we tested whether any associations of cerebral microbleeds with depression depend-
ed on the localization of microbleeds using strictly lobar and infratentorial microbleeds 
categories. 
In the sensitivity analyses, we explored if the associations of cerebral small vessel disease 
with MDD differed between persons with a comorbid anxiety disorder and those with 
MDD only; we used the group of persons without depressive symptoms as the reference 
group for the multinomial logistic regression analyses testing this difference. These sensitiv-
ity analyses were adjusted for age and gender. Analysis of WML volume was adjusted 
for intracranial volume and analysis of cerebral microbleeds was adjusted for intracranial 
volume and WML volume.
We imputed the missing values on covariates using expectation maximization algorithm. 
Missing values on covariates were minimal (maximum, 3.1 %). The SPSS software (version 
20; SPSS, Chicago, Illinois) was used for statistical analyses. 
results
Characteristics of the study population (n=3,799) are presented in Table 1. Mean age was 
58.7 years (standard deviation [SD]= 7.8) and 2070 (54.5 %) participants (n=2070) were 
women. In total, 322 (8.5 %) participants had clinically signifi cant depressive symptoms, 
60 (1.6%) participants had prevalent depressive disorders according to the DSM-IV. Of 
the 60 participants with major depressive disorder, 31 (51.7 %) had a comorbid anxiety 
disorder. 
A larger WML volume was positively related with the severity of depressive symptoms as 
indicated by the higher CES-D scores in the fully adjusted model (regression coeffi cient per 
ml increase in WML volume= 0.44; 95 % Confi dence Interval [CI]= 0.14; 0.75; p= 0.005). 
Presence of lacunar infarcts was related with high CES-D scores (regression coeffi cient 
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for yes versus no= 1.07; 95% CI= 0.04-2.11, p= 0.04). There was no association of the 
presence of cerebral microbleed (regression coefficient for yes versus no= 0.17; 95% CI=-
0.48 - 0.81; p= 0.61) with the severity of depressive symptoms. 
Second, we assessed the associations of the cerebrovascular determinants with clinically 
significant depressive symptoms (CES-D≥ 16). Table 2 shows that, consistent with the 
continuous analyses, WML volume was positively associated with clinically significant 
table 1. Characteristics of the study population
characteristics
study sample
N= 3,799
Age, years, mean (SD) 58.7 (7.8)
Women, n (%) 2070 (54.5)
Education, n (%)
Low 438 (11.5)
Intermediate 2411 (63.5)
High 950 (25)
Smoking status, n (%)
Current smoker 1429 (37.6)
Former smoker 1152 (30.3)
Never smoked 1218 (32.1)
Diabetes mellitus (yes) , n (%) 304 (8)
Hypertension, n (%) 1834 (48.3)
Lipid lowering medication, n (%) 831 (21.9)
Total serum cholesterol, mmol/l, mean (SD) 5.6 (1)
Serum HDL cholesterol, mmol/l, mean (SD) 1.4 (0.4)
Body mass index (kg/m2), mean (SD) 27.5 (4.2)
Mini mental state examination score, mean (SD) 28.1 (1.7)
Depressive symptom score, mean (SD) 5.3 (7)
Clinically significant depressive symptoms, n (%) 322 (8.5)
Depressive disordersa, n (%) 60 (1.6)
Cerebral microbleeds (yes), n (%) 538 (14.4)
Strictly lobar microbleeds, n (%) 371 (9.9)
Deep or infratentorial microbleeds, n (%) 167 (4.5)
White matter lesion volume, ml, mean (SD) 4.3 (7)
Intracranial volume, ml, mean (SD) 1125.7 (123.4)
Lacunar infarcts (yes), n (%) 184 (4.8)
Cortical infarct (yes), n (%) 98 (2.6)
a Depressive disorders category includes persons with major depressive disorder or dysthymia 
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depressive symptoms. Neither lacunar infarcts nor cerebral microbleeds were related with 
clinically signifi cant depressive symptoms. 
table 2. Associations between the indicators of cerebral small vessel disease and depressive symptoms 
and clinical depression
clinically signifi cant 
depressive symptoms a
N= 322
Dsm-iV depressive 
disorders b
N= 60
N or 95% ci p or 95% ci p
White matter lesion volume, ml 3741
Age and gender adjusted 1.28 1.10-1.48 0.001 1.37 1.18-1.59 <0.001
Fully adjusted c 1.25 1.08-1.46 0.004 1.40 1.20-1.62 <0.001
Cerebral microbleeds 3742
Age and gender adjusted 1.14 0.82-1.58 0.44 1.45 1.02-2.06 0.04
Fully adjusted c 1.09 0.78-1.53 0.61 1.40 1.01-1.94 0.04
Lacunar infarctse 3701
Age and gender adjusted 1.22 0.71 - 2.08 0.47 1.78 1.07-2.95 0.03
a Clinically signifi cant depressive symptoms category consisted of participants with a CES-D score≥ 16. 
Participants without depressive symptoms were used as a reference group. 
b Depressive disorders category consisted of participants with a DSM-IV major depressive disorder or 
dysthymia. Participants without depressive symptoms were used as a reference group (n=3477).
c   Analyses of WML volume were age, sex, education, smoking status, hypertension, diabetes mellitus, 
BMI, MMSE score and ICV. Analyses of cerebral microbleeds were adjusted for age, sex, education, 
smoking status, hypertension, diabetes mellitus, BMI, MMSE score and ICV and WML volume. 
d Logistic regression analysis was adjusted for age, sex, education, smoking status, hypertension, diabe-
tes mellitus, BMI, and MMSE score. 
e Because of the small sample size, age and gender-adjusted model was performed only.
Next, we evaluated the association of the imaging phenotypes of cerebral small vessel 
disease with DSM-IV depressive disorders. An increase in WML volume was associated 
with an increased likelihood of DSM-IV depressive disorders (Odds Ratio [OR] per ml= 
1.40; 95 % CI= 1.20- 1.62; p< 0.001). Presence of microbleeds increased the likelihood of 
having DSM-IV depressive disorders 40% in the fully adjusted model (OR= 1.40; 95% CI= 
1.01-1.94; p= 0.04). Presence of lacunar infarcts was related to depressive disorders (OR= 
1.78; 95% CI= 1.07-2.95, p= 0.03).
In the follow-up analyses, we categorized cerebral microbleeds as deep/infratentorial cere-
bral microbleeds (n=167, 4.5%) or strictly lobar cerebral microbleeds (n=371, 9.9%). We 
found a borderline association of deep/infratentorial cerebral microbleeds with depressive 
disorders (OR= 1.41; 95% CI= 1.0-1.99, p= 0.05). There was no association between 
strictly lobar cerebral microbleeds and depressive disorders even though the effect size 
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was similar with the results of the deep/infratentorial cerebral microbleeds and depressive 
disorders (OR= 1.47; 95% CI= 0.69-1.72, p= 0.72). 
sensitivity Analyses
We examined whether markers of cerebral small vessel disease were related to depressive 
disorders with comorbid anxiety disorders. Presence of cerebral microbleeds was related 
to increased likelihood of depressive disorders with comorbid anxiety (OR= 2.15; 95% CI= 
1.65-2.81, p< 0.001). WML volume and presence of lacunar infarcts were not related to 
depressive disorders with comorbid anxiety. 
DisCussioN
In this population-based study, the imaging markers of cerebral small vessel disease were 
differently related to depressive symptoms and disorders. WML volumes were consistently 
associated to depressive symptoms and MDD. Cerebral microbleeds were related to de-
pressive disorders only, in particular to depressive disorders with comorbid anxiety. 
In the last two decades, WMLs have been studied in persons with depression. Investi-
gators repeatedly demonstrated the association of WMLs with clinical and non-clinical 
presentations of depression. This suggests that WMLs are relatively non-specific vascular 
pathologies seen in people with depressive symptoms or clinical depression and even in 
other common psychiatric disorders including anxiety and dementia 9, 10, 12, 13, 41-45. Also, la-
cunar infarcts were related to depressive symptoms and depressive disorders in the current 
study. Previous studies mostly explored the association of lacunar infarcts with depressive 
symptoms. In contrast, studies of DSM-IV depressive disorders are limited. Silent lacunar 
infarcts, especially when located in the basal ganglia, were related to depressive symptoms 
in a small clinical study 18. A recent population-based study showed that subcortical infarcts 
predict incident depressive symptoms 29. Another study of patients with atherosclerosis 
demonstrated that lacunar infarcts in deep white matter were related with an increase of 
depressive symptom severity and a more fluctuating course of depressive symptoms dur-
ing follow-up 19. In the Rotterdam Study, we previously reported that silent brain infarcts 
predict the recurrence of clinical depression 13. 
The underlying mechanism for the relation of WMLs and lacunar infarcts with depression 
might be the detrimental local effects of cerebral small vessel disease in the frontostriatal 
and limbic regions. These local damages disrupt the neurotransmitter circuitry involving in 
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mood regulation 46, 47. This is supported by observation in the current and previous studies 
that the subcortical WMLs and lacunar infarcts are consistently related to depression 12, 13, 48. 
Cerebral microbleeds have not been tested in relation to different severity degrees of 
depression in a non-clinical sample. Previously, Tang and colleagues 26, 27 explored cerebral 
microbleeds in patients with stroke and found that the presence of cerebral microbleeds 
was related to post-stroke depression. In a longitudinal study of elderly people in general 
population; van Sloten et al. detected no association between cerebral microbleeds and 
incident depressive symptoms 29. In our population-based study, we observed an associa-
tion of cerebral microbleeds with depressive disorders in participants free of stroke. Also, 
there was a relation between cerebral microbleeds and depressive disorder with comorbid 
anxiety, which indicates a more severe form of depression. This effect was not found 
when we test the association of cerebral microbleeds with depressive symptoms although 
continuous analyses generally have more power to detect the associations. This suggests 
that cerebral microbleeds may be a specifi c vascular pathology only seen in the most severe 
form of depression.
Localization of cerebral microbleeds is of importance because they do not only signal 
an impact on different anatomical regions but this may also refl ect different underlying 
pathological processes of the vascular pathology. Lobar microbleeds are generally related 
to cerebral amyloid angiopathy whereas deep infratentorial cerebral microbleeds are associ-
ated with hypertensive microangiopathy 24. We found that deep/infratentorial microbleeds, 
which are related to cardiovascular risk factors, were associated to depressive disorders. 
In contrast, lobar microbleeds indicating an amyloid angiopathy were not associated with 
depressive disorders even though the effect size was similar with the analyses of deep/
infratentorial microbleeds. Overall, our fi ndings support a vascular etiology of depression 
rather than an involvement of the amyloid pathway in the pathology of depression.
These explanations discussed above imply that the direction of mechanisms is from cerebral 
small vessel disease to depression 13, 42, 48, 49. However, it has also been suggested that there 
is a bi-directional association between small cerebral vascular disease and depression. The 
mechanisms by which depression may contribute developing cerebral small vessel disease 
increase are not completely understood, but biological (atrophy in different brain regions, 
the hypothalamic-pituitary-adrenal axis dysfunction, infl ammation) and lifestyle changes 
(poor health, smoking, less exercise) during depressive episodes are thought to be risk 
factors to cerebral small vessel disease 23, 50-52. 
The current study has several strengths. First, the study was based on general population, 
enhancing the external validity of the fi ndings. Second, we evaluated both depressive 
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symptoms and depressive disorders. Depressive disorders were diagnosed with a clinical 
psychiatric interview in this population-based study. Additionally, depressive disorder with 
comorbid anxiety disorder that is considered a more severe form of depression was tested. 
Evaluating anxiety disorders is not common in population-based studies. Third, large study 
sample in the analyses of depressive symptoms allowed us to test several covariates. Finally, 
we were able to evaluate different imaging markers of cerebral small vessel disease, which 
allowed us to explore different aspects and mechanisms of cerebral small vessel disease 
such as ischemia and hemorrhage in the same sample. 
There are also some limitations that should be considered when interpreting the results. 
Firstly, this study was not longitudinal. We discussed above that the direction of the 
temporality is unclear. In the further studies, cerebral microbleeds needs to be tested 
longitudinally to interpret if these associations are causal. Secondly, number of participants 
with depressive and anxiety disorders was low, yet we had enough power to detect the 
association of cerebral small vessel disease and depressive disorders.
In conclusion, our study supports vascular depression hypothesis. Three imaging markers 
of cerebral small vessel disease in later life were consistently associated to depressive symp-
toms and depressive disorders. Our study suggests that deep infratentorial microbleeds can 
index impaired brain iron homeostasis or minor episodes of cerebrovascular extraversion in 
persons with depressive disorders but more studies are needed to provide evidence on the 
exact mechanisms and the nature of cerebral small vessel disease in depression. 
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AbstrACt
According to the vascular depression hypothesis, subclinical cerebrovascular disease can 
cause depression in older adults. To test this hypothesis, several cross-sectional studies have 
assessed structural brain parameters, but few have examined hemodynamic alterations in 
the brain. 
From the Rotterdam Study, we studied a cohort of 1,494 participants (age 65+) free of 
depression, dementia, and stroke at baseline. In the middle cerebral artery blood flow 
velocities and vasomotor reactivity were measured with transcranial Doppler ultrasonog-
raphy. All participants were repeatedly assessed for depressive symptoms with Centre for 
Epidemiological Studies-Depression scale (CES-D). Participants with depressive symptoms 
(CES-D ≥16) had a semi-structured interview, in order to classify the depression according 
to DSM-IV criteria. All analyses were adjusted for sociodemographics, vascular risk factors, 
and incident stroke. 
Lower peak-systolic, end-diastolic and mean blood flow velocities at baseline were associ-
ated with higher Centre for Epidemiological Studies-Depression scale scores at follow-up. 
Mean blood flow velocity predicted incident depressive symptoms (Odds ratio 0.74, 95% 
confidence interval 0.60-0.91, p= .004) and depressive disorders (Odds ratio 0.83, 95% 
confidence interval 0.69-0.98, p= .032), whereas decreased baseline vasomotor reactivity 
predicted incident depressive disorders only (Odds ratio 0.66, 95% confidence interval 
0.53-0.83, p< .001). 
Lower blood flow velocity, indicating reduced cerebral metabolism, predicted depressive 
symptoms and depressive disorders. Reduced vasomotor reactivity, which may indicate 
cerebral microangiopathy, predicted depressive disorders only, in healthy older adults. 
These findings provide prospective evidence for vascular depression hypothesis. 
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iNtroDuCtioN
The vascular depression hypothesis suggests that subclinical cerebrovascular changes 
may ‘predispose, precipitate, or perpetuate’ depressive disorders in older adults 1. This 
hypothesis is supported by several observations. First, depression is associated with estab-
lished stroke and more mild manifestations of cerebrovascular diseases such as transient 
ischemic attacks as well as cerebral infarcts which refl ect small-vessel diseases 2-9. Second, 
late-life depression has been associated with white-matter and deep grey-matter lesions 
and cerebral atrophy without an overt evidence of clinical cerebrovascular disease 5, 10, 11. 
Third, an association between peripheral atherosclerosis and depression has been reported 
repeatedly 12, 13 although, we could not replicate this association in a longitudinal study 
of the present population using several peripheral atherosclerosis indicators 14. Finally, 
studies exploring pathophysiological alterations of the brain showed regional cerebral 
hemodynamic alterations in individuals with depressive disorders 15-17. Cerebral blood fl ow 
velocity, which increases during mental activity, and vasomotor reactivity, a compensatory 
mechanism for maintaining constant cerebral blood fl ow in cerebral arterioles, are the 
important cerebral hemodynamic indices. It is known that cerebral hemodynamics are as-
sociated with ischemic changes in the brain that may cause stroke or white-matter lesions 
18. Therefore, measuring cerebral hemodynamics allows testing cerebrovascular functions 
and autoregulation directly before cerebrovascular changes occur, if studies are performed 
longitudinally. Depressive disorders have been associated with lower global blood fl ow 
velocity and vasomotor reactivity in previous cross-sectional clinical studies 19-21. However, 
only depressive symptoms were cross-sectionally associated with reduced blood fl ow veloc-
ity and reduced vasomotor reactivity in a population based study 22. 
Despite the growing evidence, the debate about the causality of such altered cerebro-
vascular hemodynamics is unresolved. Because studies exploring the association between 
cerebrovascular hemodynamics and depression were all cross-sectional, it remains unclear 
whether blood fl ow velocity and vasomotor reactivity decrease as a result of current de-
pression. Moreover, previous studies were mostly carried out in clinical settings and in 
small samples, which are more likely to suffer from selection bias. In this study, which was 
designed to overcome these shortcomings, we postulated that reduced cerebral blood 
fl ow velocity and vasomotor reactivity are underlying risk factors for incident depression in 
healthy older adults. 
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MethoDs AND MAteriAls
study setting and Design 
This study was part of the Rotterdam Study, a prospective population-based cohort on 
chronic and disabling diseases in the elderly. Detailed information on the design of the Rot-
terdam Study has been published elsewhere 23. The Rotterdam Study has been approved by 
the institutional review board of the Erasmus University Medical Center and by the review 
board of the Netherlands Ministry of Health, Welfare and Sports. All participants provided 
written informed consent after complete description of the Rotterdam Study.
Baseline measurements for the current study were done at the third examination (1997-
1999). This included a home interview and a research-centre visit in which cerebral tran-
scranial Doppler ultrasonography was performed and depression screening was introduced. 
At the fourth examination (2002-2004), depression was assessed during home interviews. 
Mean duration of follow-up was 4.1 years (standard deviation= 0.5). 
study Population
In total, 4797 participants were involved at the third examination. We attempted to perform 
transcranial Doppler ultrasonography in 3104 participants. In 998 of these participants 
(32.2 %), no results were obtained due to window failure on both sides (n= 776), restless-
ness/discomfort of participants during the procedure (n= 59), participants’ lack of time 
(n= 5) and other reasons (n= 158). Excluded participants were more likely to be older (p< 
.001) and female (p< .001). Within 2106 participants with a valid transcranial Doppler ul-
trasonography measurement, 32 were excluded due to lack of a complete CES-D screening 
and 2 due to lack of dementia screening at baseline. Further, we excluded screen-positive 
participants (CES-D score ≥ 16) (n= 116), screen-negative participants (CES-D score < 16) 
who were on antidepressant treatment (n= 48), participants with dementia (n= 8), and 
participants with prevalent stroke (n= 43). 
Of these 1857 participants, 174 died (9.4%) after the baseline interview and 142 refused 
to participate (7.6%) to the follow-up interview. At the follow-up visit, 1541 participants 
were screened with CES-D and 47 did not have a valid CES-D interview. The final study 
sample thus consisted of 1494 participants. Within this study sample, the following indices 
of cerebral hemodynamics were available for participants as follows: end-diastolic blood 
flow velocity, n= 1488; peak-systolic blood flow velocity, n= 1488; mean blood flow veloc-
ity, n= 1488; vasomotor reactivity, n= 1445.
Participants with transcranial Doppler ultrasonography measures but who were excluded 
from the study were older (p< .001) and more likely to be female (p< .001). 
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Assessment of Depression
Depressive disorders were diagnosed using a two-step procedure. First, all participants 
were screened for depressive symptoms on the basis of a Centre for Epidemiological 
Studies-Depression scale (CES-D) 24 during the home interview at the baseline and at the 
follow-up visit. A cut-off of 16 was used to detect participants with clinically signifi cant 
depressive symptoms. This score has a very high sensitivity for major depression in older 
adults in the Netherlands 25.
In the second step, screen-positive participants were invited for a semi-structured interview, 
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 26, which was performed 
by trained and experienced clinicians. Depression was categorized according to the Diag-
nostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR). 
The category of clinical depressive disorders included DSM-IV-TR defi ned major depressive 
disorder, dysthymia, and depressive disorder not otherwise specifi ed (including the former 
category of minor depression). Participants who were screen-positive according to CES-D, 
did not meet criteria for diagnoses of major depression, dysthymia, or minor depression, 
and had at least one core symptom of major depression (i.e. depressed mood or loss of 
interest), and associated with evidence of dysfunction were categorized as persons with 
subthreshold depression 27. 
History of depression was evaluated with CES-D and Hospital Anxiety- Depression Scale in 
the second examination of the Rotterdam Study. A score of 16 or greater for CES-D and 9 
or greater for HADS were considered as depressive symptoms.
transcranial Doppler Assessment
Details on the transcranial Doppler ultrasonography procedure used in the Rotterdam 
Study have been described earlier 28. Transcranial Doppler ultrasonography was performed 
(Multi-Dop X-4, DWL, Sipplingen, Germany) during the third visit of the Rotterdam Study. 
Cerebral blood fl ow velocity (cm/sec) was measured in the middle cerebral artery, on both 
sides when possible. End-diastolic, peak-systolic, and mean cerebral blood fl ow velocities 
were recorded automatically. All velocities were measured at a depth of 50 mm or as close 
as possible. If a fl ow velocity was measured on both sides, the mean value was used. 
Otherwise, the available measurement was used. 
Cerebrovascular CO2 reactivity was measured as follows: during the continuous cerebral 
blood fl ow velocity measurements, participants fi rst breathed room air through an anes-
thetic mask that fi tted tightly over the nose and mouth. When a steady expiratory end-tidal 
CO2 has been obtained, participants inhaled a mixture of 5% CO2 in 95% O2 for two 
minutes. Cerebrovascular CO2 reactivity was defi ned as a percentage increase in mean 
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cerebral blood flow velocity during inspiration of 5% CO2 divided by the absolute increase 
in end-tidal CO2 during the same time period (% / kPa). 
covariate Assessment
Age, sex, education, cognitive function, incident stroke, hypertension, diabetes mellitus, 
peripheral arterial disease were considered to be possible confounding variables based on 
previous publications 5, 22. Education was rated from primary education to university level 
and then grouped into three categories: low, intermediate, and high education. Cognitive 
function was evaluated with the Mini Mental State Examination (MMSE). Smoking status 
was categorized as never, former, and current smoker based on the baseline interview. 
Participants with no smoking history were categorized as never smokers.  Former smokers 
were categorized in two groups: those quitted smoking at least 10 years ago and less than 
10 years ago. Finally, participants who are currently smoking were categorized as current 
smokers. Both prevalent stroke at baseline and incident stroke at follow-up were obtained 
through automated linkage of the study database with files from general practitioners, 
hospital records, and the municipality. Diabetes mellitus was defined as having fasting 
blood glucose concentrations 11.1 mmol/L or over or the use of antidiabetic medication 
according to pharmacy records. Blood pressure was measured in the right upper arm with 
a random-zero sphygmomanometer after the participant had been seated for ≥5 minutes. 
Systolic and diastolic blood pressures were calculated as the average of two consecutive 
measurements. Hypertension was defined as a systolic blood pressure ≥140 mm Hg or a 
diastolic blood pressure ≥90 mm Hg or the use of antihypertensive medication according 
to pharmacy records. As an indicator of peripheral arterial disease, the ankle-brachial index 
was used by taking the ratio of the systolic blood pressure measured at the tibial artery 
to that measured at the right arm. Intima-media thickness was measured as the average 
of the near and the far wall measurements of both the right and left common carotid 
artery. B-mode ultrasonography was performed using a 7.5-MHz linear-array transducer 
(ATL Ultra-Mark IV; Advanced Technology Laboratories, Bethel, Wash) 29. 
statistical Analyses
Cerebral hemodynamic variables were used continuously in all analyses. The covariates 
of age, education, MMSE score, ankle-brachial index and intima-media thickness were 
also used as continuous variables. Sex, hypertension, diabetes mellitus, smoking status, 
and new-onset stroke between baseline and follow-up visits were analyzed as categorical 
variables. We assessed the associations between cerebral hemodynamic measurements 
and depression in three ways. First, linear regression analyses were performed using CES-D 
score at follow-up continuously to test the linear association between cerebral hemody-
namic variables and depression scores. Second, logistic regression analyses were used 
to calculate the odds ratios and 95 % confidence intervals for the association between 
Cerebral hemodynamics and incident depression: the Rotterdam Study 131
3
baseline hemodynamic variables and presence of incident depressive symptoms (CES-D 
score ≥ 16). The group of screen-negative participants (CES-D score <16) at follow-up was 
used as a reference category in all analyses. After performing initial unadjusted analyses, 
all analyses were adjusted for age, sex, education, and MMSE score. Then, additional 
covariates including ankle-brachial index, hypertension, diabetes mellitus, incident stroke, 
and smoking were entered into the same model. To examine if intima-media thickness 
explained any association between cerebral hemodynamics and depressive symptoms, 
we further adjusted analyses for intima-media thickness. The goodness-of-fi t of the fully 
adjusted models were assessed with the Hosmer and Lemeshow test. 
Additional analyses were done to test the effect of previous depressive symptoms on the 
association between cerebral hemodynamics and incident depression by excluding partici-
pants with a history of depression. 
Finally, multinomial logistic regression analyses were used to test the association of cere-
brovascular hemodynamics with incident clinical depressive disorders and subthreshold 
depression. Due to the small number of participants and the very limited change of the 
effect estimate in prior analyses, only age, sex, education level, and MMSE score were 
used as potential covariates. The goodness-of-fi t of the fully adjusted models were as-
sessed with Pearson chi-square test. SPSS version 17 was used for statistical analyses. 
We applied a Bonferroni adjustment to correct for the multiple testing. Because, mean 
blood fl ow velocity was derived from peak-systolic and end-diastolic blood fl ow velocities, 
we considered the tests in which these variables were used to predict CES-D scores and 
incident depressive symptoms (CES-D categorized) as four independent tests (a/4= .013).
results
Table 1 shows the baseline characteristics of the study sample. The mean age was 70.1 
years (standard deviation= 5.9) and 47.7% of the participants were female. At follow-
up, 124 subjects (8.7%) experienced incident depressive symptoms based on high CES-D 
score. Among those, 16 individuals refused to participate to the SCAN interview, 36 had 
no clinical depressive disorder or subthreshold depression, 34 diagnosed with a clinical 
depressive disorder and 38 had subthreshold depression. Participants without a SCAN 
interview had higher CES-D scores compared to the participants who completed the SCAN 
interview (25.6 vs. 22.6), although the difference was not statistically signifi cant (p= .061). 
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table 1. Baseline characteristics of the study population (1997-1999) (n=1494) 
Baseline characteristics
Gender, (female), n (%) 712 (47.7)
Age (years), mean (SD) 70.1 (5.9)
Education, n (%)
Low 336 (22.5)
Intermediate 956 (64.0)
High 202 (13.5)
Smoking status, n (%)
Never 424 (28.4)
Former ≥ 10 years 720 (48.2)
Former < 10 years 125 (8.4)
Current 225 (15.0)
Diabetes Mellitus, n (%) 73 (4.9)
Hypertension, n (%) 644 (43.1)
Ankle-brachial index, mean (SD) 1.05 (0.2)
Intima-media thickness (mm), mean (SD) 0.86 (0.1)
Body Mass Index, mean (SD) 26.6 (3.8)
Mini Mental State Examination score, mean (SD) 28.1 (1.5)
Mean blood flow velocity (cm/sec), mean (SD) 50.9 (11.3)
End-diastolic blood flow velocity (cm/sec), mean (SD) 33.0 (8.8)
Peak-systolic blood flow velocity (cm/sec), mean (SD) 86.8 (18.6)
Vasomotor reactivity [%/kPa], mean (SD) 4.1 (2.8)
First, we studied CES-D scores continuously to test the association of cerebral hemodynam-
ics with depression. Peak-systolic (beta= -0.43 per 1-standard deviation increase, standard 
error (SE)= 0.18, p=.015), end-diastolic (beta= -0.69 per standard deviation increase, 
SE= 0.18, p< .001) and mean blood flow velocities (beta= -0.59 per standard deviation 
increase, SE= 0.18, p= .001) were negatively associated with CES-D scores at follow-up 
in the unadjusted models. Except the association of peak-systolic blood flow velocity, all 
of these results remained significant after the Bonferroni adjustment. Peak-systolic (beta= 
-0.47 per 1-standard deviation increase, standard error (SE)= 0.17, p= .007), end-diastolic 
(beta= -0.47 per standard deviation increase, SE= 0.18, p= .011) and mean blood flow 
velocities (beta= -0.50 per standard deviation increase, SE= 0.18, p= .005) were negatively 
associated with CES-D scores at follow-up in the model which was adjusted for age, sex, 
level of education, MMSE. In the fully adjusted models, in which ankle-brachial index, 
hypertension, diabetes mellitus, incident stroke, and smoking were entered into the mod-
els, the associations between cerebral blood flow velocities and CES-D score remained 
significant (beta= -0.54 per 1- standard deviation increase in peak-systolic blood flow, SE= 
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0.17, p= .002; beta= -0.47 per 1- standard deviation increase in end-diastolic blood fl ow 
velocity, SE= 0.19, p= .012; beta= -0.53 per 1- standard deviation increase in mean blood 
fl ow velocity, SE= 0.18, p= .003). These results were signifi cant after the Bonferroni cor-
rection for multiple testing. Baseline vasomotor reactivity was not associated with CES-D 
scores in any models. 
Next, we studied CES-D scores categorically based on the defi ned cut-off (CES-D ≥16). 
In unadjusted models, reduced mean blood fl ow velocity, peak-systolic blood fl ow veloc-
ity, and end-diastolic blood fl ow velocity were related to incident depressive symptoms. 
Adjustment for age, sex, level of education, and MMSE score also showed that reduced 
mean blood fl ow velocity (odds ratio (OR) 0.74 per 1- standard deviation increase, 95% 
confi dence interval (CI) 0.61-0.91, p= .004), peak-systolic blood fl ow velocity (OR 0.76 per 
1- standard deviation increase, 95% CI 0.62-0.92,  p= .005) and end-diastolic blood fl ow 
velocity (OR 0.76 per 1- standard deviation increase, 95% CI 0.62-0.94, p= .010) predicted 
incident depressive symptoms. Adjustment for ankle-brachial index, hypertension, diabetes 
mellitus, incident stroke, and smoking did not change the results (Table 2). Additional 
adjustment for IMT also showed that reduced mean blood fl ow velocity (OR 0.74 per 1- 
standard deviation increase, 95% CI 0.60-0.91, p= .004), peak-systolic blood fl ow velocity 
(OR 0.75 per 1- standard deviation increase, 95% CI 0.61-0.91, p= .004) and end-diastolic 
blood fl ow velocity (OR 0.76 per 1- standard deviation increase, 95% CI 0.61-0.94, p= 
.011) predicted incident depressive symptoms. Results remained signifi cant after the 
Bonferroni correction for multiple testing. Vasomotor reactivity was not associated with 
incident depressive symptoms in any models. There was no association between vasomotor 
table 2. The longitudinal association between cerebral hemodynamic parameters and incident depres-
sive symptoms a 
Depressive symptoms
(n=124)
Unadjusted model
Depressive symptoms
(n=124)
multivariable model b
cerebral hemodynamic parameters n or 95% ci p or 95% ci p
Mean BFV, per SD 1488 0.74 0.61-0.90 .003 0.74 0.60-0.90 .003
End-diastolic BFV, per SD 1488 0.73 0.60-0.89 .002 0.76 0.61-0.94 .011
Peak-systolic BFV, per SD 1488 0.78 0.64-0.95 .011 0.74 0.61-0.90 .003
Vasomotor reactivity, per SD 1445 0.94 0.78-1.15 .549 1.03 0.85-1.26 .735
a Blood fl ow velocity (BFV) measurements and vasomotor reactivity were analyzed continuously and 
divided by 1 standard deviation (SD). 
b Adjusted for age, sex, education, diabetes mellitus, hypertension, ankle-brachial index, smoking status, 
incident stroke, and MMSE score.
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reactivity and incident depressive symptoms in the model with additional adjustment for 
IMT (OR 1.04 per 1- standard deviation increase, 95% CI 0.85-1.26, p= .73). The fit of the 
fully adjusted models were good, as shown by the Hosmer and Lemeshow test (p> .050).
Excluding participants with a history of depression did not change the results (supplemen-
tary table 1).
Next, participants with incident depressive symptoms (CES-D score ≥ 16) were further clas-
sified according to the DSM-IV based depressive disorders. Lower mean blood flow velocity 
was predictive both for incident depressive disorders and incident subthreshold depression. 
In these analyses, lower vasomotor reactivity also predicted incident depressive disorders. 
Vasomotor reactivity was associated with incident subthreshold depression. However, it 
is notable that this odds ratio is in an unexpected direction as it shows that increased 
vasomotor reactivity is positively associated with incident subthreshold depression (Table 
3). The fit of the models were good as indicated by Pearson chi-square test (p >.050). 
table 3. Association of cerebral hemodynamic parameters with subthreshold depression and depressive 
disorders a,b
cerebral hemodynamic parameters d
subthreshold depression
(n=38)
Depressive disorders c
(n=34)
or 95 % ci p or 95 % ci p
Mean BFV, per SD 0.77 0.65-0.90 .002 0.83 0.69-0.98 .032
End-diastolic BFV per SD 0.78 0.66-0.93 .006 0.89 0.74-1.07 .209
Peak-systolic BFV, per SD 0.77 0.66-0.91 .002 0.79 0.67-0.94 .007
Vasomotor reactivity, per SD 1.18 1.03-1.34 .022 0.66 0.53-0.83 <.001
a All analyses were adjusted for age, sex, education, and MMSE score.
b Persons with depressive symptoms according to CES-D were categorized into subthreshold depression 
and depressive disorders on a psychiatric interview. Persons refused to participate to the interview and 
persons who did not meet the criteria for subthreshold depression were excluded (n=52).
c Major depression (n=15), dysthymic disorder (n=4) and minor depression (n=15) were included in this 
category.  
d Blood flow velocity measurements and vasomotor reactivity were analyzed as a continuous variable and 
divided by 1 standard deviation (SD).
DisCussioN
In this population-based prospective study of older adults, reduced cerebral blood flow 
velocity predicted incident depressive symptoms, subthreshold depression, and depressive 
disorders. Lower vasomotor reactivity was not associated with incident depressive symp-
toms, but with incident depressive disorders only. 
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Previous cross-sectional fi ndings were supported and extended by exploring the direction 
of this association in a longitudinal setting. To our knowledge, the current study is the 
fi rst study supporting a possibly causal association between cerebral hemodynamics and 
incident depression by a temporal longitudinal design.
In a cross-sectional study, in which all participants were free of common cerebrovascular 
diseases, reduced vasomotor reactivity was associated with depressive disorder 19. This was 
confi rmed in another study of the same group examining participants free of vascular risk 
factors 20. In a previous publication from the Rotterdam Study we found that persons with 
depressive symptoms had reduced blood fl ow velocity and vasomotor reactivity 22. Overall, 
these fi ndings from cross-sectional studies of cerebral hemodynamics support the vascular 
depression hypothesis. But, the temporal direction remained uncertain. Our observations 
provide empirical evidence that the vulnerability for depression is indeed enhanced by 
cerebrovascular changes. Moreover, the fi ndings may shed light on the mechanism un-
derlying the cerebrovascular effect on depression. Cerebral blood fl ow velocity, which is 
modulated by blood viscosity and vascular tone, refl ects cerebral metabolism 30. Alterations 
in cerebral blood fl ow velocity occur as a result of age-related structural and biochemical 
changes in the cerebral vessels, dysfunction in autonomic neurons, and reduced demand 
30, 31. Insuffi cient autoregulation of cerebral vessels has been found to be associated with 
cerebrovascular risk factors, cerebrovascular diseases, and subcortical and periventricular 
white-matter lesions without an overt disease 18, 32, 33. Damage to end-arteries, particularly 
in the frontal-subcortical circuits, may therefore disrupt neurotransmitter systems involved 
in mood regulation, thus causing depression. 
In contrast, vasomotor reactivity, which refl ects the compensatory dilatory mechanism of 
cerebral arterioles to maintain constant cerebral blood fl ow, may indicate microangiopathy 
in cerebral vessels.  In the current study, reduced vasomotor reactivity predicted depressive 
disorders only. Participants with depressive symptoms and subthreshold depression are a 
heterogeneous group, which includes participants with other psychiatric conditions such 
as prolonged grief, anxiety disorders or participants with stressful life events resulting in 
depressive complaints. Therefore, we carefully postulate that impaired vasomotor reactiv-
ity, which refl ects microangiopathy but also refl ects autonomous disturbances in cerebral 
arteries, is a more specifi c predictor of depressive disorders.  
There might be several underlying mechanisms for the observed association between 
cerebral hemodynamics and incident depression. First, cerebral blood fl ow velocity has 
been found to be associated with incident stroke 34, and depressive disorders are common 
in patients with stroke 7, 8. It is possible that altered cerebral blood fl ow may lead to depres-
sion via the development of stroke. However, in the current study, this is unlikely because 
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we excluded participants with stroke at baseline and adjusted for any new-onset stroke 
between baseline and follow-up visits. 
The second possibility is that the vascular pathology due to generalized atherosclerosis 
is the underlying mechanism both for altered cerebrovascular hemodynamics 18 and for 
depression 13, 35, although peripheral atherosclerosis was not associated with depression 
in a longitudinal study 14. Neither were the results in our study changed by adjustment 
of ankle-brachial index, a measure of peripheral artery disease, or adjustment for intima-
media thickness of common carotid artery, which has been qualified as a marker of cerebral 
atherosclerosis 36. Undetected cerebral atherosclerosis is still a very plausible underlying 
mechanism 14. 
The third possible explanation is that the observed association reflects reverse causation, i.e., 
long-term effects of previous depressive episodes influenced the cerebral hemodynamics at 
baseline. Indeed the association between depression and cerebrovascular diseases, such as 
stroke, is bidirectional. Depression increases the risk of stroke and cardiovascular mortality. 
However, it is still unclear whether subclinical alterations to cerebral hemodynamics seen in 
depression remain after treatment of depression. Reduced cerebral blood flow velocity and 
vasomotor reactivity have been found to persist after remission of depression 37, although 
this has also been contested 21. In our study, results did not change substantially when 
participants with a history of depression were excluded. Although, depression in older 
adults is generally chronic, reversed causality cannot be fully ruled out. on the basis of 
these additional analyses because depression was assessed approximately 4 years before 
the baseline. To clarify this point, future studies are needed in which the first-ever depres-
sion, further episodes, and remission periods are closely monitored. 
Finally, poor health causing hemodynamic alterations and independently related to depres-
sion might also explain our findings, although results did not change when vascular risk 
factors and diseases were controlled for. 
The current study has several strengths. First, the large number of participants enabled us 
to evaluate a large number of covariates including sociodemographic, cardiovascular, cere-
brovascular variables. Second, the study was based on general population, enhancing the 
external validity of the findings. Third, depression was based not only on CES-D scoring, 
but also on a clinical psychiatric interview. This method let us to evaluate screen-positive 
participants with depressive disorders. Finally, the prospective design allowed us to assess 
the causal association between cerebral hemodynamics and depression. 
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Still, some limitations of the study should also be considered. Due mainly to window fail-
ure, which has also been reported in previous studies 38, 39, transcranial Doppler ultrasound 
measurements were unsuccessful in about one third of the participants. Window failure, 
which occurred most frequently in older participants and in postmenopausal women, 
depends primarily on temporal bone thickness 40. However, it is diffi cult to imagine how 
this selection at baseline could have biased the associations observed, although it might 
infl uence generalizability of the results. This might have caused true association to be 
underestimated. Selective drop-out of participants might also have led to the participants 
with incident depression to be underrepresented, yet we retained enough power to detect 
the association between vasomotor reactivity and depressive disorders.
In conclusion, the current study supports the vascular depression hypothesis in older 
adults, and the temporal relation provides support for a causal association between 
cerebrovascular hemodynamics and depression. Overall, impaired cerebrovascular function 
without any clinical representation might predispose older adults to depression. Therefore, 
vascular prevention strategies in older adults might be benefi cial and decrease the risk of 
depression. 
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s 1. The longitudinal associations between cerebral hemodynamic parameters and depressive symptom 
scores and incident depressive symptoms in participants without a history of depression
cerebral hemodynamic 
parameters
Depression scores
multivariable model b
Depressive symptoms
(n=90)
multivariable model b
n Beta standard 
error
p or 95 % ci p
Mean blood fl ow velocity 1270 -0.46 0.18 .012 0.71 0.56-0.91 .006
End-diastolic blood fl ow velocity 1270 -0.48 0.19 .012 0.72 0.56-0.93 .011
Peak-systolic blood fl ow velocity 1270 -0.41 0.18 .025 0.73 0.58-0.92 .007
Vasomotor reactivity 1232 0.07 0.18 .673 1.02 0.82-1.28 .838
a Blood fl ow velocity measurements and vasomotor reactivity were analyzed continuously and divided by 
1 standard deviation (SD). 
b Adjusted for age, sex, education, diabetes mellitus, hypertension, ankle-brachial index, smoking status, 
incident stroke, and MMSE score.
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AbstrACt 
Plasma amyloid beta (Aβ) levels have been associated with an increased risk of Alzheimer’s 
disease (AD). As depression is common before the onset of AD, a few clinical studies 
tested the cross-sectional association of Aβ levels with depression in elderly and showed 
incongruous findings. Hence, we tested the longitudinal association between Aβ levels 
and depressive symptoms in community-dwelling elderly. The study is embedded in a 
population-based cohort of 980 participants aged 60 years or older from the Rotterdam 
Study with Aβ levels. Participants were evaluated for depressive symptoms with the Centre 
for Epidemiological Studies-Depression scale at baseline and repeatedly over the mean 
follow-up of 11 years. We first performed cross-sectional analyses. Then, we tested the 
longitudinal association between A levels and depressive symptoms after excluding par-
ticipants with dementia during follow-up. In cross-sectional analyses, persons with high 
Aβ1-40 levels had more clinically relevant depressive symptoms. However, this association 
was accounted for by persons with clinically relevant depressive symptoms who developed 
dementia within the next 11 years. In longitudinal analyses, persons with low levels of Aβ1-
40 and Aβ1-42 without dementia had a higher risk of clinically relevant depressive symptoms 
during the follow-up. These findings suggest that the cross-sectional association between 
high plasma Aβ levels and clinically relevant depressive symptoms in the elderly is due to 
prodromal dementia. In contrast, the longitudinal association between low plasma Aβ 
levels and depressive symptoms could not be explained by dementia during follow-up 
suggesting that Aβ peptides may play a distinct role on depression aetiology.
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iNtroDuCtioN
Two soluble forms of amyloid  peptides, amyloid  beta 1-40 (Aβ1-40) and amyloid beta 1-42 (Aβ1-
42), have been associated with an increased risk of Alzheimer’s disease (AD) 1, 2. On the basis 
of the observation that depression is common before the onset of AD, several studies have 
tested the association of Aβ levels with depression in older adults. The fi ndings of these 
cross-sectional studies were inconsistent. While high Aβ1-42 levels in people with depression 
were found in some studies, an association between low Aβ1-42 levels and depression was 
observed in others 3-9. Moreover, to what extent prodromal dementia contributes to the 
cross-sectional associations is unknown. A longitudinal study that excluded all participants 
with dementia at baseline or during 5 years of follow-up showed that higher baseline Aβ1-
42 levels were associated with incident depression 10. However, as Aβ levels start to change 
5 to 10 years before the onset of AD 11, a longer follow-up is needed to clarify whether 
this association is independent of the prodromal effects of AD. In addition, it is important 
to explore Aβ1-40, as it has not been tested longitudinally. We therefore investigated the 
cross-sectional association between A peptides and clinically relevant depressive symptoms 
with and without exclusion of persons who developed dementia during the follow-up. 
Next, we conducted longitudinal analyses excluding those who develop dementia during 
the follow-up.
MAteriAl AND MethoDs
study sample
This study is embedded in the Rotterdam Study, an ongoing prospective population-based 
cohort of older adults 12, which has been approved by the institutional review board of 
Erasmus University Medical Centre and by the review board of the Netherlands Ministry 
of Health, Welfare and Sports. All participants provided written informed consent after 
receiving a complete description of the Rotterdam Study.
Baseline measurements for the current study were performed at the examination round 
between 1997- 1999. The fi rst and the second follow-up examinations were performed 
between 2002- 2004 and 2009- 2011, respectively. Mean time interval between baseline 
and the fi rst interview was 4 years (Standard deviation [SD]= 0.5) and between baseline 
and the second interview was 11 years (SD= 0.6).
At baseline (1997-1999), 4797 participants were involved in the study. From this source 
population, we formed a random sample of 1023 people for Aβ1-40 or Aβ1-42 measure-
ments. Twenty-two participants who did not have a valid Centre for Epidemiological 
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Studies Depression scale (CES-D) score and 9 participants with dementia at baseline were 
excluded from the current study, leaving 992 participants with at least one measurement of 
Aβ. Also, we excluded participants with Aβ1-40 (n= 12) or Aβ1-42 (n= 4) concentrations that 
were out of the mean range of ± 3 standard deviation (SD). The final population for cross-
sectional analyses consisted of 980 participants for whom Aβ1-40 levels were available and 
970 for whom Aβ1-42 levels were available. People who excluded from the baseline random 
sample (n= 43) were older than the participants (p< .001). There was no significant gender 
difference between participants and non-participants (p= .881). 
For the longitudinal analyses, we further excluded 67 participants with clinically relevant 
depressive symptoms (CES-D score ≥ 16) at baseline and 107 participants with incident 
dementia by the end of the second follow-up (2011). Of the remaining 806 participants, 
86 died (10.7%) between baseline and the follow-up examinations, 58 refused to partici-
pate (7.2%) to any follow-up, and 5 (0.6%) did not have a valid CES-D measurement in 
any follow-up. This provided an overall sample of 657 participants with a valid depression 
evaluation and at least one Aβ measure (participants with Aβ1-40, n= 657; participants with 
Aβ1-42, n= 650) for the longitudinal analyses of repeated CES-D measure. A flow diagram 
of the study population at baseline and at follow-up visits was presented in figure 1. 
Assessment of Aβ Levels
Fasting morning blood samples were collected in sodium citrate containing vacutainers 
and put on ice immediately after collection. These samples were centrifuged within 60 
minutes, and aliquots of the plasma were stored at -80 ºC. A double-antibody sandwich 
enzyme-linked immunosorbent assay (ELISA) method was used to determine Aβ plasma 
concentrations 1. The mean coefficients of within- and between-assays variation were 
4.4 % and 10.1% for Aβ1-40 and 4.9% and 14.8% for Aβ1-42. The detection limits were 
10–1000 pg/ml for Aβ1-40 and 5–100 pg/ml for Aβ1-42. 
Assessment of Depression
We used the CES-D, a self-report scale, for measuring depressive symptoms at baseline 
and at follow-up visits 13. The CES-D interviews were part of the home interviews, which 
were performed by research assistants who monitored the completion of the questions. 
The CES-D scores were analysed continuously (depressive symptom scores) and a cut-off 
of 16 was used to detect participants with clinically relevant depressive symptoms. This 
score has a very high sensitivity for major depression in older adults in the Netherlands 
14. Incident clinically relevant depressive symptoms were defined in participants free of 
clinically relevant depressive symptoms at baseline as the CES-D score of 16 or over at one 
of the follow-up assessments.  
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For additional analyses, we studied past clinically relevant depressive symptoms. In the pre-
vious examination wave of the Rotterdam Study (1993-1995), history of clinically relevant 
depressive symptoms was evaluated with the CES-D or the Hospital Anxiety-Depression 
Scale (HADS). We used a cut-off score of 16 for the CES-D and a cut-off score of 9 for the 
HADS to detect participants with clinically relevant depressive symptoms in the past 15.
Assessment of Dementia
Dementia was assessed with multiple sources including diagnostic evaluation at follow-up 
visits and continuous monitoring to capture more events. Participants were screened for 
dementia at baseline and follow-up visits using a 3-step protocol 16. First, all participants 
were screened for the cognitive functions using the Mini-Mental State Examination (MMSE) 
and Geriatric Mental State Schedule (GMS) organic level. Then, participants with a MMSE 
score < 26 or a GMS organic level > 0 underwent the Cambridge Examination for Mental 
Disorders of the Elderly. Finally, participants who were suspected to have dementia were 
examined by an experienced neuropsychologist, if necessary. Additionally, participants were 
continuously monitored for incident dementia by a computerized system that synchronised 
the study database with the digitized medical records of general practitioners and the 
regional Institute for Outpatient Mental Health Care 16, 17. A consensus panel of a neurolo-
gist, neuropsychologist, and research physician decided on the fi nal diagnose on the basis 
of the DSM-III-R criteria for dementia 18 and the NINCDS-ADRDA for Alzheimer’s disease 
19. Follow-up for incident dementia was complete until January 1, 2011. Participants who 
were free of dementia at baseline but were diagnosed with dementia during the maximum 
follow-up of 13 years were considered as participants with prodromal dementia at baseline. 
Assessment of covariates
Age, sex, level of education, cognitive functions, creatinine levels, antidepressant use 
and cardiovascular risk factors were considered as possible confounders. Education was 
grouped into eight categories in an ordinary scale from primary education (1) to university 
level (8). The MMSE was used to evaluate cognitive state. 20 Plasma creatinine level, which 
is considered as a determinant of amyloid beta levels 21, were measured with an enzymatic 
in-vitro assay (Roche, Germany). Antidepressant use was determined from the cabinet check 
at home interviews. Body mass index, smoking status, prevalent stroke, diabetes mellitus 
and hypertension were considered as vascular risk factors. Height (meters) and weight 
(kilograms) were measured and body mass index was calculated as weight in kilograms 
divided by height in meters squared. Smoking status was categorized as never, former, and 
current smoker, on the basis of the baseline interview. Information about prevalent stroke 
at baseline was obtained through automated linkage of the study database with fi les from 
general practitioners, hospital records, and the municipality. Diabetes mellitus was defi ned 
as having fasting blood glucose concentrations ≥ 11.1 mmol/L or the use of antidiabetic 
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medication. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, a diastolic 
blood pressure ≥ 90 mmHg, or the use of antihypertensive medication. 
statistical Analyses 
Aβ levels were analysed continuously. To approach normality, we log transformed the CES-
D scores for the continuous analyses. We also tested the CES-D scores categorically using 
the established cut-off of 16 for clinically relevant depressive symptoms. Aβ levels had 
normal distribution when we excluded outliers.
To estimate the cross-sectional associations between Aβ levels and the odds of clinically 
relevant depressive symptoms, we ran two analyses. First, we included all participants 
with clinically relevant depressive symptoms as cases at baseline. Second, we defined two 
groups of cases with clinically relevant depressive symptoms at baseline: 1) persons with 
clinically relevant depressive symptoms and no dementia during follow-up (n= 54), 2) 
persons with clinically relevant depressive symptoms and dementia during follow-up (n= 
13). For the second analysis, we used multinomial logistic regression analysis to compare 
the two case groups with the reference group, which consisted of persons free of clinically 
relevant depressive symptoms and dementia during follow-up (n=806).
We tested the longitudinal associations in those who remained free of dementia during the 
follow-up. The longitudinal association of Aβ levels with continuously measured depressive 
symptoms was assessed with the Generalized Estimating Equations (GEE), to combine the 
scores from follow-up visits. This statistical method increases the power and reduces the 
type I error caused by multiple testing, but also takes account of the correlation between 
the repeated depression measures. To study the short- and long-term follow-up associa-
tions of Aβ levels with depressive symptom scores at first and second follow-up visits, we 
additionally performed linear regression analyses. Finally, we used the GEE method with 
a binary logistic function to predict incident clinically relevant depressive symptoms dur-
ing the mean follow up of 11 years. Additionally, we used logistic regression analyses to 
investigate the associations at individual follow-up visits. 
All analyses were adjusted for age and gender. Additional covariates including educa-
tion, MMSE score, plasma creatinine levels, and antidepressant use were entered into 
the model. To investigate to what extent any association of Aβ levels with depressive 
symptoms is explained by an effect on vascular risk factors, we additionally controlled the 
GEE analyses for vascular risk factors including smoking status, body mass index, prevalent 
stroke, hypertension and diabetes mellitus.
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We performed a series of sensitivity analyses. First, to test the possible reverse causality, 
we excluded participants with a history of clinically relevant depression and performed 
additional GEE analyses. Second, to test the possible effect of including extreme values 
of Aβ (those above 3 SD) on the associations, we performed sensitivity analyses assigning 
the outlier values to the value equivalent to 3 SD and repeated the GEE analyses. Finally, 
we performed a sensitivity analysis considering antidepressant users at follow-up visits as 
persons with clinically relevant depressive symptoms. This makes it possible any misclas-
sifi cation of persons with clinically relevant depressive symptoms that were successfully 
treated.
SPSS version 17 was used for statistical analyses. A two-sided p< .05 was considered to 
indicate statistical signifi cance.
results
The baseline characteristics of the study sample are presented in table 1. The mean age 
was 71.6 years (SD= 6.8), and 581 (59.3%) of the participants were female. At baseline, 
67 (6.8%) participants had clinically relevant depressive symptoms. 
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table 1. Baseline characteristics of the study population
Baseline information
study sample
N= 980
Age, mean years (SD) 71.6 (6.8)
Female, n (%) 581 (59.3)
Education (range: 1 to 8), mean (SD) 3.7 (1.9)
Smoking status
Current smoker, n (%) 160 (16.3)
Former smoker, n (%) 472 (48.2)
Never smoked, n (%) 348 (35.5)
Stroke, n (%) 32 (3.3)
Hypertension, n (%) a 447 (45.6) 
Diabetes Mellitus, n (%) 124 (12.7)
Body mass index (kg/m2) , mean (SD) 26.9 (3.7)
Mini mental state examination score, mean (SD) 27.8 (1.8)
Clinically relevant depressive symptoms b, n (%) 67 (6.8)
History of clinically relevant depressive symptoms, n (%) 60 (6.1)
Antidepressant use at baseline, n (%) 39 (4)
Creatinine level (μmol/l), mean (SD) 79.4 (17.8)
Amyloid β1-40 (pg/ml), mean (SD) 205.6 (62.5)
Amyloid β1-42 (pg/ml), mean (SD) 18.6 (8.4)
Abbreviations: SD= Standard Deviation
a In total, 945 participants had hypertension data. 
b People with a CES-D score ≥16 are considered as people with clinically relevant depressive symptoms.
The fully adjusted cross-sectional analyses showed that the likelihood of having clinically 
relevant depressive symptoms was 34% higher per standard deviation increase in Aβ1-40 
levels (Table 2). However, when we categorized participants on the basis of whether they 
developed dementia during follow-up in a further analysis, we found that this association 
was accounted for by persons with clinically relevant depressive symptoms that preceded 
incident dementia (prodromal dementia). Per standard deviation increase in Aβ1-40 levels 
were related to an approximately two times higher likelihood of having clinically relevant 
depressive symptoms in participants who developed dementia during follow-up compared 
to the non-depressed reference group. Aβ1-42 levels were not related with clinically relevant 
depressive symptoms in the cross-sectional analyses (Table 2).
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table 2. Cross-sectional associations between aβ levels and clinically relevant depressive symptoms by 
prodromal dementia status (n=980) a
All clinically relevant 
depressive symptoms b
(n=67)
clinically relevant 
depressive symptoms 
without prodromal 
dementia c
(n=54)
clinically relevant 
depressive symptoms 
with prodromal 
dementia c
(n=13)
or 95 % ci p or 95 % ci p or 95 % ci p
Aβ1-40 (per SD)
Model 1 1.20 0.95 - 1.52 .12 1.07 0.82 - 1.40 .61 1.65 1.04 - 2.62 .03
Model 2 1.34 1.04 - 1.71 .02 1.17 0.88 - 1.55 .29 2.22 1.33 - 3.73 .002
Aβ1-42 (per SD)
Model 1 1.09 0.87 - 1.37 .45 0.98 0.74 - 1.29 .87 1.24 0.86 - 1.79 .25
Model 2 1.12 0.89 - 1.41 .32 1.00 0.76 - 1.32 .98 1.34 0.92 - 1.95 .12
Abbreviations: Aβ, Amyloid beta; OR, Odds ratio; CI, Confi dence interval; SD, Standard deviation
Model 1 is adjusted for age and gender and model 2 is adjusted for age, gender, education, mini mental 
state examination score, creatinine levels, and antidepressant use.
a Persons with a CES-D score 16 or greater are considered as persons with clinically relevant depressive 
symptoms. 
b Logistic regression analyses were used to test the cross-sectional association between A� levels and clini-
cally relevant depressive symptoms at baseline in the total study population.  
c We tested the cross-sectional associations of A� levels with clinically relevant depressive symptoms fi rst 
in persons with and then in persons without prodromal dementia using multinomial logistic regression 
analyses. We used persons free of clinically relevant depressive symptoms and free of prodromal demen-
tia at baseline as the reference category.
The longitudinal analyses of repeated CES-D measurements showed that high Aβ1-40 and 
Aβ1-42 levels at baseline were associated with a decreased risk of having high depressive 
symptom scores. As table 3 shows, lower Aβ1-40 and Aβ1-42 levels were associated with 
higher depressive symptom scores at the fi rst follow-up in those free of dementia during 
follow-up visits. At the second follow-up visit, there were also inverse associations between 
A βlevels and depressive symptom scores, but neither of these associations was statistically 
signifi cant. Combining two CES-D measurements in different time points increased the 
precision of estimate as can be seen by the narrower CIs in GEE analyses when compared 
to the analyses of the individual follow-up visits. 
When we used the CES-D scores categorically, we found consistent results. Lower Aβ1-42 
levels were associated with a higher risk of clinically relevant depressive symptoms (Table 3) 
in the combined analyses. At the fi rst follow-up, there was a borderline signifi cant associa-
tion between Aβ1-42 levels and incident clinically relevant depressive symptoms, whereas 
that association was clearly signifi cant at the second follow-up. There was an inverse rela-
tion also between Aβ1-40 levels and clinically relevant depressive symptoms at the second 
follow-up, but this association was not observed when we used the GEE method.
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Additional adjustment for vascular risk factors or excluding participants with a history of 
clinically relevant depressive symptoms did not improve the model in the additional GEE 
analyses (data not shown). Sensitivity analyses in which we assigned the extreme outlier 
values equivalent to 3 SD did not change the results of the GEE analyses (data not shown). 
When we considered antidepressant users as persons with clinically relevant depressive 
symptoms (cases), our results did not change marginally (data not shown).
DisCussioN
This population-based cohort study explored the cross-sectional and longitudinal associa-
tions of Aβ peptides with depressive symptoms in elderly people. Participants with high 
levels of Aβ1-40 were more likely to have prevalent clinically relevant depressive symptoms 
but only if they developed dementia during follow-up. Longitudinal analyses showed that 
lower plasma concentrations of Aβ1-40 and Aβ1-42 were associated with a higher risk of clini-
cally relevant depressive symptoms and lower levels of Aβ1-42 predicted incident clinically 
relevant depressive symptoms during the mean follow-up of 11 years. 
The relation of plasma Aβ levels with depression has been tested mostly in cross-sectional 
studies. A series of studies by one group found lower levels of plasma Aβ1-42 in patients 
with depressive symptoms, whereas plasma Aβ1-40 levels were not related to depressive 
symptoms 5-9. However, these results have not been confi rmed by other studies 3, 4, 22 and 
it is not clear whether these associations are due to changes in Aβ levels before the onset 
of overt dementia. The present cross-sectional analyses showed a positive association be-
tween Aβ1-40 levels and clinically relevant depressive symptoms. However, this association 
was accounted for by participants with dementia during follow-up (i.e. those are at the 
latent or prodromal phase of dementia at baseline) 23. This fi nding is also in line with a 
previous report from the Rotterdam Study, which showed that high Aβ1-40 but not Aβ1-42 
levels predict dementia many years prior to onset of clinical disease 1.
Plasma Aβ levels change 5 to 10 years before the onset of AD 11, 24. Therefore, it is im-
portant to consider the new-onset dementia occurring after baseline when exploring the 
independent association of Aβ levels with depression. Only one longitudinal study with 5 
years of follow-up by Blasko et al. excluded new-onset dementia 10. Blasko et al. found that 
high plasma Aβ1-42 levels were associated with the fi rst episode of late onset depression, 
in contrast to our prospective cohort study with a more than 10 years of follow-up for 
depressive symptoms and dementia. 
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Several mechanisms may explain the inverse relation between plasma Aβ levels and depres-
sive symptoms that we found in our longitudinal analyses. As cerebral and peripheral levels 
of Aβ are probably in dynamic equilibrium 25, any deposition of Aβ peptides in the brain 
may reduce the plasma levels of Aβ. These brain depositions occur in the neurons and in 
cerebral vessels which may play a role in the etiology of depression 26, 27. Neurotoxic effects 
are characterized by a damage to serotoninergic, noradrenergic and cholinergic markers in 
neurons 28 and increased free radical production 27. Furthermore, Aβ peptide aggregations 
in small cerebral vessels can decrease cerebral blood flow and glucose utilization. This may 
cause white-matter lesions and lacunar infarcts in the brain and precipitate late life depres-
sion 26, 29-32. However, our analyses showed that adjustment for the common vascular risk 
factors did not change the results substantially. 
Some non-causal explanations should also be discussed. Reversed causality might be 
responsible for the observed associations. Reversed causality occurs if the outcome is caus-
ally related to the exposure. Depressive symptoms before baseline could have altered Aβ 
levels by the increased platelet activation, which can stimulate Aβ release to the circulation 
33-35. However, excluding the participants with a history of clinically relevant depressive 
symptoms did not change the results in our study. 
Residual confounding due to unmeasured or unknown confounders e.g. diet, physical 
activity, non-clinical cerebrovascular changes, etc., which are associated with both Aβ 
levels and depression, cannot be ruled out and may partially explain our observations 36.
There are several strengths of the current study. First, the large study sample and existence 
of numerous data collection enabled us to evaluate a large number of covariates. Second, 
the population-based setting increased the generalizability of the findings. Third, the pro-
spective design allowed us to assess the temporal association between Aβ peptides and 
depressive symptoms. Finally, evaluation of the mediating effect of dementia was rendered 
possible by complete screening for new-onset dementia during follow-up.
Some limitations in our study should be mentioned. Depression was evaluated with the 
CES-D, which is commonly used in population-based studies to evaluate clinically relevant 
depressive symptoms. Therefore, it remains unanswered whether these results can be gen-
eralized to clinical depressive disorders. Second, loss to follow-up was not very substantial, 
but may yet be a source of downward bias because participants with clinically relevant 
depressive symptoms are underrepresented in the study population. However, we had 
enough power to observe an association between Aβ levels and depressive symptoms. 
Finally, long time interval between baseline and follow-up interviews may affect our results 
as those persons with chronic or recurrent depressive symptoms are more likely to be 
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identifi ed as a case. However, when we consider antidepressant users as persons with 
clinically relevant depressive symptoms, our results did not change largely.
In conclusion, decreased Aβ levels were associated with clinically relevant depressive symp-
toms in participants free of dementia during follow-up. Our study provides evidence that 
Aβ peptides may play a role in aetiology of depression independent of dementia.  
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AbstrACt
The genetics of depression has been explored in genome-wide association studies that fo-
cused on major depressive disorder or depressive symptoms with mostly negative findings. 
A broad depression phenotype including both phenotypes has not been tested previously 
using a genome-wide association approach. We aimed to identify genetic polymorphisms 
significantly associated with a broad phenotype from depressive symptoms to major depres-
sive disorder.  We analysed two prior studies of 70,017 participants of European ancestry 
from general and clinical populations in the discovery stage. We performed a replication 
meta-analysis of 28,328 participants. SNP-based heritability and genetic correlations were 
calculated using LD score regression. Discovery and replication analyses were performed 
using a P-value based meta-analysis. Lifetime major depressive disorder and depressive 
symptom scores were used as the outcome measures. The SNP-based heritability of major 
depressive disorder was 0.21 (SE= 0.02), the SNP-based heritability of depressive symptoms 
was 0.04 (SE= 0.01), and their genetic correlation was 1.001 (SE= 0.2). We found one 
genome-wide significant locus related to the broad depression phenotype (rs9825823, 
chromosome 3: 61,082,153, p= 8.2x10-9) located in an intron of the FHIT gene. We rep-
licated this SNP in independent samples (p= 0.02) and the overall meta-analysis of the 
discovery and replication cohorts (p= 1.0x10-9). This large study identified a new locus for 
depression. Our results support a continuum between depressive symptoms and major 
depressive disorder. A phenotypically more inclusive approach may help achieve the large 
sample sizes needed to detect susceptibility loci for depression.
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iNtroDuCtioN
The etiology of depression – a worldwide leading cause of disability 1 – is not well under-
stood. As indicated by family, twin and adoption studies, genetic factors mediate part of 
vulnerability to major depressive disorder (MDD) with a modest heritability of around 40% 
2. However, we understand little of the specifi c genetic architecture of MDD. Multiple 
genome-wide association studies (GWAS) for MDD have been published 3-10. The larg-
est MDD GWAS was the mega-analysis by the MDD Working Group of the Psychiatric 
Genomics Consortium (PGC). In that study, more than 9,000 MDD cases and 9,500 control 
subjects were analyzed, but no association with MDD reached genome-wide signifi cance 
7. Recently, the CONVERGE (China, Oxford and VCU Experimental Research on Genetic 
Epidemiology) consortium identifi ed two genome-wide signifi cant associations in 5,303 
Chinese women with severe and recurrent MDD (near the SIRT1 gene, p= 2.53x10-10 and 
in an intron of the LHPP gene, p= 6.45x10-12) 11.  A GWAS of depressive symptoms (23%-
29% heritability) 12, 13 in the Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy (CHARGE) consortium in approximately 50,000 people from the general population 
found no genome-wide signifi cant associations 14. Owing to the relatively small sample 
sizes, the previous GWAS of depressive disorders and depressive symptoms were arguably 
underpowered to detect small genetic effects 15, 16. 
Depression can be conceptualized along a continuum of severity from subthreshold or 
minor depression to MDD of varying severity (e.g., mild, moderate, severe) 17. Using a 
continuum approach may augment statistical power as sample size can be increased 
substantially and patients who fall into the ‘grey area’ can be assessed. Several lines of 
evidence support a depression continuum. In longitudinal studies, there is an increased 
risk of MDD in patients with minor depression and subthreshold depression 18, 19. Statisti-
cal studies of disorder classifi cation (taxometric) suggested that severity of depression is 
continuously distributed and there is no discontinuity in the latent structure of depression 
19, 20. Family studies report that relatives of probands with milder forms of depression have 
greater risk of MDD compared to relatives of probands without any mood disorders 21-24. 
A higher number of depressive symptoms is related to greater disability, worse quality of 
life, and a higher mortality risk 18, 25-29. MDD and continuous measures of depression are 
highly correlated, and severity of depressive symptoms along the continuum is linear 30, 31.
The goal of the current study was to combine the results of the largest GWAS using cat-
egorical lifetime MDD and continuous measures of depression to identify genetic variants 
underlying the entire depression continuum.
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study Design and samples
This study was a collaboration between investigators on the PGC MDD and CHARGE 
genome-wide association meta-analyses (GWAMA). In the discovery phase, we aggregated 
two GWAMA published in 2013 7, 14. Basic descriptive features and phenotype definitions 
of the contributing samples are provided in Supplemental Table S1. The mega-analysis 
of MDD consisted of nine studies of 9,240 cases meeting international criteria for life-
time MDD and 9,519 healthy control subjects. The CHARGE meta-analysis of depressive 
symptoms included 22 cohorts and comprised 51,258 persons. Each cohort contributing 
to the GWAMA of the PGC and CHARGE were distinct. In the replication analyses, 16 
case-control studies with DSM-IV MDD (6,718 cases and 13,453 controls) were included 
along with 8,157 subjects from the general population with assessment of depressive 
symptoms. All subjects were of European ancestry. Institutional review boards approved all 
studies, and all participants provided written informed consent. 
Phenotype characteristics
In the PGC GWAMA, MDD was established with structured clinical interviews (e.g., Clinical 
Interview Schedule-Revised, Diagnostic Interview for Genetic Studies, and the Structured 
Clinical Interview for DSM-IV). All clinical evaluations were made by experienced clinicians/
interviewers. Most cases were ascertained from clinical sources. Controls were screened 
in most of the studies to require the absence of MDD and recruited from the general 
population. Full details about the PGC samples can be found in the previous publication 
7. In the CHARGE GWAMA, depressive symptoms were assessed with validated question-
naires. Measures include the Center for Epidemiological Studies-Depression scale, Geriatric 
Depression Scale, Patient Health Questionnaire-9, and the Beck Depression Inventory-II, 
mostly assessing depressive symptoms during previous weeks rather than lifetime MDD 14. 
Persons with schizophrenia, bipolar disorder, and dementia were excluded. Persons aged 
40 years or older and with genotype data and depressive symptom score were included.
The 16 MDD case-control replication samples were part of an expanded but unpublished 
PGC MDD analysis. MDD was diagnosed with interviews. In the depressive symptom rep-
lication cohort, the Health and Retirement Study, the 8-item Center for Epidemiological 
Studies-Depression scale was applied. Respondents were excluded if they were less than 
40 years of age or evidence of cognitive impairment.
Genotyping and imputation
In the PGC samples, (Supplemental Table S1), individual genotypes were assembled, 
processed through a central quality control pipeline and imputed using the CEU (Central 
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Europe) and TSI (Toscani in Italy) HapMap3 reference panels. Quality control procedures 
were extensive 7. In the CHARGE cohorts, genotype quality control and imputation were 
conducted in each study separately. The imputation reference was the HapMap2 CEU panel 
14. In the MDD replication cohorts (Supplemental Table S3), imputation was performed 
using IMPUTE2 or SHAPEIT (chunk size of 3 Mb and default parameters). The imputation 
reference set consisted of 2,186 phased haplotypes from the 1000 Genomes Project. In 
the Health and Retirement Study, imputation was performed using the HapMap2 CEU 
reference panel. 
statistical Analyses
Linkage disequilibrium score regression was used to compute the single nucleotide poly-
morphism (SNP)-based heritability and the genetic correlation using the 1000 Genomes 
CEU reference panel 32. 
In the PGC GWAMA, a logistic regression analysis was used to test the association between 
MDD and imputed SNP dosages under an additive model and adjusting for study indicators 
and fi ve principal components 7. In the CHARGE GWAMA, a linear regression analysis was 
applied to test the association of depressive symptom score on imputed SNP dosages in 
the contributing studies adjusting for age and sex. Analyses were adjusted for principal 
components for most, but not all, cohorts in the CHARGE GWAMA. A p-value-based 
meta-analysis was applied in the CHARGE GWAMA 14. Effect size estimates were based 
on a dichotomous outcome in the PGC and on a continuous outcome in the CHARGE 
GWAMA. To combine these effect estimates, a p-value-based meta-analysis weighted by 
sample size with METAL was used. This method allows different weights for each study and 
takes into account the direction of effect at each SNP 33. To specify the direction of the ef-
fect, the PGC used the logistic regression coeffi cient beta and the CHARGE used Z-scores. 
Weights were based on the number of the MDD cases in the PGC study (n= 9,240), and 
the number of individuals in the CHARGE with clinically signifi cant depressive symptoms 
(n= 5,976) using population-specifi c cutoff scores of the questionnaires was considered 
for weighting. To test whether the results are affected by different sample size weightings, 
equal weights per study, or no weight as suggested by Stouffer et al. 34, we carried out a 
series of sensitivity analyses. 
We selected the genome-wide signifi cant SNPs in two loci from the discovery stage for 
replication. After analyzing these data, we performed a p-value-based meta-analysis 
combining all replication samples. Further, we analyzed the results of the discovery and all 
replication samples weighting for number of cases. 
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results
In the discovery stage, we performed a GWAMA in 70,017 participants of European ances-
try by combining the PGC MDD 7 and CHARGE GWAMA 14. We applied a linkage disequilib-
rium score regression to the summary statistics from each study to compute the SNP-based 
heritabilities and the genetic correlation. As reported previously 35, the SNP-based liability 
scale heritability of MDD was 0.2 (SE= 0.02) for 20% of prevalence. The lambda was 1.1 
and the regression intercept was 1.0 (SE= 0.01). The SNP-based heritability of depressive 
symptoms was 0.04 (SE= 0.01). The lambda was 1.1 and the regression intercept was 1.0 
(SE= 0.01). The SNP-based heritability of the broad depression phenotype was 0.3 (SE= 
0.04). MDD and depressive symptoms showed significant co-heritability (1.001, SE= 0.2, 
z-score= 4.6, p=4.6x10-6). This result supports the contention of a continuum between 
depressive symptoms and MDD. However, the genetic correlation should be interpreted 
carefully because linkage disequilibrium score regression is quite sensitive to environmental 
confounding, and like twin studies, often lacks precision. In addition, different evaluation 
methods of the depression phenotypes might cause different genetic correlation estimates 
that cannot easily be compared.
We conducted a meta-analysis of the PGC MDD and the CHARGE depressive symptoms 
GWAMA using a weighted, p-value-based meta-analysis. The results are summarized in 
Figure 1 and Supplemental Figures S1 to S3. The combined meta-analysis was conducted 
for 918,921 SNPs. Two loci were genome-wide significant: an SNP in an intron of the FHIT 
gene (rs9825823, chromosome 3: 61,082,153, p= 8.2x10-9) and an SNP in an intron of 
PLEK2 (rs9323497, chromosome 14: 67,873,128, p= 3.3x10-8) (Table 1). All SNPs with a 
p value of association <5x10-5 are presented in Supplemental Table S2. Using different 
weights or Stouffer’s unweighted method had only slight effects on the results (data not 
shown). Supplemental Figures S4 and S5 show forest plots for two SNPs shown in Table 1. 
Table 2 presents the replication analyses and the meta-analysis of discovery and replication 
results. One of the genome-wide significant variants within the FHIT gene (rs9825823) was 
associated with depression continuum in the replication cohorts (z-score=2.4, p=0.02). 
The result of the final meta-analysis of discovery and replication samples also indicated a 
positive replication as indexed by a lower p value (z-score=6.1, p=1.0x10-9). This SNP had 
a positive association with depressive symptoms in the CHARGE study (p= 5.5 x 10-4), and 
a similar pattern was observed in the PGC study (p= 4.1 x 10-6). The SNP in an intron of 
PLEK2 (rs9323497) was not related to depression continuum significantly (z-score= 0.2, 
p= 0.9).
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Figure 1: Manhattan Plot . The x-axis represents the chromosomal position for each SNP, and the y-axis 
represents the -log10(p) value for association with depression.
table 1. Meta-analysis results of the PGC MDD GWAMA and the CHARGE depressive symptoms 
GWAMA(discovery) 
combined meta-analysis* 
(Ntotal=70,017)
sNP chr BP closest 
Gene
Location Allele mAF Direction z-score p
rs9825823 3 61,082,153 FHIT intron T/C 0.46 ++ 5.8 8.2x10-9
rs9323497 14 67,873,128 PLEK2 intron T/C 0.05 ++ 5.5 3.3x10-8
Chr: chromosome, BP: base pair, MAF: minor allele frequency (GRCh37/hg19). Allele: Minor/Major on 
the + strand. Direction of effect: CHARGE (N=51,258; continuous outcome analysis), PGC (n=18,759; 
of which 9,240 were MDD cases). * This analysis was weighted for number of participants with clinically 
signifi cant depressive symptoms in the CHARGE study (n=5,976) and number of cases in the PGC study 
(n=9,240). 
We performed an additional replication analysis of our two genome-wide signifi cant SNPs 
using the publicly available data of the recently published GWAMA of depressive disorders 
in a sample of Chinese women (the CONVERGE study) 11. In CONVERGE, rs9825823 
(odds ratio= 1.01, p= 0.12) and rs9323497 (odds ratio= 0.97, p= 0.0002, with a differ-
ent direction of association than in our discovery sample) were not related to depression 
at the genome-wide signifi cance level, although the latter reached nominal signifi cance. 
However, in the joint meta-analysis of the Health and Retirement Study, PGC MDD study 
and the CONVERGE study, we found that the association between rs9825823 and the 
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depression continuum (z-score= 2.85, p= 0.004) was slightly stronger than our initial 
replication analysis. When these replication and discovery samples were combined, the 
association with our top hit also became stronger (analyses without the CONVERGE data: 
z-score= 6.1, p= 1x10-9; with the CONVERGE data: z-score= 6.2, p= 6.8x10-10). Results of 
additional replication analyses are given in Supplemental Table S4. 
DisCussioN
We report the results of a combined GWAMA of depression continuum including MDD 
(18,759 cases and control subjects) and depressive symptoms (51,258 participants). In the 
discovery stage, we found genome-wide signifi cant associations in the FHIT and PLEK2 
genes. One SNP in the intron of the FHIT gene showed a signifi cant association in the 
combined analysis of discovery and replication samples of MDD and depressive symptoms 
samples, and exceeded a genome-wide signifi cance threshold. 
The signifi cant locus (rs9825823, chromosome 3: 61,082,153) maps to the intronic region 
of the FHIT gene, a tumor suppressor protein implicated in several cancers 36. FHIT is ex-
pressed in multiple brain regions (amygdala, anterior cingulate cortex, caudate nucleus, 
prefrontal cortex, hippocampus, and hypothalamus, http://www.gtexportal.org/home/
gene/FHIT, accessed 10.07.2016). It plays an important role in oxidative stress and level 
of DNA damage 37, biological processes implicated in MDD 38, 39. FHIT is a circadian clock 
modifi er gene 40 and has been related to daytime sleepiness 41, which may be salient to the 
etiology of depression. 
In a GWAS of recurrent, early-onset MDD, three SNPs located in the FHIT gene were among 
the strongest associations in the overall and sex-stratifi ed analyses 8 although none had 
genome-wide signifi cance. Genetic variants located in FHIT have been reported in genetic 
studies of anxiety,42 autism 43, mental stress 44, comorbid depressive syndromes and alcohol 
dependence 45, citalopram-induced side effects 46 and in a latent class analysis of MDD 
symptoms 7, but none has met genome-wide signifi cance. 
Several methodological aspects should be discussed. First, we evaluated depression con-
tinuum by combining cases from clinical populations diagnosed with MDD and participants 
from the general population who had been assessed for depressive symptoms. Such 
an inclusive approach may increase heterogeneity of the phenotype especially because 
lifetime MDD was evaluated, whereas depressive symptoms indicate past weeks only. 
If anything, such approach would cause an underestimation of the effects because less 
information on depressive symptoms was obtained. However, the advantages of a large 
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sample can outweigh the disadvantages of a less precisely defined phenotype. This has 
been observed in the GWAS of educational attainment that was successfully used as a 
proxy for intelligence 47. Our additional replication analysis showed that increasing the 
sample size yielded a stronger association of the top hit with depression continuum. It 
is complex to calculate statistical power of the current analysis because quantitative and 
qualitative measures were combined. In the current study, a genetic association with the 
depression continuum may reflect an effect on broad depressive phenotypes but could 
also be accounted for by an association with low levels of general well-being (12-18% 
heritability) that co-occur with depressive symptoms 48. Second, we used a p-value-based 
meta-analysis, because effect estimates could not be directly evaluated in a straightforward 
manner. Third, the heterogeneity of the imputation methods used in the PGC and CHARGE 
discovery samples might reduce the statistical power. However, different imputation refer-
ences did not change the results in the published PGC MDD study 7. 
In conclusion, in this large GWAMA of a broad depression phenotype, we detected a locus 
associated with depression in clinical and general population samples. Our results suggest 
the importance of a broader depression phenotype to identify genetic variants underlying 
depression. Large samples with different depression phenotypes may also help disentangle 
the genetic background of different forms of depression. 
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AbstrACt
Major depressive disorder (MDD) is moderately heritable, however genome-wide associa-
tion studies (GWAS) for MDD, as well as for related continuous outcomes, have not shown 
consistent results. Attempts to elucidate the genetic basis of MDD may be hindered by 
heterogeneity in diagnosis. The Center for Epidemiological Studies Depression (CES-D) 
scale provides a widely used tool for measuring depressive symptoms clustered in four 
different domains which can be combined together into a total score but also can be 
analysed as separate symptom domains. We performed a meta-analysis of GWAS of the 
CES-D symptom clusters. We recruited 12 cohorts with the 20- or 10-item CES-D (32,528 
persons). One single nucleotide polymorphism (SNP), rs713224, located near the brain-
expressed melatonin receptor (MTNR1A) gene, was associated with the somatic complaints 
domain of depression symptoms, with borderline genome-wide significance (p discovery = 
3.82 × 10-8). The SNP was analyzed in an additional five cohorts comprising the replication 
sample (6,813 persons). However, the association was not consistent among the replication 
sample (p discovery+replication= 1.10 × 10-6) with evidence of heterogeneity. Despite the effort to 
harmonize the phenotypes across cohorts and participants, our study is still underpowered 
to detect consistent association for depression, even by means of symptom classification. 
On the contrary, the SNP-based heritability and co-heritability estimation results suggest 
that a very minor part of the variation could be captured by GWAS, explaining the reason 
of sparse findings.
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iNtroDuCtioN
Genetic factors play an important role in the susceptibility to depression. A meta-analysis 
of twin studies on major depressive disorder (MDD) estimated a heritability between 31 
and 42%.1 The success of genome-wide association studies (GWAS) aiming to fi nd genes 
underlying vulnerability for depression, however, has been limited; the most promising 
fi ndings to date are poorly replicated and explain only a small portion of this heritability. 
2-4 This may be explained by the polygenic architecture of the trait as well as diffi culties in 
diagnosis. A validated biomarker for depression does not exist and the diagnosis is based 
solely on symptoms. Such symptoms include depressed mood states, loss of interest in 
activities, feelings of worthlessness or inappropriate guilt, recurrent thoughts of death, 
poor concentration, and somatic symptoms such as changes in appetite, sleep patterns, 
fatigue, and weight gain or loss 5, 6. Depression can manifest with different patterns of 
symptoms, and such phenotypic heterogeneity may refl ect genetic heterogeneity. It is 
plausible that different genetic pathways are associated with the various symptom clusters, 
and analyses of more narrowly defi ned phenotypes may reduce genetic heterogeneity. 
Indeed, the diverse domains of complaints, which result in variations in presentation of 
the disease within and between populations, may lead to problems for gene discovery. A 
focus on outcomes based on depressive symptoms and endophenotypes has been shown 
to increase power in association studies 7, 8. However, the genetic architecture of these 
outcomes is also complex and may involve the effects of multiple common variants 9.
Depressive symptoms can be measured by questionnaires, such as the Centre for Epidemio-
logical Studies Depression (CES-D) scale, which shows moderate heritability 10. The CES-D 
scale measures symptoms clustered in somatic complaints, lack of positive affect, negative 
affect and interpersonal problems domains, which are usually combined into a single score 
11. The CES-D subscales can also be analyzed separately in order to focus on the specifi c 
symptom domains. We conducted a meta-analysis of GWAS of specifi c symptom domains 
measured by CES-D scale. The discovery set consisted of 12 cohorts (n= 32,528) and the 
replication set consisted of fi ve cohorts (n= 6,813).
MAteriAls AND MethoDs
Table 1 summarizes the characteristics of the discovery and replication cohorts from the 
Cohorts for Hearth and Aging Research in Genetic Epidemiology (CHARGE) Consortium. 
The main aim of CHARGE is to facilitate GWAS meta-analyses and replication opportunities 
among multiple large and well-phenotyped longitudinal cohort studies 12. The discovery 
sample consisted of the CHARGE cohorts with eligible 20-item CES-D (CES-D-20) data. 
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These cohorts were the Baltimore Longitudinal Study of Aging (BLSA) 13, the Dortmund 
Health Study 14, 15, the Erasmus Rucphen Family Study (ERF) 16, 17, the National Heart, Lung, 
and Blood Institute’s Framingham Heart Study (FHS) 18-20, the Helsinki Birth Cohort Study 
(HBCS) 21, European ancestry participants from the Health, Aging and Body Composition 
study (HEALTH ABC-Eur) 22, the Rotterdam Study I-II and III (RS I-II and RS-III) 23 and SardiNIA 
24 and two studies in which the symptoms of depression were measured with the 10-item 
version of CES-D (CES-D-10): the Atherosclerosis Risk In Communities (ARIC) study25 and 
the Swedish Twin Registry (STR) study 26. FINRISK 27, the Health and Retirement Study (HRS) 
28, 29, Invechhiare in Chianti (InCHIANTI), and the Memory and Aging Project and Religious 
Order Study of Rush Alzheimer’s Disease Centre (RUSH-ROS and RUSH-MAP) 30, 31 were 
used as replication analysis of rs713224 (see online Supplementary text S1 for the study 
descriptions and Supplementary text S2 for the items of CES-D scale). With these sample 
sizes, we had about 80% power to detect associations that explain about 0.12% of the 
trait variation in the discovery cohort and replication cohort with a p-value of 5 x 10-8 
and 0.05, respectively. In case of multiple measurements the study centers preferred to 
analyze the measurements that maximize the number in the analysis. This is usually the first 
measurement as the response declines by years of follow-up. In this case the mean age of 
the samples refers to the time of measurement date.
GWAS analyses were performed individually by the study centers, according to the same 
analysis plan; each study excluded dementia cases (Mini-Mental State Examination score < 
22), and anti-depressive medication users (except BLSA), since the effect of anti-depressive 
medication on the scales was not consistent across the studies. There was no restriction on 
age. Each study center computed the subscales of the CES-D questionnaire that resulted in 
four separate scores for each individual, measuring different domains of complaints. The 
reliability coefficients (Cronbach’s alpha) for the somatic complaints (seven items), lack of 
positive affect (four items) and negative affect (seven items) domains were adequate and 
ranged between 0.68 to 0.84 whereas for the interpersonal problems domain (two items) 
those were between 0.45 to 0.63 for the 20-item CES-D scale cohorts. For the 10-item 
scale, Cronbach’s alpha’s for the somatic complaints (three items) ranged from 0.52 to 0.78 
and for lack of positive affect (two items) and negative affect (three items) between 0.64 
and 0.71. Each study implemented linear regression models, adjusted for age, age-square 
and sex, under the assumption of an additive genetic model, regressing each subscale 
on allele dosage and reported the summary statistics. The genotyping and imputation 
methods for each study are given in Supplementary Table S1. Additional study site-specific 
adjustments included linear mixed-effect models to account for familial correlations in the 
FHS and ERF, and adjustment for the top three Eigen vectors in RUSH-MAP, RUSH-ROS and 
STR. Prior to meta-analysis, all single nucleotide polymorphism (SNP) IDs were mapped 
to dbSNP Build 129. Possible measurement and scoring differences across different study 
A genome-wide association study of the CES-D domains 181
4
centers were checked through extracting median standard error from the GWAS sum-
mary statistics of each study center and plotting it against the square-root of the sample 
size. Allele frequencies for all SNPs were compared to HapMap frequencies. Stratifi ed Q-Q 
plots were generated for minor allele frequency (MAF) and imputation quality strata to 
assess potential sources of infl ation. Meta-analyses were performed using the sample size-
weighted method as implemented in METAL software package 32. Due to poor psychomet-
ric properties and differences in the median standard errors across the cohorts we excluded 
interpersonal problems domain from further analysis. Furthermore, this domain has been 
criticized for not being consistent with the current criteria for depression and therefore 
introducing confounding in the validity of the CES-D 33. SNPs with a MAF less than 2.5% or 
an observed: expected variance ratio (imputation quality) less than 0.30 were excluded on 
a per-study basis. SNPs for which the total sample size was lower than 5000 were removed 
from further analysis. We did not use genomic control as this method has been shown to 
be too conservative 34. SNP-based heritability was calculated using 1,069,063 markers that 
were common in the meta-analyses results and linkage disequilibrium (LD) scores were 
computed using the 1000 Genomes Central EUropean (CEU) reference panel as suggested 
by the tutorials and provided by the developers of the method. 
To test the amount of variance explained by the genetic risk score, we performed a genetic 
risk score analysis. We excluded one of the cohorts (RS I) (n=3, 709) from the discovery set 
and used this cohort as the target sample. The total score for individuals was calculated for 
each set of SNPs that were defi ned on the basis of the p-values in the discovery set (e.g. p< 
0.00001, 0.0001, 0.1, 0.2). Genetic risk scores were calculated by multiplying the Z-score 
that was obtained in the discovery analyses with the risk alleles per SNP (0, 1, 2). The PLINK 
toolset was used to calculate the risk scores 35. Linear regression analysis was used to test 
the association of the genetic risk scores with somatic item scores in the target sample.
results
The infl ation factors for the discovery GWAS of the three scales varied between 1.026 and 
0.984. We did not observe any genome-wide signifi cant SNPs for any of the scales in the 
discovery set apart from the top SNP, rs713224, that showed signifi cant association with 
somatic complaints scale (p discovery = 3.82 × 10-8). Q-Q plots and Manhattan plots of this 
analysis are presented in the Supplementary Figs S1 and S2. Supplementary Table S2 shows 
the SNPs with p< 10-4 from the discovery set of 32,528 persons for the somatic, positive 
and negative domains. The analysis of the rs713224 was further extended to a second 
stage, which included 6,813 persons from fi ve study samples, as shown in Table 1. Study-
specifi c summary results for rs713224 are given in Supplementary Table S3. The overall 
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analysis yielded a non-significant result (pdiscovery&replication = 1.10 × 10-6) in the genome-wide 
scale. Testing for heterogeneity showed evidence for outliers (phet = 0.07) in the combined 
analysis, compared with the discovery phase (phet = 0.17). 
table 1 Study sample characteristics of discovery and replication cohorts
 somatic 
items
Negative 
items
Positive 
items
interpersonal 
items
Age (years) N Women 
% 
Discovery sample 
20 item
mean(sD) mean(sD) mean(sD) mean(sD) mean(sD)   
BLSA 2.92 (2.81) 1.42(2.41) 10.31(2.45) 0.22(0.65) 71.6(13.8) 827 45.1
DHS 2.92(3.18) 1.54(2.91) 7.03(3.25) 0.22(0.72) 52.4(13.7) 991 52.6
ERF 3.78(3.76) 2.07(3.36) 8.43(3.40) 0.40(0.89) 55.0(10.1) 1107 55.2
FHS 1.05(0.751) 0.61(0.75) 0.596( 0.739) 0.15(0.35) 56.1(10.5) 6636 51.8
HBCS 3.79 (3.31) 2.00 (3.05) 9.22 (2.40) 0.37(0.79) 63.4(2.9) 1360 59.4
HEALTH ABC (Eur) 1.68 (2.13) 0.93(1.85) 10.74(1.82) 0.13(0.49) 73.8(2.8) 1520 46.4
RS I 1.52 (2.61) 1.24(2.65) 10.36(2.59) 0.09(0.42) 72.7(7.2) 3709 58.1
RS II 1.98 (2.78) 1.34(2.66) 10.19(2.60) 0.15(0.53) 64.8(8.0) 1995 53.3
RS III 2.66 (3.32) 1.17(2.58) 10.37(2.41) 0.18(0.58) 56.0(5.7) 1917 55.1
SardiNIA 3.27(2.91) 2.51(3.08) 4.81(2.53) 0.48(0.85) 58.0(11.4) 2608 58.1
ARIC10 item 2.31(2.15) 1.19(1.72) 5.62(0.95) 0.21(0.65) 72.7(5.5) 384 42.1
STR10 item 1.10(1.60) 0.79(1.43) 1.22(1.27) 0.21(0.58) 57.7 (8.9) 9474 52.7
Replication sample        
FINRISK 10 item 1.74(1.63) - - - 53.1(13.4) 605 49.7
HRS 10 item 1.38(1.50) - - - 69.3(5.5) 3753 58.1
InCHIANTI 20 item 3.23(3.18) - - - 66.0(15.0) 1019 47.0
RUSH MAP10 item 0.50(0.80) - - - 80.8(6.5) 721 71.7
RUSH ROS10 item 0.57(0.82) - - - 75.5(7.2) 715 65.9
Mean; mean value of each scale, SD, Standard deviation of the mean, N; number of subjects included. BLSA; 
Baltimore Longitudinal Study of Aging, DHS; Dortmund Health Study, ERF; Erasmus Rucphen Family Study, 
FHS; Framingham Heart Study, HBCS; Helsinki Birth Cohort Study, HEATLH ABC (Eur); Health, Aging and Body 
Composition study (of European ancestors), RS I-II-III; Rotterdam study first, second and third waves, SardiNIA; 
SardiNIA study, ARIC; Atherosclerosis Risk in Communities study, STR; Swedish Twin Registry, FINRISK; 
National FINRISK Study of Finland, RUSH MAP, RUSH Memory and Aging Project; RUSH ROS, RUSH Religious 
Orders Study. 
SNP-based heritability estimates (h2) were 0.038 (SE= 0.01), 0.01 (SE= 0.01) and 0.024 
(SE= 0.01) for the somatic, positive, and negative domains, respectively. The somatic and 
negative domains showed significant co-heritability (genetic correlation= 1.1, SE= 0.23, z-
score=4.6, p= 4.3 x10-6). The positive domain did not show significant genetic correlation 
with the negative domain (genetic correlation: 1.5, SE= 1.4, z-score= 1.1, p= 0.27) or with 
the somatic domain (genetic correlation: 1.5, SE= 1.3, z-score= 1.1, p= 0.27).
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In order to search for possible real associations among the subthreshold loci we have 
performed also a risk score analysis using the discovery set after excluding one of the 
cohorts as discovery and the RS as the training set. The SNPs with p values less than 10-5 
explained a signifi cant but very small part of the variance on somatic items scale (p= 0.001, 
R2 = 0.3%) (Supplementary Figure S4). 
DisCussioN
We conducted a GWAS on specifi c symptom domains of depression in which we com-
bined the results of 12 population-based studies including 32,528 individuals to fi nd 
common variants that increase the vulnerability to a particular symptom domain (somatic 
complaints, lack of positive affect and negative affect). In the discovery set we found 
evidence for one SNP near the brain-expressed melatonin receptor (MTNR1A) gene with 
respect to somatic complaints domain only (pdiscovery = 3.82 × 10-8). This is in line with an 
earlier study showing that symptoms of depression linked with physiological functions may 
show higher heritability compared with symptoms related to negative affect 36. Rs713224 
was further analyzed in fi ve separate samples and also in combined meta-analyses of the 
discovery and replication sets. However, the level of signifi cance of this SNP was attenu-
ated (pdiscovery+replication = 1.10 × 10-6). The negative and positive domains did not yield any 
genome-wide signifi cant SNPs. 
Our top SNP, rs713224 is located near the MTNR1A gene, which encodes one of the two 
melatonin receptors expressed in brain. Melatonin is a circadian and seasonal regulator 
in many organisms including humans and is secreted in darkness by the pineal gland. Al-
though melatonin is the hormone of the pineal gland, MTNR1A is ubiquitously expressed, 
predominantly in suprachiasmatic nucleus, hypothalamus and prefrontal cortex. The mela-
tonin receptor pathway is known to be involved in depression 37-42 and its relationship with 
somatic complaints, and vitality in general, makes it a biologically plausible gene. 
However, lack of replication raises the conclusion that our fi nding for this SNP is likely 
to be a false positive. Among other reasons, population stratifi cation can result in false-
positive fi ndings. To avoid population-stratifi cation, only individuals of European descent 
were included in this study. Including only individuals from population-based studies of 
European descent also minimized measurement error caused by cultural differences in 
response to the CES-D 43. On the other hand, this does not count for the replication set. 
Among them, for instance RUSH sample included more included more women and older 
persons and reported very low mean values for the somatic items (Table 1). Difference in 
age across the study samples can introduce heterogeneity since melatonin and melatonin 
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receptors are shown to decrease by age 44. An additional sensitivity analysis, excluding the 
RUSH study, yielded a pdiscovery+replication = 4.96 × 10-7 and decreased the heterogeneity (phet 
= 0.08), but did not exclude it completely. A particular reason of heterogeneity for the 
melatonin receptor signaling-related outcomes is the interaction with melatonin levels as 
reviewed extensively before 45 and therefore the influence on depressive symptoms maybe 
season specific, depending on the calendar time and latitude that the depression screening 
took place. However, it was not possible to control for this in current study.
 Although our study is among the largest ones conducted thus far on the common genomic 
variation in depression with power to detect effects explaining 0.12% of the variation, our 
study failed to clearly detect and replicate a single loci related to symptoms of depression. 
Among several reasons one is that the trait may not be genetically controlled. 
The CES-D questionnaire measures depressive symptoms in the past week and the total 
CES-D scale has been shown to be conserved through life 11, while this does not rule out the 
fact that responses to different symptom clusters may differ throughout lifetime as there is 
no study to our knowledge has focused on this. In addition, response to specific symptom 
clusters may be population specific due to cultural acceptance or practices. Moreover, 
age differences across the CHARGE cohorts might have played a role as presentation of 
depressive symptoms strongly differs by age whereas some genetic variants hypothesized 
to interact with age 46. These would probably introduce phenotypic and genetic hetero-
geneity. To see if the individual studies were indeed genetically controlled we estimated 
the SNP-based heritability from the separate GWAS summary statistics collected in this 
research. The SNP-based heritability estimations in the meta-analysis were surprisingly low 
(1-4%), indicating the reason for sparse findings. This is partially due to several reasons 
sourcing from the genetic architecture of the traits, which are not adequately addressed by 
the simple association models; such as exclusion of X chromosome, and limiting the analy-
sis only with additive genetic model which deviates from sufficient power when the MAF < 
0.5. Another important reason is that interaction of any genetic determinant with stressful 
life events, traumas, therapeutic agents, smoking or menopause, which may confer risk 
to depression 47,were neglected. We further estimated the co-heritability to see if there 
are genetic outliers amongst the meta-analysis cohorts. This revealed surprisingly low co-
heritability across the contributing cohorts, explaining the lack of successful meta-analysis 
and replication in our study. The low co-heritability estimations are the indicators of high 
genetic and phenotypic heterogeneity across the cohorts and are the plausible explanation 
of insignificant replication in our research. Here it is important to note that the estimates 
from LD score regression have to be treated with caution because of the small sample size 
in some individual cohorts.
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We also considered the possibility that individual common SNPs explain only very small 
proportion of some complex traits, as shown by the polygenic risk score analyses in the cur-
rent study in which only 0.3% of variance was explained by the most signifi cant SNPs. The 
risk score for the remaining thresholds did not improve the explained variance, contrary of 
previous reports 9. Previous studies exploring complex traits (e.g. educational attainment, 
MDD) revealed similar results 48, 49. 
The diffi culty in fi nding and replicating GWAS signals for major depression has been a 
common experience both for depressive symptoms and MDD. A previous study of depres-
sive symptoms of the CHARGE Consortium 50 on a partially overlapping sample suggested 
a region on 5q21 in a combined analysis of more than 50,000 persons. A meta-analysis of 
eight GWAS of MDD status (about 6,000 MDD cases and about 7,000 controls), yielded 
only one genome-wide signifi cant fi nding in the solute carrier family 6 member 15 gene 
(SLC6A15) 51, while the recent Psychiatric Genomic Consortium (PGC) mega-analysis (9,238 
cases and 8,039 controls) pointed out one region on 3p21.1 that reached genome–wide 
signifi cance 49; however to our knowledge no replication has been reported so far. PGC-
MDD GWAS also showed association of rs4478239, located within 800 kB of MTNR1A, 
with recurrent depression (p= 4.7 ×10-7) in a study including 6743 cases and 9519 controls 
(Supplementary Fig. S3). However, the proxy for our top SNP in that region (rs2375800) 
was not associated with MDD. Similarly we were not able to replicate the two main fi nd-
ings of a recent report by the CONVERGE Consortium52 who attributed the success to the 
recruitment of relatively homogeneous cases with severe illness. For the LHPP gene region 
the proxy SNP rs12258489 yielded insignifi cant p-values for negative items (z-score= 1.52, 
p= 0.12), for positive items (z-score= -0.52, p= 0.59) and for somatic items (z-score= 1.23, 
p= 0.22). For the sirtuin 1 (SIRT1) region, the SNP of interest rs12415800 did not associate 
with negative items, (z-score= 0.12, p= 0.89), positive items (z-score= -0.57 , p= 0.56) or 
somatic items scales (z-score= 1.81, p= 0.07).
To conclude, our efforts in a large collaboration utilizing phenotypes defi ned by symptom 
clustering yielded no genome-wide signifi cant hit except the somatic complaints domain. 
One SNP, associated with somatic complaints, reached genome-wide signifi cance in the 
combined sample and suggested the involvement of MTNR1A in the melatonin signaling 
pathway, but was not further replicated. Our results suggest that GWAS for depression 
in large population-based samples remain underpowered due to phenotypic and genetic 
heterogeneity.
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DisCussioN
5.1 rationale 
In this thesis, I investigated hormonal, vascular and genetic determinants of the most 
common mental health disorder, depression. These determinants have been examined 
previously in clinical and epidemiological studies. In the studies presented I attempt to 
advance our knowledge by exploring hormonal, vascular and genetic risk factors in a 
population-based sample including milder and more severe forms of depression. Also, we 
used various methodological approaches to explore the associations more in detail. 
In the current chapter, I will discuss the main fi ndings of the studies included in this thesis. 
Also, I will discuss methodological challenges encountered in the studies. Additionally, I will 
summarize clinical implications of the fi ndings and future directions for research. 
5.2 main fi ndings 
Epidemiological studies of the HPA axis
Dysfunctional stress response is a key fi nding of several chronic diseases. Intense investiga-
tions have been made to elucidate the effects of the dysfunctional stress response on 
the development of chronic diseases. However, these studies were mostly performed in 
small clinical samples. The number of large scale epidemiological studies is limited and 
evolved only in the last decades with the advances in biological sample collection and 
measurement. Measurement of diurnal cortisol rhythm is not feasible in blood or urine 
samples and more valid assessments require repeated sampling over the day. Therefore, 
progress on saliva assessments of cortisol made it possible to collect several saliva samples 
without any professional assistance. Also, modifi cations in the dose of dexamethasone in 
the suppression test and the assessment of the cortisol response in saliva facilitates HPA 
axis suppression research in epidemiological studies. In the last decade, large-scale cohort 
studies published the result of cortisol research of psychiatric traits and other chronic 
diseases which provided novel information about this biological marker of many chronic 
diseases. These epidemiological studies generally assess many exposures and outcomes 
that make systematic assessment of cortisol levels particularly valuable. Further, these 
large-scale studies often include genetic data providing a great opportunity to explore 
common genetic variants in relation to HPA axis activity as measured by cortisol.
In chapter 2.1, we explored possible effects of smoking, a common risk factor for mental 
and physical diseases, on the HPA axis to elucidate a possible pathway to chronic diseases. 
We found that smoking was independently associated with hypercortisolemia throughout 
the day and a higher morning increase of cortisol. Also, we found that effects of smoking 
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on the HPA axis were temporary as there were no difference in terms of cortisol measures 
between former and never smokers. Moreover, time since quitting was associated with a 
decline in the average daytime cortisol levels. 
In accordance with our study of older adults, high cortisol levels and increased cortisol 
awakening response in younger smokers were reported previously 1, 2 . The cortisol 
awakening response, which is related to hippocampal networks controlling memory and 
orientation and preparing individuals to the demands of the upcoming day 3. Smoking is a 
physiological stressor that might activate the HPA axis directly. Also, smokers might involve 
more stressful life events or perceive more stress compared to non-smokers which might 
explain high cortisol levels and increased CAR. 
One of the most important finding of our work was showing the temporary effect of 
smoking on cortisol measurements. We know that many chronic disease risks decrease 
after smoking cessation if no permanent changes occurred in the body. We showed one of 
the mechanisms underlying increased HPA axis activity. 
In chapter 2.2, we evaluated the determinants of the negative feedback of the HPA axis 
using a very low-dose (0.25 mg) dexamethasone suppression test. Being female, low 
income, lack of exercise, instrumental disability and smoking were related to a strong 
suppression of the HPA axis as measured by low cortisol levels after dexamethasone intake. 
However, clinically relevant depressive symptoms and anxiety disorders were more preva-
lent in people with a non-suppression of cortisol as measured by high cortisol levels after 
dexamethasone intake. Determinants of the negative feedback in general population have 
been explored in the NESDA study 4. The authors found that smoking, low daily activity and 
sampling on a weekday were related to a non-suppression of cortisol after dexamethasone 
intake. However, these studies are not truly comparable as in the NESDA study the authors 
used a higher dose of dexamethasone, which suppressed the HPA axis in almost 87% 
of the study population. In our study, we evaluated cortisol levels continuously to use 
all possible information and detect subtle differences. Also, we used a cut-off to define 
non-suppressors only to test non-linear associations of psychiatric traits, even though 
defining an arbitrary cut-off is not the optimal way to test such associations as it might be 
misleading. Our results suggest a non-linear association between non-suppression of the 
HPA-axis and depression and anxiety in the general-population. 
As mentioned above, in this chapter, we aimed to uncover pathophysiological pathways 
underlying the association of cortisol and chronic diseases. In chapter 2.3 the genetics 
basis of plasma cortisol was explored. Plasma cortisol is a heritable (30-60%) trait 5, 6. To 
date, only small candidate gene studies have been done to identify genetic variants of 
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plasma cortisol. In this study, we performed a GWAS on morning plasma cortisol in 12,597 
people. We found and replicated common genetic variants at chromosome 14q32 which 
contains the SERPINA6 and SERPINA1 gene. We explored also the functional consequences 
of these genetic variants and found that they affect plasma cortisol levels as they alter the 
level cortisol binding globulin (CBG). Additionally, we found that the top hit affect the 
cleavage of the CBG from the reactive center loop. It is known that the cleavage decreases 
the cortisol binding affi nity of the CBG resulting in higher levels of circulating cortisol 7. In 
this large GWA study, we have shown the genetic variants related to the plasma cortisol as 
well as their biological effects. 
In chapter 2.4, we explored the SNP-based heritability of single time point measure of 
plasma and saliva cortisol levels. We used the data of plasma cortisol GWAS that was 
presented in Chapter 2.4. Additionally, we performed a GWAS using morning saliva cor-
tisol levels in 7703 participants in eight European cohorts and found no genome-wide 
signifi cant hit. We detected low SNP-based heritability of plasma and saliva cortisol levels. 
A Single time point of a cortisol assessment has large intra-individual variability that is 
affected by various environmental factors. Therefore, it can be expected to have low vari-
ability to be explained by genetic markers as they can be considered as a state-marker 
rather than a trait. Using a more stable marker of cortisol secretion such as area under the 
curve using consecutive days, hair cortisol that are not free-of environmental factors might 
be more useful to calculate SNP-based heritability. 
Vascular depression hypothesis in epidemiological studies
Cerebral small vessel disease is a term that can be conceptualized with pathological, clinical 
and neuroimaging fi ndings. The clinical presentation ranges from no to severe neurological 
symptoms and disability. With the advances in neuroimaging techniques, it is now possible 
to detect non-clinical cerebral small vessel disease. This created the opportunity to test the 
vascular depression hypothesis. 
In chapter 3, we aimed to scrutinize the association of several neuroimaging indicators of 
cerebral small vessel disease with depression in cross-sectional and longitudinal analyses in 
community-dwelling subjects. 
Walking down memory lane, in chapter 3.1. we revisit white matter lesions and silent 
brain infarcts in relation to depression. Here, we aimed to establish the longitudinal asso-
ciations of white matter lesions and silent brain infarcts with depressive disorders in 1047 
non-demented participants. Severe subcortical white matter lesions increased the risk 
of incident depression. Asymptomatic brain infarcts were related with almost three-fold 
increased risk of a recurrent depressive episode during a mean follow-up of 3.6 years. In 
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more recent work presented in chapter 3.2. we tested several imaging markers of cerebral 
small vessel disease and different severity degrees of depression in 3799 participants cross-
sectionally. White matter lesion volume and lacunar infarcts were related to depressive 
symptoms and disorders. Cerebral microbleeds were associated to depressive disorders 
only. This association was seen particularly pronounced in persons with depression and 
comorbid anxiety, which indicate a more severe form of depression. Deep/infratentorial 
cerebral microbleeds were found more often in persons with depressive disorders, whereas 
no association was detected between lobar microbleeds and depressive disorders. 
The high prevalence of white matter lesions in people with depression is one of the earliest 
findings supporting vascular depression hypothesis 8, 9. We detected a cross-sectional asso-
ciation between white matter lesion volume and depression. Also, we found that presence 
of severe white matter lesions doubled the risk of incident depression in longitudinal analy-
ses. Overall our results are consistent with previous studies 10-14. Similarly, silent lacunar 
infarcts have been related to depression especially in late life 15-18 which was replicated in 
cross-sectional and longitudinal studies presented in this chapter. 
According to Taylor et al. 11 there are several hypotheses which explain the association 
between white matter lesions or silent infarcts and depression. First, the group proposed 
the threshold model, which posits that more severe vascular burden in the white matter of 
brain regions regulating mood such as frontolimbic tracts would increase vulnerability to 
depression 12, 19. After a certain threshold of cerebrovascular burden is exceeded, symptoms 
of depression emerge. Second, they defined the disconnection hypothesis, which posits 
that focal lesions in specific tracts related to mood regulation are more important than 
global vascular burden. In our studies, we did not evaluate the locations of the lesions in 
detail. But we found that lesions located in subcortical regions, which includes regions 
regulating mood, are related to incident depression rather than the periventricular lesions. 
Similar to white matter lesions and lacunar infarcts, cerebral microbleeds are the silent 
lesions of cerebral small vessel disease. They are small hemorrhages occurring as a result 
of structural vascular damage in small cerebral arteries that are common in elderly. They 
have been related to stroke and post-stroke depression. However, it has not been tested 
whether there is a relationship between cerebral microbleeds and depression that is inde-
pendent of stroke. In our study, we observed an association between cerebral microbleeds 
and major depressive disorder in stroke-free participants. Interestingly, the association with 
depression was significant for deep/infratentorial cerebral microbleeds only. According to 
the literature, deep/infratentorial cerebral microbleeds are related to cerebrovascular risk 
factors and hypertension, whereas strictly lobar microbeads are related to cerebral amyloid 
angiopathy. Overall, our findings further the knowledge on vascular depression hypothesis 
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showing the association of cerebral microbleeds with depressive disorders as these lesions 
differs from white matter lesions and lacunar infarcts. Additionally, fi ndings on the location 
of the microbleeds are in favor of vascular etiology of depression.
In the light of the studies in this chapter and previous publications, we postulate that 
white matter lesions and lacunar infarcts might be an unspecifi c marker of vascular lesions 
in depression. Ischemia is an important underlying pathology behind white matter lesions 
and silent infarcts 20. However, ischemia itself is not a specifi c pathological mechanism as 
it is a result of several vascular pathologies from endothelial dysfunction to cerebral hemo-
dynamics. A constant cerebral blood fl ow is needed for cerebral hemostasis. Alterations of 
the cerebral blood fl ow or defects in the autoregulation of cerebral blood fl ow can cause 
vascular lesions many years before the clinical onset of a cerebrovascular disease. Also, 
cerebral perfusion defi cits may affect protein synthesis important for cognitive networks 
and synaptic plasticity 11, 21. 
Cerebral blood fl ow velocity and vasomotor reactivity are two important dynamic measures 
of cerebral vasculature. While cerebral blood fl ow velocity is considered as an indicator of 
cerebral metabolism, vasomotor reactivity is an indicator of microangiopathy refl ecting 
autonomous disturbances in the cerebral vessels 22. In Chapter 3.3. we explored the link 
of cerebral blood fl ow velocity and vasomotor reactivity with clinical and subthreshold 
depression in 1494 elderly people. We found that low mean cerebral blood fl ow velocity 
at baseline were related to higher depressive symptom scores at follow-up. Mean cerebral 
blood fl ow velocity predicted incident depressive symptoms and depressive disorders. Low 
baseline vasomotor reactivity predicted depressive disorders only. Our results are in line 
with the results of cross-sectional studies 23-25. Here, we furthered the evidence showing a 
temporal association between cerebral hemodynamics and incident depression in people 
free of cerebrovascular diseases. In this study, analyses were controlled for several vascular 
risk factors, cerebral atherosclerosis, indicators of poor health, and stroke during follow-up 
and results did not change substantially. Therefore, we can conclude that early changes in 
cerebrovascular hemodynamics predict depression supporting vascular depression hypoth-
esis.
The co-occurrence of depression and dementia is well-known from clinical and non-clinical 
studies 26-29. To date, it is still not clear if they share the same etiology or depression is a 
risk of dementia or both. We know that depression in late life is related to cognitive distur-
bances especially when vascular risk factors are present 30. Many studies explored vascular 
risk factors to explain the association between depression and dementia. However, there 
is not only a large body of evidence implicating vascular pathology in Alzheimer’s disease 
but also amyloid pathology 31. In Chapter 3. 4., we explored amyloid pathology in persons 
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with depression taking prodromal dementia into account. Previous studies on Ab and 
depression were mostly cross-sectional and yielded conflicting results 32-39. We assessed the 
association of plasma amyloid beta (Ab) levels with depressive syndromes in a cohort of 980 
dementia-free people. In cross-sectional analyses, we found that high levels of Ab1-40 were 
related to clinically relevant depressive symptoms. However, this association was explained 
by prodromal dementia. In prospective analyses, we found that low Ab1-40 and Ab1-42 levels 
were related to a higher risk of incident clinically relevant depressive symptoms at follow-
up in people with no dementia prodrome during the follow-up. In these analyses, persons 
who developed dementia during the maximum follow-up of 13 years were excluded. 
Therefore, it is unlikely that these results were driven by dementia prodrome. Cerebral and 
peripheral amyloid levels are in a dynamic equilibrium. When amyloid peptides accumulate 
in the brain, peripheral levels are decreased 40. An Ab accumulation in the brain can well 
be related by lower circulating levels in peripheral blood. In these analyses, we controlled 
for common vascular risk factors and diseases and results did not change substantially. 
However, we cannot rule out that non-overt cerebrovascular disturbances contributed to 
the associations as we could not control for white matter lesions, cerebral microbleeds, 
or cerebrovascular hemodynamics. Cerebral small vessel disease is related to perivascular 
Ab accumulation and transient Ab deposition in the brain causing alterations in cerebral 
perfusion and is neurotoxic for monoaminergic neurons 31, 41-44. Therefore, it is still possible 
that the association of low Ab levels with incident depression in dementia-free persons is 
related to underlying vascular pathology. 
Depression and genetic epidemiological studies
One of the most striking developments in epidemiology in the last decades is the develop-
ment of GWAS. Many novel genetic variations have been detected in GWAS of different 
phenotypes in psychiatry. However, genetic research on depression, although a heritable 
phenotype, was no success story – even when using a GWA approach. In Chapter 4, we 
aimed to explore the genetic variants related to depression using different perspectives of 
methodologies and phenotype definitions. 
In chapter 4.1, we combined two previously published GWAS studies in which depressive 
symptoms and depressive disorders were evaluated separately. We found and replicated 
one locus related to the broad depression phenotype located in the intron of the FHIT 
gene that is related to circadian clock modification, oxidative stress, and the level of 
DNA-damage. This is the first locus detected in a GWAS study of the broad depression 
phenotype of people of European ancestry. One of the most problematic aspects of GWAS 
in depression is the lack of statistical power for such heterogeneous phenotype. Using a 
more inclusive approach helped us to increase the statistical power. 
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In chapter 4.2, we assessed the genetic variants that are related to depressive symptom 
clusters based on the CES-D scale. One common variant located in the brain-expressed 
melatonin receptor (MTNR1A) gene was related to the somatic symptoms. The melatonin 
pathway is well-known for depression. As somatic symptoms include sleep, appetite and 
fatigue, it is a very plausible gene for this symptom cluster. However, this variant was not 
replicated. Even though we aimed to harmonize depression phenotype, our study was still 
underpowered. 
5.3 methodological considerations 
Cortisol assessment in large population-based studies
Cortisol follows a diurnal rhythm increasing with awakening, maximizing approximately 30 
minutes after awakening and then decreases during the day. Therefore, a single measure-
ment of cortisol levels is generally not informative about the HPA-axis function. However, 
repeated plasma measurements are not feasible especially in population-based studies. 
Cortisol can be measured in saliva with sampling devices that can be applied by individuals 
at home requiring no special assistance. This was the catalyzer of cortisol research in large 
epidemiological studies in the last decade. In the Rotterdam Study, saliva samples were 
used to assess cortisol levels. This large data collection enabled us to evaluate cortisol 
levels over the day and to calculate important summary measures indicating diurnal cortisol 
rhythm. 
Negative feedback control of the HPA-axis is an important and distinct function that 
requires dexamethasone suppression test in which participants need to take a dexametha-
sone pill. However, interventional methods, especially the classical DST which requires 1 
mg dexamethasone intake, are almost impossible to use in population-based studies as this 
dose might be too high for general population. Such high dose may suppress the HPA-axis 
and does not let to evaluate the negative feed-back of the axis as most of the subjects 
would have a fully-suppressed HPA-axis. Therefore, using a very low dose dexamethasone 
(0.25 mg) let us to evaluate several determinants of the negative-feedback of the HPA-axis. 
Overall, applying such an invasive method and assessing cortisol in saliva in a large-scale, 
population-based study with an extensive data collection was helpful to consider several 
covariates and to assess many determinants of the HPA-axis which is not possible in a 
small, clinical study. 
HPA-axis studies in large population-based studies generally suffer from non-compliance 
to the sampling protocol and ingestion of dexamethasone. Evaluating the dexamethasone 
levels would be helpful to assess the compliance to the dexamethasone ingestion. In the 
Rotterdam Study, this was not feasible as we used a very-low dose of dexamethasone. 
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However, non-compliance of dexamethasone ingestion does not seem to be common in 
studies 4, 45. Accurate time of awakening and time of sampling are vital to evaluate the 
cortisol awakening response. Electronical monitors can be used to obtain accurate time of 
sampling but these devices are costly for large scale studies. Most of the epidemiological 
studies give clear instructions emphasizing the importance of actual sampling time. Studies 
have shown that participants report their awakening and sampling times accurately 46. In 
the Rotterdam Study, all participants are given clear instructions about time of sampling. 
When we excluded participants with poor compliance to the DST protocol, we did not 
observe a meaningful change of the effect estimates. As our definition of poor compliance 
relies on the self-report data, there is still a risk of residual information bias. 
Phenotype definitions in epidemiological studies
Depression is phenotypically heterogeneous psychiatric disease including affective, somatic, 
and cognitive symptoms. In medicine, it is common practice to diagnose a disease on the 
basis of symptoms only. Yet, no other discipline completely relies on observation and symp-
toms report only. Different combinations of several symptoms can yield the same diagnosis 
in psychiatry and other disciplines. Consequently, many diseases have the problem of het-
erogeneity to a certain degree. However, the heterogeneity problem is more prominent in 
psychiatric phenotypes because of weak measurement tools, lack of accurate and precise 
biomarkers, non-empirical and convention-based categorical definitions, and unreliable 
subtype definitions. To make the matter worse, both a decreased or increased levels of 
behavioral symptoms like appetite, sleep and activity level are considered symptoms of 
depression. Including both extremes of symptoms is unusual in a single non-psychiatric 
disease entity. 
Classification systems are very important in medicine in general, as they are required for 
treatment decisions. Psychiatric diagnoses are made using the prevailing diagnostic systems 
like DSM or ICD. However, such approaches obscure both the variations within the disease 
and similarities between the diseases. This has emerged as a great problem in psychiatry 
research. 
A growing body of evidence indicate that depression is better conceptualized, measured 
and even categorized (using convention-based cut-offs) better when dimensional models 
are used. Evidence supporting the depression continuum is derived from statistical and 
epidemiological studies. Statistical studies indicate that latent structure of depression has 
no discontinuities as defined in DSM or ICD and severity of depression is continuously 
distributed. Also, dimensional models of depression showed better predictive validity than 
the DSM-based categorical models 47-49. In longitudinal epidemiological studies, it was re-
peatedly shown that milder forms of depression such as subthreshold depression or minor 
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depression increase the risk of subsequent major depressive episodes. 50-52 Also, milder 
forms of depression or greater numbers of depressive symptoms have been related to 
increased mortality, disability and worse life quality 52, 53. 
Dichotomization of the diseases on the basis of classifi cation systems is used mostly for 
effi cacy and to enhance the contrast in non-clinical research. In the studies presented in 
this thesis, we studied depressive symptom scores continuously and categorically using 
a cut-off score to defi ne clinically relevant depressive symptoms. Among persons with 
clinically relevant depressive symptoms, we further defi ned different forms of clinical 
depression to evaluate biological characteristics separately. Subthreshold depression was 
defi ned as a combination of depressive symptoms including at least one of the cardinal 
symptoms of MDD, however, not meeting DSM-IV MDD criteria for duration, impairment 
or number of symptoms. Additionally, we considered depressive episodes comorbid with 
anxiety disorders as a more severe form of depression. This approach helped us explain and 
detect indicators of severe MDD as well as less severe forms of depression in Chapter 3. 
Enhancing the contrast using categories made it possible to assess the probability and risk 
of having less and more severe types of clinical depression compared to a reference group 
in a very straightforward way (e.g. using odds ratio estimated) even though that comes 
with a risk of misclassifi cation and multiple testing yielding false-positive results. 
One of the obstacles to be overcome by GWAS studies in depression is the lack of suf-
fi cient power to detect common variants with small effect sizes. Therefore, any attempt 
to increase the sample size in GWAS is welcome. Following this reasoning and a known 
correlation between depressive disorders and depressive symptoms, we pooled the results 
of two largest GWAS of life-time depressive disorders and depressive symptoms. Using this 
approach, we achieved to collect genetic data from one of the largest meta-analyses in 
a GWAS in psychiatry to date at the risk of having substantial phenotypic heterogeneity 
which would most likely lead to an underestimation of the effects. However, it must be 
admitted that increasing sample size using well-defi ned subgroups is more effi cient for 
a GWAS as most of the information on a continuous depressive symptoms score is less 
informative if the population has very low scores.
In the depression GWAS, we combined two GWAS-meta-analyses in which categorical and 
continuous traits were used. We used a p-value based meta-analysis approach implemented 
in the program METAL. In this method, Z-scores for each allele is calculated and combined 
across samples using weights. Weights are proportional to the square root of the sample 
size 54. Choosing an optimal weight to obtain suffi cient power is challenging as each 
method has its own particular pros and cons 55. However, using the overall sample sizes 
for two meta-analyses in which categorical and continuous traits were used could cause 
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inconvenient weighting as the data from the CHARGE consortium had a larger sample size 
with a continuous trait than in the PGC MDD GWAS. In that kind of situations, performing 
a series of sensitivity analysis is most helpful. We therefore tested the change in our results 
with sensitivity analyses using equal weights, weights derived from effective sample size, 
using proportional sample sizes, and finally using no weights as suggested by Stouffer 56. 
Results did not change substantially with different weightings. This approach can be useful 
when pooling GWAS results with slightly different phenotypes to perform a meta-analysis. 
Longitudinal data and interpreting the results
Longitudinal studies are the best designs to test causal associations even though there is 
no clear definition of criteria for causality. Temporality is a prerequisite for causality even 
though it is not very straightforward to assess temporality in association studies of diseases 
with a non-clinical prodrome as is the case for many chronic diseases including dementia, 
schizophrenia, atherosclerosis, cancer, or for any episodic diseases. In these conditions, 
exposure might seem to precede overt disease, therefore appearing as a causal factor 
for the disease. In fact, the prodrome or a previous episode of a disease of interest might 
give rise to the exposure, a phenomenon that is termed reverse causality. In chapter 3.4., 
we tested whether the association between amyloid beta levels and incident depression 
was dependent on depressive episodes that occurred before the exposure assessments to 
assess reverse causality (Figure 1). 
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 Figure 1. Reverse causality that history of depression causes alterations on amyloid beta levels
In chapter 3.4. we used longitudinal dementia data in cross-sectional analyses t  efine 
participants with depression and dementia prodrome as a subtype of depression. The 
terms used for a study design and the data collection are often confused. For example, 
prospective (i.e., more recent) data in a cross-sectional study nested in a cohort can be 
used which was done in chapter 3.4 to define the outcome (i.e. Depression with prodromal 
dementia) better. 
5.4 recommendations 
Clinical implications
In this thesis, I explored behavioral, biological and genetic determinants of the stress 
response and depression to unravel etiology and the risk factors using epidemiological 
approaches in a non-clinical population. As expected, implementing the conclusions made 
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in this thesis directly to the clinical practice is not easily possible. Nevertheless, the fi ndings 
invite some clinical refl ections. 
Smoking is one of the most important risk factors of chronic cardiovascular and cerebro-
vascular diseases. Smoking cessation, if irreversible changes did not happen, decreases 
the abovementioned risks rapidly. 57 In this thesis, I have found that smoking cessation is 
related to lower cortisol levels, which was related to time since quitting. The results suggest 
that the disturbed stress response, which contributes to the development of chronic vas-
cular diseases on smokers, is reversible. This fi nding would be helpful to promote smoking 
cessation programs providing biological evidence for an effect of stopping with smoking.  
In this thesis, I broadly explored the vascular depression hypothesis, which was described 
fi rst as a clinical subtype of depression in spite of the fact that it is now a more research 
than a clinical entity. I found that early vascular changes such as non-clinical white matter 
lesions, silent brain infarcts, cerebral microbleeds, low blood fl ow velocity, and decreased 
vasomotor reactivity of the cerebral vessels, measured before the disabling symptomatol-
ogy occurs, increase the risk of incident depression and the recurrence of depression. 
Overall, these fi ndings indicate that preserving vascular health and prevention of vascular 
diseases are needed to be implemented in the prevention programs of depressive disorders 
occurring in later-life.
The genetic studies presented in this thesis show some novel genes and functions about 
depression etiology and functions of the HPA-axis. In general, results of a GWAS cannot be 
easily implemented in clinical setting as the predictive power of a SNP for a certain disease 
is generally low. However, these studies provide data to understand the overall genetic 
vulnerability of a person and the genetic correlation of different diseases. Personalized 
genetic liability might have an impact on changing behavior to decrease preventable risk 
factors.58 Detecting genetic overlap between diseases using polygenic risk score methods 
would be helpful to understand the etiology of psychiatric disorders. Also, this approach 
could provoke a paradigm shift in psychiatric nosology as more and more genetic studies 
show strong genetic overlap between psychiatric diseases. 
Future directions for research
Acute and chronic stress response are interconnected yet distinct entities of the stress 
response. Repeated saliva sampling over the day and even on sequential days is informative 
about the general activity of the HPA-axis, only. Acute stress response can be evaluated 
using psychological or physiological stress tests that are burdensome for large scale stud-
ies. Easier or even modifi ed methods are required. To assess chronic cortisol secretion, a 
relatively novel method, hair cortisol, can be used in large population-based studies 59. 
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In terms of genetics of the HPA-axis, polygenic risk score analyses can be used to as-
sess whether common risk variants may explain the relationship of cortisol levels with 
psychiatric traits such as depression, bipolar disorder, psychotic disorders, anxiety disorders, 
and cognitive problems. Also, more stable markers of the HPA-axis such as hair cortisol, 
repeated sampling of cortisol in consecutive days might be more useful to detect SNP-
based heritability of cortisol. Such traits might be helpful to detect novel SNPs if used in a 
GWAS as they will be less prone to the environmental factors and noise than single-point 
saliva cortisol levels. 
The vascular depression hypothesis has been tested repeatedly in studies of large vessel 
diseases. Such an approach does not allow researchers to disentangle direct biological 
from psychological effects of vascular disease in depressed persons. To overcome this is-
sue, many others and we used non-clinical vascular changes as an exposure measure. 
Further studies are needed to explore the microcirculation and markers of vascular integrity 
in depression. Also, longitudinal study design is needed to detect early changes of the 
vascular status in healthy people to predict subsequent depression. Further, assessment 
of polygenic risk of vascular pathologies and imaging findings and depression would add 
another dimension to the vascular depression hypothesis.
In this thesis, I presented different approaches to detect polymorphisms in complex traits. It 
is obvious that large sample size is required when studying heterogeneous traits. Another 
lesson taken from the studies was to focus on more homogeneous traits. Therefore, future 
research on GWAS will be determined by large collaborations with extensive data collec-
tions which allow studies of more homogenous phenotypes. 
Novel methods using summary statistics of the GWAS now allow to examine the explained 
variance by a polygenic risk of a certain trait 60. This type of research summarizes the total 
effect of common variants with small effects (imprecisely) indicating the individual risk 
and also common genetic variation between different phenotypes. Also, the SNP-based 
heritability can be calculated now. Therefore, any new GWAS with better phenotyping and 
large sample size would help to increase the precision of the risk calculations and would be 
to even better estimate the shared genetic etiology between diseases. 
To date, many genes have been detected for psychiatric traits. However, each variant is 
different in terms of the allele frequency and the effect size (Figure2). We still do not 
know how much overall variance of a disease is explained by genetic variations when we 
combine all data. Further methodological studies would help to disentangle this issue. 
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Figure 2. Adapted from Manolio 200961
5.5 concluding remarks
The whole process of this thesis and my clinical observations of depressed patients made 
me to believe that the biological determinants of depression should be explored more in 
detail especially in older adults. Even though vascular depression hypothesis has been ex-
amined repeatedly, there are still many questions to be answered. I conclude that subclini-
cal cerebral vascular pathologies rather than peripheral indicators play an important role 
in etiology and progress of depression. Also, more powerful genetic studies of depression 
would reveal novel genes that would lead to discover or disentangle biological mechanisms 
playing a role in depression etiology. It is good to know that at the time of writing of this 
thesis, these studies were on their way and have been successful. Moreover, being part of 
these studies Being part of these further studies was a which I have contributed. Moreover, 
it was a privilege to be able to contribute to this endeavor. 
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sUmmAry
Understanding the biology behind depression has a long history in research. To date, no 
unique marker or specifi c etiological factor was detected. However, we know more about 
the possible mechanisms that predispose depression or affect clinical presentation and 
prognosis of depression (chapter 1). 
In chapter 2, I aimed to scrutinize the determinants and the genetic control of differ-
ent functions of the HPA-axis, a well-known neurohormonal correlate of depression. 
In chapter 2.1, I explored the effect of smoking on daily cortisol to understand how 
smoking contributes on health via stress-response. I found that smoking is related with 
hypercortisolemia and quitting smoking reverses the increased cortisol secretion. chap-
ter 2.2 presents determinants of the negative feed-back function of the HPA-axis that 
was measured using a very low dose (0.25 mg) dexamethasone suppression test. In this 
study, I found that being female, low income, lack of exercise, instrumental disability and 
smoking were related to low cortisol levels after dexamethasone intake. However, clinically 
relevant depressive symptoms and anxiety disorders were related with a non-suppression 
of cortisol after dexamethasone intake. In chapter 2.3, I explored common variants related 
to plasma cortisol levels using a genome-wide association approach. In this study, I found 
and replicated common genetic variants at chromosome 14q32 which contains SERPINA6 
and SERPINA1. We also explored the functional consequences of these genetic variants 
and found that they affect plasma cortisol levels via the cortisol binding globulin (CBG). 
Also, we showed some evidence of the CBG cleavage which was activated by the reac-
tive centre loop. In chapter 2.4 we performed a genome-wide analysis of morning saliva 
cortisol level and measured the SNP-based heritability of saliva and plasma cortisol levels. 
We found no genome-wide signifi cant association between autosomal SNPs and morning 
saliva cortisol level. Also, we detected low SNP-based heritability of single-point plasma 
and saliva cortisol levels.
The potential vascular etiology of depression has been discussed for a long time and has 
been studied repeatedly. However, studies are mostly clinical with small sample sizes. In 
chapter 3, I revisited the vascular depression hypothesis and explored the associations 
of non-clinical cerebrovascular alterations with depression. In chapter 3.1, I found that 
silent brain infarcts are related with the risk of depression recurrence, whereas subcortical 
white matter lesions are related to incident depression in non-demented elderly people. In 
chapter 3.2, I used several neuroimaging markers to test the associations with depression. 
I found that white matter lesion volume and lacunar infarcts were related to different se-
verity degrees of depression whereas cerebral microbleeds were related with severe depres-
sion only. In chapter 3.3 relationship between cerebral blood fl ow, vasomotor reactivity 
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and depression were assessed longitudinally. Low mean blood flow velocity at baseline was 
associated with depressive symptoms and disorder longitudinally. Also, decreased vasomo-
tor reactivity was related to incident depressive disorders in people with no-dementia and 
no-stroke. In chapter 3.4 we evaluated the association of plasma amyloid beta (Ab) levels 
with depressive syndromes in dementia-free people. We found that high levels of Ab1-40 
were related to clinically relevant depressive symptoms cross-sectionally and this associa-
tion was explained by prodromal dementia. In longitudinal analyses, we found that low 
Ab1-40 and Ab1-42 levels were related to a high risk of incident clinically relevant depressive 
symptoms in people with no dementia prodrome during the follow-up.
chapter 4 reports the results of genome-wide association studies in depression. In chapter 
4.1 I present the results of two previously published genome-wide association studies that 
were performed in depressive symptoms and disorders separately. I found and replicated 
a locus located in the FHIT gene that is related to circadian clock, oxidative stress and the 
DNA-damage. In chapter 4.2 I assessed common genetic variants in subdomains of the 
CES-D scale that is consisted of negative affect, positive affect, somatic symptoms and in-
terpersonal relationships. One variant in the brain-expressed melatonin receptor (MTNR1A) 
gene was related to the somatic symptoms. The melatonin pathway is well-known for 
depression. As somatic symptoms include sleep, appetite and fatigue, it is a very plausible 
gene for this symptom cluster. However, this variant was not replicated.  
In chapter 5, I discussed the most important findings of the studies and summarized 
methodological issues and clinical implications.
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sAMeNVAttiNG
Het begrijpen van het biologie mechanisme achter depressie heeft een lange geschiedenis 
in het onderzoek. Tot op heden is geen unieke marker of specifi eke etiologische factor 
gedetecteerd. We weten echter wel meer over de mogelijke mechanismen die voor de-
pressie predisponeren of de klinische presentatie en prognose van depressie beïnvloeden 
(hoofdstuk 1). 
In hoofdstuk 2 heb ik kritisch de determinanten en genetische controle van verschillende 
functies van de HPA-as bestudeerd, wat een bekende neuro hormonale correlatie van 
depressie is. In hoofdstuk 2.1 onderzocht ik het effect van roken op dagelijkse cortisol 
om te begrijpen hoe roken bijdraagt aan de gezondheid via stress-respons. Ik ontdekte 
dat roken verband houdt met hypercortisolemie en dat stoppen met roken de verhoogde 
cortisolafscheiding omkeert. Hoofdstuk 2.2 presenteert determinanten van de negatieve 
terugvoerfunctie van de HPA-as die werd gemeten met behulp van een zeer lage dosis 
(0,25 mg) dexamethason suppressietest. In deze studie vond ik dat vrouw zijn, een laag 
inkomen, gebrek aan lichaamsbeweging, een instrumentele handicap en roken betrekking 
hadden op lage cortisol niveaus na dexamethason-inname. Klinisch relevante depressieve 
symptomen en angststoornissen waren echter gerelateerd aan een niet-suppressie van 
cortisol na dexamethason-inname. In hoofdstuk 2.3 onderzocht ik gemeenschappelijke 
varianten met betrekking tot plasma cortisol niveaus met behulp van een genoom-wijde 
associatie benadering. In deze studie vond en repliceerde ik gemeenschappelijke geneti-
sche varianten bij chromosoom 14q32 die SERPINA6 en SERPINA1 bevat. We hebben ook 
de functionele gevolgen van deze genetische varianten onderzocht en ontdekt dat zij het 
cortisolgehalte van plasma beïnvloeden via de cortisolbindende globuline (CBG). Ook lieten 
we een bewijs zien van de CBG-splitsing die door de reactieve center lus werd geactiveerd. 
In hoofdstuk 2.4 beschrijf ik de resultaten van een genoom brede associatiestudies van 
het cortisol-niveau gemeten in speeksel die is afgenomen in de vroege ochtend. Verder 
beschrijf ik de SNP-gebaseerde erfelijkheid van speeksel- en plasmacortisol metingen. We 
hebben geen genoom-brede signifi cante associatie gevonden tussen autosomale SNP’s en 
cortisol speekselmetingen in de ochtend. Verder waren de SNP-gebaseerde schattingen 
voor de erfelijkheid van plasma en speekselcortisol zeer laag.
De vasculaire depressie hypothese is al lang bekend en is uitgebreid bestudeerd. Echter, 
deze studies zijn meestal klinisch met kleine steekproefgroottes. In hoofdstuk 3 heb ik deze 
hypothese herzien en de associaties van niet-klinische cerebrovasculaire veranderingen met 
depressie onderzocht. In hoofdstuk 3.1 vond ik dat zware herseninfarcten verband houden 
met het risico op depressie, terwijl subcorticale witte stof letsels verband houden met 
incidentele depressie bij niet-dementeerde ouderen. In hoofdstuk 3.2 heb ik verschillende 
222 Chapter 7
neuro imaging markers gebruikt om de associaties met depressie te testen. Ik ontdekte 
dat het volume van de laesie en de lacunair-infarcten in de witte stof verband houden 
met verschillende ernstgraden van depressie, terwijl cerebrale micro bloedingen alleen 
verband houden met ernstige depressie. In hoofdstuk 3.3 is de relatie tussen de cerebrale 
bloedstroom, vasomotorische reactiviteit en depressie longitudinaal geëvalueerd. Lage 
gemiddelde bloedsnelheid bij baseline werd longitudinaal geassocieerd met depressieve 
symptomen en depressieve stoornis. Ook verminderde vasomotorische reactiviteit was 
gerelateerd aan depressieve stoornissen bij mensen zonder dementie en zonder hersen in-
farcten. In hoofdstuk 3.4 hebben we de associatie van plasma amyloïde beta (Ab) niveaus 
met depressieve syndromen in dementie-vrije mensen geëvalueerd. We vonden dat hoge 
niveaus van Ab1-40 cross-sectioneel gerelateerd waren aan klinisch relevante depressieve 
symptomen en deze associatie werd verklaard door de prodromale fase van dementie. In 
longitudinale analyses bleken lage Ab1-40- en Ab1-42-niveaus verband te houden met een 
hoog risico op incidentele klinisch relevante depressieve symptomen bij mensen zonder 
prodromale fase van dementie tijdens de follow-up.
Hoofdstuk 4 rapporteert de resultaten van genoom-wijde associatie studies in depressie. 
In hoofdstuk 4.1 presenteer ik de resultaten van twee eerder gepubliceerde genoom-
wijde associatie studies die afzonderlijk bij depressieve symptomen en stoornissen werden 
uitgevoerd. Ik vond en repliceerde een locus in het FHIT gen dat verband houdt met de 
circadiane klok, oxidatieve stress en DNA-schade. In hoofdstuk 4.2 heb ik gemeenschappe-
lijke genetische varianten in sub domeinen van de CES-D-schaal beoordeeld die bestaat uit: 
negatieve effecten, positieve effecten, somatische symptomen en interpersoonlijke relaties. 
Eén variant van het in het hersenen tot expressie komende melatonine receptor (MTNR1A) 
gen was gerelateerd aan de somatische symptomen. Het is bekend dat melatonine een 
rol speelt bij depressie. Somatische symptomen van depressie bevatten slaap, eetlust en 
vermoeidheid, het is dus een zeer aannemelijk gen voor dit cluster van symptomen. Deze 
variant is echter niet gerepliceerd.
In hoofdstuk 5 heb ik de belangrijkste bevindingen van de studies besproken en methodo-
logische kwesties en klinische implicaties samengevat.
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